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Summary	  
Platelets	   are	   a	   key	   constituent	   in	   haemostasis	   and	   thrombosis.	   Platelet	   function	  
testing	  has	  clinical	  benefit,	   through	   identifying	   those	  who	  are	  potentially	  at	   risk	   to	  
bleeding	   or	   thrombosis.	   Empirically,	   the	   challenge	   is	   to	   produce	   tests	   that	   can	  
effectively	   replicate	   the	   flow	   and	   shear	   environment	   that	   platelets	   experience	   in	  
vivo.	  	  
	  
Our	  research	  group,	  previously	  developed	  a	  Dynamic	  Platelet	  Function	  Assay	  (DPFA),	  
that	  uses	  novel	  parallel	  plate	   flow	  chambers	  coated	  with	  purified	  human	  VWF	  and	  
custom-­‐designed	  platelet	   tracking	  software	   (Kent	  et	  al.,	  2010,	  Lincoln	  et	  al.,	  2010).	  
This	   custom-­‐designed	   platelet	   tracking	   software	   was	   capable	   of	   deriving	   novel	  
parameters	  of	  platelet	   function	  that	  related	  to	  the	  biological	  activity	  of	  platelets	   in	  
vivo.	  However,	  the	  reliability	  and	  the	  clinical	  relevance	  of	  the	  measured	  parameters	  
of	   the	  DPFA	  were	  unclear,	  and	  there	  were	  errors	   in	   its	  platelet	   tracking	  process.	  A	  
primary	   objective	   of	   this	   PhD	   thesis	   was	   to	   investigate	   the	   above	   issues	   through	  
validation	  and	  clinical	  evaluation	  of	  the	  DPFA.	  Validation	  of	  the	  assay	  was	  achieved	  
computationally	   using	   an	   ideal	   data	   set,	   which	   determined	   the	   percentage	  
systematic	  error	  for	  each	  measured	  parameter	  of	  platelet	  behaviour,	  and	  biologically	  
using	   a	   P2Y1	   receptor	   inhibitor	   MRS2179.	   Clinical	   evaluation	   was	   performed	   in	  
adults,	   neonates,	   healthy	   pregnancy	   and	   pregnancy	   with	   utero-­‐placental	   disease,	  
through	   observation	   and	   recording	   of	   subtle	   changes	   in	   the	   behavior	   of	   platelets	  
translocating	  on	  VWF.	  	  
	  
The	  results	  conveyed	  in	  this	  thesis,	  validated,	  clinically	  evaluated	  and	  enhanced	  the	  
DPFA,	   through	   the	   refinement	  and	  adaptation	  of	   its	  platelet	   tracking	   software	  and	  
parameter	   outputs.	   It	   is	   concluded	   that	   the	   DPFA	   is	   capable	   of	   detecting	   subtle	  
changes	  in	  platelet	  function.	  These	  changes	  in	  platelet	  function	  are	  cognizant	  to	  the	  
behaviours	  of	  platelets	   in	  vivo.	   It	   is	   recommended	  that	   future	  work	  should	  seek	  to	  
enhance	  and	  further	  understand	  the	  assays	  outputs.	  
	  
	   18	  
Acknowledgements	  
Thanks	  Science	  Foundation	  Ireland	  for	  funding	  this	  project.	  	  
	  
Particular	   thanks	   and	   appreciation	   to	   my	   supervisor	   Prof.	   Dermot	   Kenny	   for	  
affording	  me	  the	  opportunity	  to	  do	  my	  PhD	  in	  his	  lab.	  I	  would	  like	  to	  thank	  him	  for	  
his	  patience,	  guidance	  and	  supervision	  throughout.	  I	  arrived	  in	  Dermot’s	  lab	  as	  a	  boy	  
but	  left	  as	  a	  man.	  
	  
I	  would	  like	  to	  acknowledge	  Prof.	  Antonio	  (Tony)	  Ricco	  for	  his	  assistance	  during	  my	  
PhD.	   It	  was	   inspiring	   to	  have	  conversations	  and	  pints	  down	  the	  Swan	  with	  a	  NASA	  
scientist.	  	  
	  
I	  would	  like	  to	  express	  appreciation	  to	  the	  Biomedical	  Diagnostics	  Institute	  (BDI)	  and	  
CVD1	   research	   group	   in	   RCSI	   and	  DCU.	  Eimear	  Dunne,	  who	  was	   always	   there	   any	  
time	  I	  had	  questions	  or	  needed	  clarification.	  Our	  project	  manager,	  Dr.	  Barry	  Byrne,	  
who	  I	  plagued	  during	  my	  PhD.	  Thank	  you	  for	  proof	  reading	  my	  PhD	  chapters	  and	  the	  
football	  debates.	  Dr.	   Irene	  Oglesby,	   thanks	   for	   the	  direction	  with	  my	  writing	  style.	  
Siobhan	  McFadden,	  thanks	  for	  the	  chats	  and	  providing	  me	  with	  blood	  collections	  for	  
my	  experiments.	  Martin	   Somers,	   thanks	   for	  helping	  me	  somewhat	  understand	  the	  
very	  basic	  concepts	  of	  software	  design.	  Peter	  McCluskey,	   I	  am	  honestly	  shocked	  at	  
your	  knowledge	  of	  practically	  anything	  that	  exists.	  Dr.	  Niamh	  Gilmartin,	   thanks	  for	  
your	  help	  and	  advice.	  I	  would	  also	  like	  to	  thank	  Dr.	  Nigel	  Kent	  of	  the	  Dublin	  Institute	  
of	   Technology	   (DIT)	   and	  Dr.	   Conor	   Burke	   associate	  director	   (commercialisation)	   in	  
BDI.	  Dr.	  Gerardene	  Meade,	   thank	  you	  for	  help	  and	  advice	  during	  the	  early	  days	  of	  
my	  PhD.	  
	  
I	  would	   like	   to	  acknowledge	   the	   contributions	  of	  my	   collaborators	  during	  my	  PhD.	  
Prof.	   Eric	   Shaqfeh	   and	   Dr.	   Sean	   Fitzgibbon	   of	   Stanford	   University	   in	   California.	  
Thanks	  Dr.	  Nuala	  Quinn,	  Dr	   Sarah	  Geoghegan	   and	  Prof.	   Eleanor	  Molloy	   of	  Holles	  
street	  maternity	  hospital	  in	  Dublin.	  My	  first	  visit	  to	  the	  Neonatal	  Intensive	  Care	  Unit	  
(NICU)	  was	  amazing.	  Thanks	  Prof.	  Brian	  Meenan	  and	  David	  Bishop	  of	  the	  University	  
	   19	  
of	  Ulster’s	  Nanotechnology	  and	  Integrated	  Bioengineering	  Centre	  (NIBEC).	  For	  their	  
support	  and	  clinical	  facilitation,	  a	  warm	  thanks	  to	  Prof.	  Fergal	  Malone,	  Dr.	  Liz	  Tully	  
and	  Dr.	  Sieglinde	  (Siggy)	  Müllers	  of	  the	  Rotunda	  hospital	  in	  Dublin.	  Thank	  you	  Siggy	  
for	  helping	  me	  during	  the	  past	  two	  years,	  I	  learned	  a	  lot	  from	  you	  about	  pregnancy	  
and	  utero-­‐placental	  disease.	  I	  would	  like	  to	  acknowledge	  Prof.	  Robert	  Montgomery,	  
Blood	  Research	   Institute,	  Milwaukee,	  WI,	  USA	   for	  providing	   von	  Willebrand	  Factor	  
(VWF)	  for	  my	  studies.	  Thanks	  to	  the	  guys	  in	  the	  Irish	  Centre	  for	  High-­‐End	  Computing	  
(ICHEC),	  Dr.	  Adam	  Ralph,	  Dr.	  Simon	  Wong	  and	  Dr.	  Bruno	  Voisin.	  
	  
I	   would	   like	   to	   thank	   everyone	   in	   Molecular	   and	   Cellular	   Therapeutics	   (MCT).	   In	  
particular,	   Olwen	   Foley,	   Kay	   McKeon,	   Mary	   Ledwith	   and	   Anne	   Grady.	  
Phlebotomists	  Una,	  Helen	   and	  Pauline.	   Thanks	  Dr.	  Maria	  Morgan	   for	   the	   evening	  
chats	  we	  had	  when	  I	  was	  working	  late	  and	  providing	  the	  office	  with	  chocolate.	  	  
	  
Thank	   you	   to	  Dr.	   Heiko	   Dussmann	   and	  Brenton	   Cavanagh	   in	  RCSI	   for	   all	   the	  help	  
with	  the	  microscope.	  Whenever	  I	  had	  a	  problem	  you	  guys	  would	  always	  sort	  it	  out.	  
	  
To	  the	  porters	  Frank	  D,	  Frank	  B,	  Brian,	  Eddie,	  Dave	  and	  Phil,	  some	  of	  you	  I	  worked	  
with	   over	   the	   summer	   many	   years	   ago	   before	   starting	   my	   PhD.	   It	   was	   a	   real	  
experience	  and	  one	  I	  will	  not	  forget.	  	  
	  
I	  have	  made	  many	  friends	  in	  RCSI	  who	  have	  moved	  on	  to	  greener	  pastures.	  I’d	  like	  to	  
acknowledge	  Niamh	   Cooke,	  Aideen	   Collins	   and	   Ana	   Lopez-­‐Alonso.	   Thanks	   to	  Karl	  
Egan,	  you	  are	  one	  of	  the	  most	  genuine	  blokes	  I	  have	  ever	  met.	  Seamus	  (Shambosis)	  
Allen,	  we	  had	   some	  craic	  over	   the	  years,	  enjoyed	  your	   joke	  of	   the	  day.	  The	   lovely	  
Naadiya	   Carrim	   (Benzema),	   thanks	   for	   being	   a	   great	   friend	   and	   listening	   to	   me	  
moan.	  Emily	  Reddy	  (Reddy),	  what	  can	  I	  say;	  we	  had	  some	  serious	  craic	  in	  the	  office,	  
the	  laughs	  about	  Father	  Ted,	  the	  Simpsons	  and	  South	  Park.	  The	  office	  was	  so	  quiet	  
without	  you	   that	   I	  actually	  got	   some	  work	  done.	  My	   favourite	   Indian	  Kalyan	  Golla	  
(Prof.	  Golla),	  number	  one	  in	  my	  eyes.	  Missed	  you	  dearly	  when	  you	  left	  for	  the	  states,	  
hopefully	   you’ll	   be	   back	   in	   your	   “real”	   home	   (Ireland)	   soon.	   The	   Italian	   stallion	  
Annachiara	   Mitrugno	   (Ms.	   Italia),	   teaching	   you	   English	   and	   I	   pretending	   to	   learn	  
	   20	  
Italian	  was	  mighty.	  Tadhg	  (lord	  wellington)	  Mcgivern,	  some	  man	  for	  one	  man,	  never	  
have	  I	  heard	  someone	  use	  the	  word	  “well”	  as	  much	  as	  you.	  Thea	  Tilly,	  we	  had	  the	  
craic,	  will	  never	  forget	  that	  house	  party	  at	  yours,	  sore	  heads	  all	  round	  the	  next	  day.	  
Tony	   (T-­‐Bad)	  Walsh,	   I	   have	  multiple	   names	   for	   you,	  missed	   all	   our	   football	   chats.	  
Graham	  Kelly	  some	  man	  for	  the	  pints.	  To	  my	  gym	  buddies	  and	  friends	  John	  O’Brien	  
and	  Damir	  Vareslija	  thank	  for	  you	  “setting	  the	  tone”	  in	  the	  gym	  and	  the	  pints	  down	  
the	  Swan.	  	  	  
	  
Finally,	   I	  would	   like	  to	  thank	  my	  family	  and	  friends	  from	  home,	  you	  know	  who	  you	  
are,	  for	  always	  being	  there	  for	  me	  whenever	  I	  was	  down	  or	  needed	  someone	  to	  talk	  
to.	   In	   particular,	   I	   would	   like	   to	   thank	   my	   parents	   Seamus	   and	   Nenette	   who	   I	  
dedicate	  this	  thesis	  too.	  Thank	  you	  for	  everything	  you	  have	  provided	  me	  with	  in	  life.	  
There	  were	  times	  where	  I	  struggled	  but	  you	  always	  encouraged	  me	  and	  I	  got	  there	  













































“Physical	  fitness	  is	  not	  only	  one	  of	  the	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  important	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  to	  healthy	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  and	  creative	  intellectual	  activity”	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1.1 The	  platelet	  	  
In	  the	  blood	  stream	  there	  are	  3	  types	  of	  circulating	  cells,	  platelets,	  white	  blood	  cells	  
(WBCs)	   and	   red	  blood	   cells	   (RBCs).	   Platelets	   are	   small	   discoid-­‐shaped	   cells	   ranging	  
from	   2–5	   μm	   in	   diameter	   with	   a	   thickness	   of	   0.5	   μm	   and	   are	   produced	   by	  
megakaryocytes	   in	   the	   bone	  marrow.	   The	   normal	   platelet	   count	   is	   approximately	  
150-­‐450	   x	   103	   platelets	   per	   microlitre	   (μL)	   of	   blood	   in	   humans.	   Platelets	   have	   a	  
lifespan	  of	  7-­‐10	  days	  after	  which	  time	  they	  are	  cleared	  by	  macrophages	  in	  the	  liver	  
and	  spleen.	  	  
1.1.1 	  Haemostasis	  
Platelets	   have	   a	   fundamental	   role	   in	   haemostasis	   (Figure	   1.1).	   In	   the	   arterial	  
circulation,	   damage	   to	   the	   vascular	   wall,	   results	   in	   the	   exposure	   of	  
vascular/subendothelial	  matrix	  proteins.	  The	  proteins	  that	  are	  exposed	  are	  primarily	  
collagens.	   Von	   Willebrand	   Factor	   (VWF)	   present	   in	   blood	   plasma,	   binds	   to	   this	  
exposed	  collagen,	  resulting	  in	  a	  conformational	  change	  in	  the	  structure	  of	  VWF.	  This	  
structural	   change	   in	   VWF	   allows	   it	   to	   capture	   platelets	   from	   flowing	   blood.	   VWF	  
captures	   platelets	   via	   its	   interaction	   with	   the	   platelet	   glycoprotein	   (GP)	   Ib-­‐IX-­‐V	  
complex.	   Platelet	   movement	   is	   slowed,	   allowing	   the	   platelet	   to	   interact	   with	  
collagen	   via	   the	   platelet	   immunoglobulin-­‐like	   receptor	   GPVI.	   The	   platelet	   GPVI	  
receptor	  generates	  powerful	  platelet	  activation	  signals	  and	  this	  results	  in	  inside-­‐out	  
activation	  of	  platelet	  integrins	  α2β1	  and	  αIIbβ3	  and	  cytoskeletal	  remodelling,	  which	  
leads	   to	   platelet	   spreading,	   granule	   secretion	   and	   release	   of	   thromboxane	   A2	   (a	  
potent	  mediator	  of	  platelet	  activation).	  The	  activation	  of	  fibrinogen	  receptor	  αIIbβ3	  
modulates	  stable	  platelet	  adhesion	  and	  aggregation	  at	   the	  site	  of	  vascular	  damage	  
(Watson,	  2009).	  	  
	  
The	   importance	  of	  platelets	   in	  haemostasis	   is	  highlighted	  by	   rare	  platelet	  bleeding	  
disorders	  such	  as	  Bernard-­‐Soulier	  syndrome	  (BSS)	  and	  Glanzmann’s	  thrombasthenia	  
(GT).	   BSS	   is	   caused	   by	   defects	   in	   the	   platelet	   glycoprotein	   (GP)	   Ib-­‐IX-­‐	   V	   complex	  
which	   results	   in	   macrothrombocytopenia.	   Macrothrombocytopenia	   is	  
thrombocytopenia	   with	   an	   increase	   in	   platelet	   size	   (Li	   et	   al.,	   1995,	   Andrews	   and	  
Berndt,	   2013).	   Thrombocytopenia	   refers	   to	   low	   platelet	   counts	   and	   is	   generally	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defined	   as	   platelet	   counts	   (<	   150	   x	   103	   per	   μL	   of	   blood	   in	   healthy	   adults).	   GT	   is	  
caused	  by	   defective	   or	   low	   levels	   of	   the	   fibrinogen	   receptor	   integrin	  αIIbβ3	  which	  
results	  in	  reduced	  platelet	  aggregation	  (Nurden,	  2006).	  	  	  
1.1.2 Thrombosis	  
Platelets	   play	   a	   key	   role	   in	   thrombosis	   (Figure	   1.1),	   namely	   the	   formation	   of	   a	  
thrombus	   in	  a	  vessel	   that	   results	   in	  obstruction	  of	  blood	   flow.	  Venous	  and	  arterial	  
thrombosis	   occurs	   where	   thrombi	   form	   in	   a	   vein	   or	   artery	   respectively.	   Venous	  
thrombosis	   is	   mainly	   mediated	   by	   the	   coagulation	   cascade	   whereas	   arterial	  
thrombosis	   is	   mainly	   mediated	   by	   the	   activity	   of	   platelets.	   Venous	   thrombosis	   is	  
initiated	  by	  a	  tissue	  factor,	  which	  activates	  the	  coagulation	  response	  (Esmon,	  2009).	  
Deep	   vein	   thrombosis	   is	   the	   most	   common	   form	   of	   venous	   thrombosis	   and	   is	  
characterised	  by	  the	  formation	  of	  a	  blood	  clot	  in	  the	  deep	  veins	  of	  the	  leg.	  The	  blood	  
clot	   can	   dislodge	   and	   become	   a	   moving	   clot	   (embolus)	   and	   travel	   to	   the	   lungs	  
resulting	   in	   the	   formation	   of	   pulmonary	   embolism	   (Hwang	   and	   Schulman,	   2013).	  
Arterial	  thrombosis	  occurs	  at	  sites	  of	  vascular	  damage,	  where	  platelets	  adhere	  and	  
aggregate	  uncontrollably.	  Arterial	  thrombosis	  can	  also	  occur	  as	  fats	  and	  cholesterol	  
are	  deposited	  along	  the	  artery	  wall,	  forming	  atherosclerotic	  plaques.	  These	  plaques	  
can	  rupture	  causing	  platelet	  adherence	  and	  aggregation	  in	  the	  vessel	  which	  result	  in	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Figure	  1.1	  Haemostasis	  versus	  thrombosis	  formation.	  Damage	  occurs	  via	  trauma	  at	  
the	  endothelial	  wall	  of	  the	  healthy	  artery.	  Platelets	  sense	  this	  damage;	  they	  adhere	  
and	  rapidly	  interact	  with	  one	  another	  forming	  a	  thrombus.	  The	  thrombus	  seals	  the	  
wound	  and	  supresses	  bleeding.	  In	  the	  diseased	  artery,	  plaque	  rupture	  causes	  
platelet	  activation	  within	  the	  vessel.	  This	  restricts	  blood	  flow	  leading	  to	  thrombosis.	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into the lumen of an injured artery prompts blood flow to accelerate 
at the surface of the growing thrombus27, subjecting platelets and 
immobilized ligands, such as vWF, to extensional drag forces. As a 
consequence, platelet recruitment onto the thrombus surface becomes 
increasingly dependent on vWF and GPIbA. The formation of stable 
platelet-platelet adhesion contacts relies on a second adhesion step 
mediated by integrin AIIbB3 binding to vWF28,29, fibrinogen30, fibrin 
and/or fibronectin31 (Fig. 1). Thus, irrespective of the type of vascular 
injury, thrombotic occlusion of blood vessels is dependent on the vWF-
GPIb interaction as well as on integrin AIIbB3. These findings help 
explain the nonredundant roles of these molecules in platelet thrombus 
formation and why qualitative or quantitative defects in these proteins 
lead to a bleeding disorder32; defects in vWF, GPIb-V-IX and integrin 
AIIbB3 cause von Willebrand’s disease, Bernard-Soulier syndrome and 
Glanzmann’s thrombasthenia, respectively. These findings also explain 
the attractiveness of these molecules as therapeutic targets.
Stable platelet adhesion and activation. Once platelets firmly adhere 
to the vessel wall or to the surface of a growing thrombus, they undergo 
a complex series of morphological and biochemical changes that lead to 
the release of the contents of the platelet granules and upregulation of 
the adhesive function of integrin AIIbB3 (refs. 33–35) (Fig. 1). Central 
to irreversible platelet activation is the generation and release of soluble 
agonists at sites of vascular injury. These include thromboxane A2 (TxA2) 
and dense-granule ADP, which act in an autocrine or a paracrine manner 
to potentiate platelet activation through specific G protein–coupled 
receptors, including the ADP purinergic receptors P2Y1 (ref. 36) and 
P2Y12 (ref. 37) and the thromboxane receptors TPA and TPB (ref. 38). 
Both ADP and TxA2 stimulate platelets in a cooperative manner to 
enhance thrombus formation; thus, pharmacological targeting of TxA2 
generation39 and/or the P2Y12 receptor40 are effective strategies to 
reduce thrombus propagation at sites of vascular injury41,42 (Table 1).
Blood coagulation and a-thrombin generation. An important func-
tion of activated platelets is their ability to support the assembly of 
coagulation complexes on their plasma membrane, which is necessary 
for localized A thrombin generation and fibrin formation. Thrombin 
is among the most potent activators of platelets through proteolytic 
cleavage of surface protease-activated receptors, including PAR1 and 
PAR4, which act on human platelets43. Both thrombin stimulation of 
platelets and fibrin generation are important for thrombus growth and 
stability, and as a consequence, drugs that target thrombin generation 
(vitamin K antagonists and FXa inhibitors), thrombin catalytic func-
tion (direct thrombin inhibitors) or thrombin activation of platelets 
(PAR1 antagonists) inhibit arterial thrombus growth41.
Although both platelet activation and blood coagulation are important 
for the formation and stability of arterial thrombi, the spatial and temporal 
regulation of these events varies considerably. For example, platelet recruit-
ment preferentially occurs at regions of high shear and disturbed flow, 
leading to the formation of predominantly ‘white thrombi’ over the site 
of vascular injury, whereas maximal fibrin generation occurs in regions 
of low flow, often leading to the development of a ‘fibrin-rich thrombus 
tail’ (Fig. 2, top; Box 2). Thus, although antiplatelet agents are the cor-
nerstone therapies of atherothrombotic disease, therapies that reduce 
thrombin generation (anticoagulants) or lyse the fibrin component of 
thrombi (fibrinolytic therapies) also have important roles in the manage-
ment of this disease.
Role of platelets in the progression of atherosclerosis
Platelet proinflammatory function. Although the central importance 
of platelets in arterial thrombosis is well defined, an emerging field of 
research is focused on how platelets promote the initiation and propa-
gation of atherosclerosis7. Adhesive interactions between platelets 
and endothelial cells at atherosclerotic-prone sites can enhance the 
recruitment and activation of proatherogenic monocytes. Through the 
release of cytokines (interleukin 1B (IL-1B)), chemokines (platelet 
factor 4 (PF4) and chemokine ligand 5 (CCL5, also called RANTES)), 
proinflammatory molecules (platelet activating factor (PAF) and 
leukotrienes) and other biological response modulators (CD40L, also 
called CD154), the interaction between platelets, endothelial cells 
and leukocytes establishes a localized inflammatory response that 
can accelerate the early formation of atherosclerotic lesions (Fig. 3). 
Platelets also release growth factors, such as platelet-derived growth 
factor (PDGF), which can stimulate smooth muscle proliferation and 
Fibrin
Red thrombus:













Figure 2 Differential composition and localization of arterial thrombi 
relative to hemostatic plugs. (a) Occlusive arterial thrombi at sites of 
atherosclerosis plaque rupture. Angioscopy studies of the coronary arteries 
of people with an acute myocardial infarction have shown the presence of 
a white thrombus (platelet-rich mural thrombus) developing at the site of 
atherosclerotic plaque rupture. A ‘red thrombus’, composed of red blood 
cells and fibrin, preferentially forms in the low flow recirculation zones on 
the downstream margin of the developing thrombus. The distinct spatial 
localization of platelets and fibrin is directly caused by local blood flow 
alterations at the site of vascular injury. (b) A primary hemostatic plug 
forms rapidly at the site of vascular injury, extending into the extravascular 
space created by the wound. Notably, there is minimal extension of the 
clot into the lumen of the healthy artery. In contrast, a platelet-rich 
thrombus builds up on the surface of a disrupted atherosclerotic plaque, 
beginning in the intima and propagating into the intraluminal space, 
where it can induce major hemodynamic changes at the site of injury.
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1.2 The	  effects	  of	  shear	  on	  platelet	  adhesion	  to	  exposed	  collagen	  	  
Platelets	   are	   small	   and	   thus	   are	   affected	   by	   the	   distribution	   of	   RBCs	   in	   the	   blood	  
vessel.	   This	   phenomenon	   is	   known	   as	   Fahraeus–Lindquist	   effect	   where	   the	   RBCs	  
migrate	   to	   the	   centre	   of	   the	   vessel	   forcing	   the	   platelets	   to	   the	   vascular	   wall	  
(Fahraeus,	   1931).	   Platelets	   are	   therefore	   in	   an	   optimal	   location	   to	   respond	   to	  
vascular	  damage.	  Upon	  damage	  of	  the	  vessel	  wall,	  collagen	  fibres	  present	  in	  the	  sub-­‐
endothelial	  layers	  are	  exposed	  to	  the	  flowing	  blood.	  The	  dynamic	  forces	  of	  the	  blood	  
influence	  how	  platelets	  respond	  to	  the	  exposed	  vascular	  collagen	  and	  create	  shear	  
within	  the	  vessel.	  Shear	  refers	  to	  the	  frictional	  force	  that	  RBCs	  apply	  to	  the	  platelets	  
when	   contacting	   the	   damaged	   vascular	   wall.	   This	   force	   results	   in	   shear-­‐induced	  
deformation	   of	   the	   platelet	   at	   the	   wall	   and	   dictates	   what	   receptors	   the	   platelet	  
utilises	   for	   adhesion	   to	   the	   damaged	   surface.	   Hence	   at	   different	   shear	   rates,	  
platelets	  use	  different	  platelet	  receptors	  to	  modulate	  the	  adhesion	  on	  the	  exposed	  
vascular	   surfaces	   (Kroll	   et	   al.,	   1996).	   Under	   venous	   shear	   conditions	   (<	   1000	   s-­‐1),	  
platelet	   adhesion	   to	   collagen	   is	   predominately	   mediated	   by	   platelet-­‐collagen	  
immunoglobulin-­‐like	   receptor,	   GPVI.	   GPVI	   engagement	   with	   collagen	   causes	  
intracellular	  signalling	  and	  activation	  of	  integrins	  α2β1,	  αIIbβ3	  (Yip	  et	  al.,	  2005).	  	  
	  
Under	   conditions	   of	   arterial	   shear	   (>	   1000	   s-­‐1),	   platelet	   adhesion	   to	   the	   exposed	  
collagen	   is	   initiated	   by	   the	   platelet-­‐VWF	   receptor	   interaction.	   VWF	   binds	   to	   the	  
exposed	   collagen	   and	   undergoes	   a	   conformational	   change	   that	   allows	   VWF	   to	  
engage	  with	  the	  platelet.	  Next,	  the	  VWF	  tethers	  the	  platelet	  and	  slows	  the	  platelet’s	  
movement,	  allowing	  platelet	  receptor	  GPVI	  to	  interact	  with	  the	  collagen,	  resulting	  in	  
activation	  of	   integrin	  α2β1,	  αIIbβ3	  and	   subsequent	  adhesion	  of	   the	  platelet	   to	   the	  
damaged	   surface.	   Under	   pathological	   shear	   conditions	   (>	   10,000	   s-­‐1),	   platelet	  
activation	   is	   not	   required	   and	   is	   exclusively	   mediated	   through	   VWF-­‐platelet	  
interactions	  in	  the	  absence	  of	  αIIbβ3	  adhesive	  function	  (Jackson	  et	  al.,	  2009).	  	  
	  
1.3 Platelet	  adhesion	  receptors	  
Platelets	   contain	   several	   key	   receptors	   on	   their	   surface,	   which	   modulate	   primary	  
platelet	  adhesion	  to	  exposed	  vascular	  surfaces.	  Platelet	  adhesion	  receptors	  GPIb-­‐IX-­‐
V	   complex	   (initiation	   of	   platelet	   adhesion),	   GPVI	   (platelet	   activation)	   and	   integrin	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αIIbβ3	   (stable	   platelet	   adhesion	   and	   aggregation)	   have	   central	   roles	   in	   the	  
haemostasis	   process.	   These	   receptors	   are	   adapted	   to	   function	   under	   high-­‐shear	  
stress	   conditions	   (Yip	   et	   al.,	   2005).	   This	   thesis,	   will	   focus	   on	   platelet	   adhesion	   to	  
immobilised	  VWF	  under	  arterial	  shear	  conditions	  in	  the	  absence	  of	  collagen.	  Platelet	  
adhesion	  to	  immobilised	  VWF	  is	  a	  two-­‐step	  dynamic	  process	  by	  which	  the	  GPIb-­‐IX-­‐V	  
complex	   mediates	   initial	   platelet	   attachment	   and	   integrin	   αIIbβ3	   supports	  
irreversible	  attachment	  of	  the	  platelet	  (Savage	  et	  al.,	  1996).	  	  
1.3.1 Glycoprotein	  (GP)	  Ib-­‐IX-­‐V	  complex	  	  
The	  GPIb-­‐IX-­‐V	  complex,	  mediates	   initial	  platelet	  adhesion	   to	  collagen	  at	   the	  site	  of	  
vascular	   damage,	   via	   its	   interaction	   with	   VWF	   under	   high-­‐shear	   stress	   conditions.	  
There	  are	  approximately	  25,000	  copies	  of	  GPIb-­‐IX-­‐V	  per	  platelet.	  The	  GPIbα	  of	   the	  
GPIb-­‐IX-­‐V	  complex	  interacts	  with	  VWF	  resulting	  in	  transmembrane	  signaling	  events,	  
activation	  of	  αIIbβ3	  and	  platelet	  aggregation	  (Canobbio	  et	  al.,	  2004).	  	  
	  
The	  GPIb	  IX-­‐V	  complex	  consists	  of	  four	  subunits,	  GPIbα,	  GPIbβ,	  GPIX	  and	  GPV.	  All	  of	  
the	  subunits	  belong	  to	  a	  leucine-­‐rich	  repeat	  (LRR)	  superfamily.	  Disulphide	  bonds	  link	  
GPIbα	   to	   two	  GPIbβ	   subunits	   and	   these	   are	  non-­‐covalently	   bonded	  with	  GPIX	   and	  
GPV	  in	  a	  ratio	  of	  2:4:2:1	  (Andrews	  and	  Berndt,	  2013).	  Notably,	  the	  cytoplasmic	  tail	  of	  
the	   GPIbβ	   subunit	   contains	   the	  membrane	   proximal	   sequence	   RRLRARARARA	   and	  
blocking	  of	  this	  sequence	  has	  been	  shown	  to	  inhibit	  platelet	  activation	  (Martin	  et	  al.,	  
2003).	  Genetic	  mutations	  in	  either	  of	  the	  subunits	  GPIbα,	  GPIbβ	  or	  GPIX	  of	  the	  GPIb-­‐
IX-­‐V	  complex	   can	  cause	  BSS	   (Li	   et	  al.,	   1995,	  Andrews	  and	  Berndt,	  2013).	  GPIb-­‐IX-­‐V	  
complex	   also	   has	   other	   roles	   in	   vivo	   other	   than	   binding	   VWF	   including	   binding	   to	  
αMβ2	  (MAC-­‐1)	  which	  promotes	  leukocyte	  migration	  and	  adhesion	  on	  mural	  vascular	  
thrombi	  (Michelson,	  2007),	  or	  binding	  of	  P-­‐selectin	  on	  endothelial	  cells	  or	  activated	  
platelets	  (Andrews	  et	  al.,	  2003).	  	  
1.3.1.1 Glycoprotein	  Ibα	  structure	  
GPIbα	  (Figure	  1.2A)	  is	  the	  major	  ligand-­‐binding	  subunit	  of	  the	  GPIb-­‐IX-­‐V	  complex.	  It	  
comprises	  of	  an	  N-­‐terminal	  flanking	  sequence	  which	  has	  seven	  leucine-­‐rich	  repeats	  
each	   containing	   24	   amino	   acids,	   a	   leucine-­‐rich	   C-­‐terminal	   flanking	   sequence,	   an	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anionic	   sequence	   which	   has	   three	   sulphated	   tyrosine,	   a	   mucin-­‐like	  
macroglycopeptide	  region	  which	  contains	  two	  cysteines	  that	  bind	  GPIbα	  and	  GPIbβ	  
together	  via	  disulphide	  bonds	  and	  finally	  a	  96	  amino	  acid	  long	  cytoplasmic	  tail	  (Dong	  
et	  al.,	  2001,	   Luo	  et	  al.,	  2007).	  The	  association	  of	  GPIbα	  with	  A1-­‐VWF	   (Figure	  1.2B)	  
results	   in	   the	   characteristic	   tethering	   of	   platelets	   from	   circulation	   at	   the	   site	   of	  
vascular	  damage	  under	  high-­‐shear	  stress	  conditions.	  GPIbα	  also	  contains	  the	  binding	  
sites	  MAC-­‐1,	   thrombin,	   P-­‐selectin,	   Factor	   XII	   and	   high	  molecular	  weight	   kininogen	  





















	  	  	  






	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   1.2	   Crystal	   structure	   of	   the	   von	   Willebrand	   Factor	   binding	   domain	   of	  
glycoprotein	   Ib	   alpha.	   Protein	   chains	   are	   colored	   from	   the	   N-­‐terminal	   to	   the	   C-­‐
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1.3.2 Platelet	  integrin	  αIIbβ3	  
Platelet	   integrin	   αIIbβ3	   is	   the	   most	   abundant	   platelet	   receptor	   consisting	   of	  
approximately	   50,000	   -­‐	   80,000	   copies	   per	   platelet	   (Wagner	   et	   al.,	   1996).	   The	  
structure	   of	   αIIbβ3	   consists	   of	   αIIb	   and	   β3	   subunits	   that	   are	   non-­‐covalently	  
associated,	  with	  one	  membrane-­‐spanning	   region	  bound	   to	  a	   short	   cytoplasmic	   tail	  
consisting	  of	   20	   and	  40	   amino	  acid	   residues,	   respectively.	   The	  αIIbβ3	  heterodimer	  
consists	  of	  an	  N-­‐terminal	  globular	  head	  containing	  the	  ligand	  binding	  region	  and	  2	  C-­‐
terminal	  rod-­‐like	  tails	  containing	  the	  cytoplasmic	  domain	  (Hato	  et	  al.,	  2002).	  Integrin	  
αIIbβ3	  plays	  an	  essential	  role	  in	  regulating	  platelet	  adhesion	  to	  VWF	  and	  is	  critical	  for	  
platelet	   aggregation	   and	   thrombus	   formation	   (Nesbitt	   et	   al.,	   2002).	   In	   its	   inactive	  
state,	  αIIbβ3	  has	  a	  poor	  binding	  affinity	  for	  VWF	  and	  fibrinogen.	  Integrin	  αIIbβ3	  can	  
be	  activated	  via	  agonist-­‐induced	  stimulation	  such	  as	  adenosine	  diphosphate	   (ADP),	  
thrombin	  or	  engagement	  of	  the	  GPIb-­‐IX-­‐V	  complex	  with	  VWF	  or	  GPVI	  with	  collagen,	  
which	  results	   in	   inside-­‐out	  signaling,	  ultimately	  resulting	   in	  conformational	  changes	  
in	  the	  structure	  of	  αIIbβ3	  (Ma	  et	  al.,	  2007).	  	  
	  
A	   critical	   pathway	   for	   inside-­‐out	   activation	   of	   αIIbβ3	   occurs	   as	   cleaved	   thrombin	  
binds	   to	   the	   protease-­‐activated	   receptor	   1	   (PAR1)	   which	   is	   found	   on	   the	   plasma	  
membrane	   of	   platelets.	   Phospholipid	   hydrolysis	   occurs	   at	   the	   site	   of	   thrombin	  
binding,	  resulting	  in	  inositol	  trisphosphate	  (IP3)	  and	  diacylglycerol	  (DAG)	  generation,	  
increasing	   cytosolic	   free	   Ca2+.	   Calcium-­‐dependent	   guanine	   nucleotide	   exchange	  
factor	   CALDAG-­‐GEFl	   and	   protein	   kinase	   C	   (PKC)	   are	   activated	   with	   the	   increased	  
concentration	   of	   Ca2+	  and	  DAG,	   leading	   to	   the	   conversion	   of	   Ras-­‐related	   protein	   1	  
(RAP1)	  from	  a	  GDP	  to	  a	  GTP-­‐bound	  form.	  The	  activation	  of	  RAP1	  recruits	  Rap1-­‐GTP-­‐
interacting	   adaptor	  molecule	   (RIAM)	   and	   talin	   1	   (binding	   partner	   of	   RIAM)	   to	   the	  
plasma	   membrane.	   Talin	   1	   interacts	   with	   the	   αIIbβ3	   integrin	   β3	   tail	   resulting	   in	  
activation	  of	  the	  integrin	  (Shattil	  et	  al.,	  2010,	  Mehrbod	  et	  al.,	  2013).	  Conformational	  
changes	  occur	  such	  as	  dissociation	  of	  the	  α	  and	  β	  tail	  of	  the	  integrin	  rendering	  the	  
αIIbβ3	  competent	  to	  bind	  its	  ligands	  such	  as	  fibrinogen.	  A	  study	  utilising	  monoclonal	  
antibodies	   (monovalent	   Fab'	   fragment)	   directed	   against	   αIIbβ3	   demonstrated	   that	  
during	   activation	   of	   platelets	   with	   thrombin	   that	   there	   was	   an	   increased	   surface	  
	   31	  
expression	   of	   αIIbβ3	   epitopes.	   These	   epitopes	   were	   functional	   and	   could	   bind	  
fibrinogen	   mediating	   platelet	   aggregation	   (Niiya	   et	   al.,	   1987).	   Increased	   surface	  
expression	   of	   αIIbβ3	   has	   been	   positively	   associated	   with	   increased	   platelet	  
aggregation	   in	   healthy	   volunteers	   and	   those	   with	   acute	   coronary	   syndrome	  
(Yakushkin	  et	  al.,	   2011).	   Integrin	  αIIbβ3	  not	  only	  has	  a	   role	   in	  platelet	  aggregation	  
but	  also	  provides	  stable	  adhesion	  upon	  interaction	  with	  VWF.	  	  
	  
1.4 Von	  Willebrand	  Factor	  (VWF)	  
Von	  Willebrand	  Factor	  (VWF)	   is	  a	  multimeric	  blood	  plasma	  glycoprotein	  which	  acts	  
as	   a	   bridging	   molecule	   between	   the	   sub-­‐endothelial	   matrix	   and	   platelets.	   VWF’s	  
major	  role	   is	  to	  regulate	  the	   initial	  platelet	   interactions	  with	  vascular	  proteins	  such	  
as	  collagen	  and	  to	  facilitate	  platelet	  aggregation	  and	  spreading	  on	  exposed	  vascular	  
surfaces.	   VWF	   is	   produced	   in	   the	   endothelial	   cells	   and	   stored	   in	   Weibel-­‐Palade	  
bodies,	   platelet	   alpha-­‐granules	   and	   is	   found	   in	   the	   extracellular	   matrix	   (ECM)	  
(Ruggeri	  and	  Ware,	  1992,	  Siedlecki	  et	  al.,	  1996).	  The	  VWF	  that	  is	  released	  from	  the	  
Weibel-­‐Palade	  bodies	  consists	  of	  ultra-­‐large	  structures	  that	  are	  highly-­‐thrombogenic	  
(Ruggeri,	   2007,	  Wagner,	   1993,	   Fernandez	  et	   al.,	   1982).	   These	  highly	   thrombogenic	  
ultra-­‐large	  VWF	  structures	  are	  regulated	  by	  a	  disintegrin	  and	  metalloproteinase	  with	  
thrombospondin	   motif	   (ADAMTS-­‐13).	   ADAMTS-­‐13	   cleaves	   the	   VWF	   at	  
Tyr1605/Met1606	   within	   the	   A2	   domain	   of	   VWF	   breaking	   the	   VWF	   down	   into	  
smaller,	   less-­‐thrombogenic	   structures	   (Michelson,	   2007,	   Dong	   et	   al.,	   2002).	  
ADAMTS-­‐13	  cleavage	  is	  of	  key	  importance	  and	  has	  to	  be	  highly	  controlled.	  Deficiency	  
of	  ADAMTS-­‐13,	  results	  in	  the	  production	  of	  abnormally-­‐large	  VWF	  multimers	  which	  
cause	  excessive	  platelet	  aggregation	   in	  vivo	   (Furlan	  et	  al.,	  1997).	  The	  VWF	  found	  in	  
the	   platelet	   alpha-­‐granules	   is	   only	   released	   upon	   platelet	   activation	   and	   enhances	  
platelet	   aggregation	  at	   the	   site	  of	   vascular	   injury	   (Michelson,	  2007,	  Kulkarni	   et	   al.,	  
2000).	  	  
	  
In	   vivo,	   VWF	   forms	  multimers	   via	  disulfide-­‐linked	  bonds	   and	   can	   reach	   sizes	  up	   to	  
20,000	  kDa.	  VWF	  has	  binding	  sites	  for	  platelet	  receptor	  glycoprotein	  (GP)	  Ib,	  αIIbβ3,	  
fibrin	  and	  factor	  VIII	  (Yuan	  et	  al.,	  2012,	  Sadler,	  1998).	  VWF	  circulates	   in	  the	  plasma	  
typically	  at	  a	  concentration	  of	  10	  μg/mL	  and	  only	  binds	  to	  platelets	  in	  its	  elongated,	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active	   conformation.	   VWF’s	   transition	   from	   a	   globular,	   inactive	   state	   to	   an	   active	  
conformation	  occurs	  upon	  exposure	  to	  vascular	  collagen	  and	  or	  shear	  stress	  (Ruggeri	  
and	   Mendolicchio,	   2007,	   Lenting	   et	   al.,	   2010).	   A	   study	   utilising	   microfluidic	   flow	  
chambers	   to	  monitor	   VWF	   response	   to	   varying	   hemodynamic	   shear	   rates	   showed	  
that	   the	   VWF	   at	   low	   shear	   rates	   (10-­‐1000	   s-­‐1)	   remained	   in	   its	   closed	   globular	  
configuration.	   However,	   at	   higher	   shear	   rates	   (5000	   s-­‐1)	   VWF	   adopts	   an	   open	  
elongated	   configuration.	   This	   process	   is	   reversible	   in	   the	   absence	   of	   any	   vascular	  
surface	   such	   that	   the	   closed	   globular	   structure	   reformed	   once	   the	   shear	   rate	  
decreased	   below	   the	   critical	   threshold	   (Schneider	   et	   al.,	   2007).	   VWF	   can	   also	   be	  
converted	  to	  its	  active	  conformation	  in	  vitro	  using	  non-­‐physiological	  modulators	  like	  
botrocetin,	   a	   C-­‐type	   snake	   venom	   lectin	   (Fukuda	   et	   al.,	   2005)	   or	   ristocetin	   an	  
antibiotic	  from	  the	  bacterial	  host	  Amycolatopsis	  lurida	  (Dong	  et	  al.,	  2001).	  	  
1.4.1 The	  structure	  of	  VWF	  
VWF	  is	  encoded	  on	  the	  short	  arm	  of	  chromosome	  12	  and	  is	  approximately	  178	  kilo-­‐
bases	  in	  length	  with	  52	  exons	  (Mancuso	  et	  al.,	  1989).	  Expression	  of	  the	  VWF	  gene	  is	  
confined	  to	  megakaryocytes	  and	  endothelial	  cells	  (Ruggeri	  and	  Ware,	  1993).	  VWF	  in	  
its	  mature	  form	  consists	  of	  approximately	  2050	  amino	  acids	  (275	  kDa)	  spanning	  the	  
molecular	   domains	   D’-­‐D3-­‐A1-­‐A2-­‐A3-­‐D4-­‐B1-­‐B2-­‐B3-­‐C1-­‐C2	   (Michelson,	   2007)	   (Figure	  
1.3A).	   However,	   more	   recently	   Zhou	   et	   al.,	   (2012)	   challenged	   this	   theory	   and	   re-­‐
annotated	  the	  molecular	  domains	  within	  VWF	  (Figure	  1.3B).	  Each	  monomer	  of	  VWF	  
contains	  10	  O-­‐linked	  and	  12	  N-­‐linked	  oligosaccharide	  chains	  (Titani	  et	  al.,	  1986).	  VWF	  
also	   contains	   a	   high	   content	   of	   cysteine	   residues,	  which	   play	   an	   important	   role	   in	  
linking	  the	  VWF	  subunits	  together,	  forming	  higher-­‐order	  structures	  of	  VWF.	  Disulfide	  
bonds	   exist	   within	   mature	   VWF,	   which	   comprises	   of	   an	   amino	   terminal	   (residues	  
283-­‐695)	   with	   30	   cysteine	   residues	   and	   a	   carboxyl-­‐terminal	   (residues	   1908-­‐2050)	  
with	   18	   cysteine	   residues.	   Dimers	   are	   formed	   via	   association	   of	   VWF	   monomers	  
within	  the	  carboxyl	  terminal	  regions,	   linked	  by	  disulfide	  bridges	  (Marti	  et	  al.,	  1987,	  
Ruggeri	  and	  Ware,	  1993).	  These	  dimers	  then	  form	  multimers	  as	  disulfide	  bridges	  are	  
formed	  at	  the	  amino	  terminal	  of	  the	  D3	  domain	  (Mendolicchio	  and	  Ruggeri,	  2005).	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VWF	  is	  produced	  in	  the	  endothelial	  cells	  and	  dimerizes	  in	  the	  endoplasmic	  reticulum	  
through	  disulfide	  bonds	  between	  C-­‐terminal	  CK	  domains.	  This	  leads	  to	  the	  formation	  
of	   “tail-­‐to-­‐tail”	   proVWF	  which	  multimerize	   in	   the	   Golgi	   apparatus.	   This	   occurs	   via	  
furin,	  which	  cleaves	  the	  propeptide	  between	  the	  D1D2	  domains	  resulting	  in	  “head-­‐
to-­‐head”	  disulfide	  bonds	  between	  D3	  domains.	  The	  end	  product	  is	  a	  VWF	  multimer	  
that	  is	  stored	  in	  highly	  compact	  tubules	  forming	  the	  Weibel–Palade	  bodies	  (Huang	  et	  
al.,	  2008).	  The	  VWF	  multimers	  present	  in	  the	  storage	  granules	  are	  ready	  for	  release	  
via	  the	  action	  of	  von	  Willebrand	  Factor	  polypeptide	  (VWFpp).	  The	  role	  of	  VWFpp	  is	  
vital	   for	   multimerisation	   and	   intracellular	   storage	   of	   the	   mature	   von	   Willebrand	  
factor	  and	   in	   its	  absence	  VWF	  multimers	  are	  not	   stored	   (Haberichter	  et	  al.,	   2002).	  
The	   different	   functional	   domains	   on	   VWF	   have	   specific	   roles.	   These	   include	   FVIII,	  
bound	  by	  the	  D’	  region	  of	  VWF.	  The	  three	  A-­‐domains	  (A1,	  A2	  and	  A3)	  within	  VWF	  are	  
responsible	   for	   platelet-­‐VWF	   mediated	   adhesion	   to	   the	   exposed	   ECM.	   The	   A1	  
domain	   contains	   the	   binding	   region	   for	   GPIbα	   on	   the	   surface	   of	   the	   platelet,	  
facilitating	   initial	   platelet	   interactions	   with	   exposed	   ECM	   protein.	   The	   A1	   domain	  
also	   has	   binding	   sites	   for	   heparin	   and	   collagen.	   The	   A2	   domain	   is	   a	   target	   for	  
cleavage	   by	   ADAMTS13	   and	   the	   A3	   binds	   to	   collagen	   enabling	   platelet	   integrin	   to	  
interact	   with	   the	   Arg-­‐Gly-­‐Asp	   (RGD)	   of	   the	   C1	   domain	   of	   VWF	   (Mendolicchio	   and	  
Ruggeri,	  2005).	  
	  











Figure	  1.3	  The	  mature	  structure	  of	  VWF.	  (A)	  Image	  showing	  commonly	  used	  domain	  
assignment	   in	   the	   literature,	   the	   mature	   VWF	   (2050	   amino	   acids)	   subunit	   that	  
contains	  recognition	  sites	  for	  FVIII,	  collagen,	  GPIbα,	  ADAMTS13	  and	  integrin	  αIIbβ3.	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1.5 Platelet	  adhesion	  to	  immobilised	  VWF	  under	  arterial	  shear	  conditions	  
VWF	  circulates	  in	  plasma	  and	  upon	  vascular	  damage	  collagen	  fibres	  are	  exposed	  to	  
the	  flowing	  blood.	  VWF	  binds	  to	  this	  exposed	  collagen	  mainly	  via	  VWF’s	  A3	  domain	  
but	   also	   via	   the	  A1	  domain	   (Cruz	  et	   al.,	   1995,	   Lankhof	  et	   al.,	   1996,	  Morales	  et	   al.,	  
2006).	  The	  immobilisation	  of	  VWF	  to	  collagen,	  in	  addition	  to	  shear	  stress	  at	  the	  wall	  
of	   the	   vessel	   causes	   a	   conformational	   change	   in	   the	   structure	   of	   VWF.	   The	   VWF	  
adopts	  its	  open	  elongated	  form,	  exposing	  the	  protected	  A1	  domain	  to	  flowing	  blood	  
(Watson,	   2009,	   Ruggeri	   and	   Mendolicchio,	   2007,	   Ulrichts	   et	   al.,	   2006).	   The	   A1	  
domain	   of	   VWF	   is	   subsequently	   recognised	   by	   the	   platelet	   receptor	   complex	  
glycoprotein	  (GP)	  Ib-­‐IX-­‐V	  (GPIbα).	  This	  interaction	  between	  the	  platelet	  and	  VWF	  has	  
a	   fast	   ‘on-­‐rate’	   association,	  which	   is	   ideal	   for	   platelet	   capture	  under	   arterial	   shear	  
conditions	  (Doggett	  et	  al.,	  2002).	  Circulating	  platelets	  in	  plasma	  are	  tethered	  to	  the	  
VWF	  following	  platelet	  interactions	  with	  the	  exposed	  A1	  domain	  of	  VWF.	  This	  initial	  
GPIbα-­‐A1-­‐VWF	  interaction	  can	  result	  in	  the	  formation	  of	  membrane	  platelet	  tethers	  
(smooth	  cylinders	  of	  lipid	  bilayer)	  that	  are	  influenced	  by	  the	  haemodynamic	  drag	  of	  
RBCs	  (Jackson,	  2007).	  An	  increase	  in	  shear	  rate	  results	  in	  a	  significant	  elongation	  of	  
the	  platelet	  tethers.	  Platelet	  tether	  formations	  are	  unlikely	  to	  play	  a	  significant	  role	  
under	  venous	   shear	  conditions,	  as	   the	  number	  of	  platelet	   tethers	   formed	  at	   lower	  
shear	  conditions	  is	  minor	  compared	  to	  those	  at	  arterial	  shear	  conditions	  (Dopheide	  
et	   al.,	   2002).	   However,	   under	   arterial	   shear	   it	   appears	   that	   platelet	   tethers	   play	   a	  
pivitol	   role	   in	  supporting	  platelet	  matrix	   interactions	  and	  platelet-­‐platelet	  adhesion	  
that	   is	   primarily	   mediated	   through	   GPIbα-­‐A1-­‐VWF	   interactions	   (Reininger	   et	   al.,	  
2006,	   Jackson,	   2007).	   Platelets	   translocate	   (stop	   start	   motion	   of	   the	   platelet)	   as	  
GPIbα-­‐A1-­‐VWF	  bonds	  are	   formed	  and	  broken	  on	  the	  damaged	  endothelial	  surface.	  
Platelet	  engagement	  with	  VWF	  induces	  downstream	  signaling	  events,	  which	  result	  in	  
remodeling	  of	  the	  platelet	  cytoskeleton	  and	  shape	  changes	  from	  disc-­‐shaped	  cells	  to	  
irregular-­‐shaped	   spheres	   (Yuan	   et	   al.,	   1999).	   This	   shape	   change	   is	   optimal	   for	  
platelet	  rolling	  and	  is	  associated	  with	  increased	  platelet	  rolling	  velocities	  (Maxwell	  et	  
al.,	  2006).	  Platelet	  translocation	  eventually	  slows	  the	  platelet,	  allowing	  engagement	  
of	  platelet	  receptors	  with	  a	  slow	  ‘on-­‐rate’	  association	  (such	  as	  GPVI)	  to	  interact	  with	  
collagen.	   The	   result	   is	   signalling	   events	   which	   activate	   the	   platelet	   integrins	   α2β1	  
and	  αIIbβ3.	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Another	  mechanism	  of	  platelet	  integrin	  αIIbβ3	  activation	  was	  recently	  described	  by	  
Zhang	   et	   al.,	   (2014).	   Zhang	   and	   colleagues	   demonstrated	   that	   the	   VWF-­‐A1	  
association	   with	   platelet	   GPIbα	   under	   shear	   stress	   results	   in	   the	   unfolding	   of	   a	  
hitherto-­‐unidentified	  structural	  domain	  between	  the	  macroglycopeptide	  region	  and	  
the	   transmembrane	  helix	   (juxtamembrane	   stalk	   region)	   of	   the	  GPIbα	   subunit.	   This	  
region	   is	   the	  mechano-­‐sensitive	   domain	   (MSD),	   which	   unfolds	   under	   shear	   stress,	  
resulting	   in	   a	   change	   in	   conformation	   of	   the	   neighbouring	   GPIbβ	   and	   GPIX.	   This	  
change	   in	   conformation	   causes	   transmission	   of	   a	   signal	   across	   the	   cell	   that	   can	  
eventually	   result	   in	   activation	   of	   platelet	   integrin	   αIIbβ3.	   The	   activation	   of	   αIIbβ3	  
promotes	   stable	   platelet	   adhesion	   and	   aggregation	   at	   the	   site	   of	   vascular	   damage	  
(Watson,	   2009).	   A	   schematic	   representation	   illustrating	   selective	   adhesion	   of	  


























Figure	  1.4	  Platelet	   interactions	  with	   immobilised	  VWF.	  Circulating	  platelets	  tether	  
to	   immobilised	   VWF	   via	   GPIbα-­‐A1-­‐VWF	   interaction.	   The	   haemodynamic	   forces	   of	  
blood	   flow	   (torque)	   break	   the	   initial	   GPIbα-­‐A1-­‐VWF	   bond	   causing	   the	   platelet	   to	  
move	  into	  a	  rolling	  state.	  New	  bonds	  are	  formed	  and	  broken	  between	  the	  GPIbα-­‐A1-­‐
VWF	   resulting	   in	   the	   stop	   start	   motion	   of	   the	   platelet,	   referred	   to	   as	   platelet	  
translocation.	  Platelet	  translocation	  continues	  until	  αIIbβ3	  is	  activated	  and	  binds	  to	  
the	  RGDS	   sequence	   in	   the	  C1	   carboxyl	   terminal	  domain	  of	  VWF.	  The	   result	   is	   firm	  





























, the second platelet receptor binding to
vWF, is the RGDS sequence located at residues 1744–1747 in
the carboxyl-terminal C1 domain.
 
von Willebrand factor function in thrombogenesis
 
The function of vWF is to promote thrombus formation by
mediating adhesion of platelets to the injured vessel wall and
to one another. There is evidence that vWF in different ana-
tomical locations participates in hemostatic processes. The cir-
culating pool, however, is probably the most important in initi-
ating platelet adhesion, since the distribution of subendothelial
vWF is not homogeneous and the protein lacks in many vessels
where platelet function is needed for hemostasis (15). More-
over, platelet vWF is not released until after activation, and
may not be immediately available at a site of injury to promote
adhesion, although its contribution to later phases of thrombus
formation has been convincingly demonstrated (16). Plasma
vWF is well suited to mediate early adhesion because it binds
rapidly and tightly to collagen (and, possibly, to other matrix
structures such as proteoglycans) whenever blood is exposed
to injured tissues. Differential reconstitution of vWF in body
compartments of pigs with severe von Willebrand disease pro-
vides good support for these concepts (16).
The unique mechanism supporting platelet adhesion to im-
mobilized vWF under high flow conditions has been eluci-
dated (17). The first step of this dynamic process is mediated




 to the vWF A1 domain, an
interaction characterized by a fast association rate that can
tether platelets to exposed thrombogenic surfaces even when





vated. This event is favored by the multimeric nature of vWF,
providing a high local density of active A1 domain sites and re-





 interaction is also characterized by a fast dissociation rate
and cannot provide bonds supporting irreversible adhesion, so
that platelets tethered to the vessel wall in this manner move
constantly in the direction of flow, albeit at a fraction of the
free flow velocity (Fig. 1). During the slow translocation plate-










 can eventually mediate irre-
versible adhesion by binding to the RGDS sequence in the











activation, relevant for initial adhesion, is limited to interac-
tion with immobilized fibrinogen or fibrin, consequently bind-
ing to vWF can only occur after platelet tethering to the sur-




. Moreover, the forward rate of










 appears to be relatively
slow, explaining why this receptor is not sufficient to mediate
initial platelet attachment to the vessel wall under high flow
conditions, even though it is always required for firm adhesion
(17). Thus, vWF is the indispensable adhesive substrate for
thrombus formation in high shear environments because of the
unique biomechanical properties of A1 domain binding to GP
Figure 2. Schematic representation of the dual step mechanism supporting platelet adhesion to immobilized von Willebrand factor. The first 
contact established between platelets and immobilized vWF is mediated by GP Ib￿. Nonactivated ￿IIb￿3 cannot pair with the RGDS sequence in 
vWF (38). The bond between the vWF A1 domain and GP Ib￿ must form rapidly, since platelets can be tethered to a vWF-coated surface re-
gardless of flow conditions (17), and must also have high resistance to tensile stress, since adherent platelets can oppose the drag force created by 
flow even when the resulting wall shear rate is greater than 30,000 s￿1, the highest tested (17). This bond, however, has an intrinsically high disso-
ciation rate, thus a limited half-life, resulting in detachment where tension is greatest, and forward rotational movement (rolling) due to the 
torque imposed by the flowing fluid. New bonds are formed as different regions of the membrane of rolling platelets come in closer contact with 
the surface. Translocation continues until ￿IIb￿3 becomes activated and binds to the RGDS sequence in the vWF C1 carboxyl terminal domain. 
The latter bond must have low dissociation rate and can mediate irreversible adhesion, dependent also on cytoskeletal reorganization. An im-
portant aspect of this mechanism is that, for tethering to be apparent, the surface density of vWF must be sufficiently high to support the forma-
tion of multiple interactions at any given time.
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1.6 Regulation	  of	  the	  VWF-­‐GPIbα	  interaction	  
The	  structural	  and	  biophysical	  basis	  of	   the	   interaction	  between	  VWF-­‐GPIbα	   in	   vivo	  
and	  how	  it	  is	  regulated	  is	  currently	  unclear.	  It	  has	  been	  shown	  that	  the	  D’D3	  amino	  
terminal	  of	  VWF	  can	  play	  a	  protective	  role	  in	  shielding	  the	  A1	  domain	  of	  VWF	  from	  
GPIbα	  when	  VWF	  is	  found	  in	   its	   inactive	  state	  (Madabhushi	  et	  al.,	  2012,	  Ulrichts	  et	  
al.,	  2006).	  Ulrichts	  et	  al.,	  (2006)	  reported	  that	  the	  D’D3	  amino	  terminal	  limits	  the	  A1	  
domain’s	  accessibility	  to	  GPIbα,	  due	  to	  its	  close	  proximity	  to	  the	  A1	  domain	  of	  VWF.	  
Following	  VWF	  immobilisation	  to	  collagen,	  the	  A1	  domain	  of	  VWF	  is	  free	  to	  bind	  to	  
GPIbα.	  Experimental	  evidence	  has	  shown	  the	  cleavage	  of	   the	  D’D3	  amino	   terminal	  
sequence	   of	   VWF	   results	   in	   a	   VWF-­‐GPIbα	   interaction.	   Subsequent	   addition	   of	   an	  
isolated	  D’D3	  fragment	  to	  the	  cleaved	  VWF	  was	  demonstrated	  to	   inhibit	   this	  VWF-­‐
GPIbα	   interaction.	  The	  A2	  domain	  of	  VWF	  can	  also	  shield	  the	  VWF-­‐A1	  from	  GPIbα.	  
Although	   direct	   binding	   of	   A2	   to	   A1	   domain	  within	   full	   length	   VWF	   has	   not	   been	  
demonstrated	  to	  date,	  the	  use	  of	  a	  recombinant	  polypeptide	  against	  the	  A2	  domain	  
was	  shown	  to	  effectively	  block	   the	   interaction	  of	  VWF	  with	  GPIbα	  under	  high	   flow	  
conditions	  (Martin	  et	  al.,	  2007).	  	  
	  
The	   A1A2A3	   tri-­‐domain	   of	   VWF	   has	   a	   protective	   role	   in	   preventing	   spontaneous	  
binding	  of	  GPIbα	  to	  VWF.	  The	  A1A2A3	  tri-­‐domain	  contains	  the	  functional	  regions	  for	  
platelet	  adhesion;	  A1	  interacts	  with	  GPIbα,	  A2	  is	  the	  site	  of	  ADAMTS-­‐13	  cleavage	  and	  
A3	  recognises	  vascular	  collagen.	  The	  tri-­‐domain	  (amino	  acids	  1238-­‐1874)	  fragments	  
of	  VWF	  can	  be	  synthesised	   in	  vitro.	  These	  fragments	  have	  similar	  characteristics	  to	  
full-­‐length	   VWF	   in	   vivo,	   making	   them	   suitable	   for	   studying	   the	   regulatory	  
mechanisms	  of	  VWF	  activation.	  Analysis	  of	  A1A2A3	  tri-­‐domain	  recombinant	  proteins	  
demonstrate	  that	  the	  stability	  of	   the	  VWF-­‐A1	   is	   linked	  to	  the	   interactions	  between	  
the	   A	   domains.	   Termination	   of	   A1A2A3	   association,	   results	   in	   a	   conformational	  
change	   to	   the	   A1	   domain,	   promoting	   platelet	   activation	   and	   thrombus	   formation	  
(Auton	  et	  al.,	  2010).	  Arterial	   shear	   flow	  studies	  with	   fibrinogen	  confirm	   that	   intact	  
tri-­‐domain	  A1A2A3	   inhibits	   the	  ability	  of	  platelets	  to	  bind	  to	  fibrinogen.	  Truncating	  
this	  sequence	  reverses	  the	  above	  process.	  Finally,	  the	  association	  of	  the	  A1A2A3	  tri-­‐
domain	   complex	   has	   an	   auto-­‐inhibitory	   role	   in	   protecting	   the	   A1	   domain	   of	   VWF,	  
thus	  preventing	   spontaneous	  binding	  of	  VWF	   to	   circulating	  platelets	   in	   flow	  under	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normal	  conditions	  in	  the	  absence	  of	  vascular	  damage	  or	  plaque	  rupture	  (Auton	  et	  al.,	  
2012).	  	  
	  
The	  N-­‐terminal	   flanking	   region	   of	   the	   A1	   domain,	   the	   amino	   acid	   sequence	   1238-­‐
1260,	  located	  outside	  the	  disulphide	  loop,	  can	  regulate	  GPIbα	  binding.	  Studies	  using	  
1238	  and	  1261-­‐A1A2A3	  VWF	  fragments,	  show	  that	  deletion	  of	  amino	  acid	  residues	  
1238-­‐1260	  can	  alter	  the	  stability	  of	  the	  A1	  of	  the	  tri-­‐domain	  complex.	  Using	  thermal	  
unfolding	  (e.g.	  applying	  heat	  to	  denature	  proteins),	  it	  has	  been	  shown	  that	  deletion	  
of	   this	   amino	   acid	   sequence	   (1238-­‐1260)	   resulted	   in	   enhanced	   binding	   to	   GPIbα	  
(Auton	   et	   al.,	   2012).	   Nowak	   et	   al.,	   (2012)	   highlighted	   the	   importance	   of	   the	   N-­‐
terminal	   flanking	   region	  by	   examining	   the	   effect	   of	  O-­‐linked	   glycosylation	  of	  VWF,	  
where	   oligosaccharide	   chains	   are	   linked	   via	   the	   hydroxyl	   groups	   of	   Serine	   or	  
Threonine	   residues.	   The	   absence	   of	   O-­‐linked	   glycosylation	   on	   VWF,	   under	   static	  
conditions	  (mediated	  by	  enzymatic	  cleavage),	  allowed	  VWF	  to	  adopt	  a	  more	  tightly-­‐
folded	  conformation	  protecting	   the	  A1	  domain	   from	  GPIbα.	  However,	  under	   shear	  
stress	  it	  was	  found	  that	  removal	  of	  O-­‐linked	  glycosylation	  (which	  occurs	  around	  the	  
1238-­‐1260	   amino	   sequence	   between	   the	   D3	   and	   A1	   domains)	   resulted	   in	   VWF	  
unfolding,	  enhancing	  its	  ability	  to	  bind	  collagen.	  Therefore,	  glycosylation	  affects	  the	  
accessibility	  of	  the	  A1	  domain	  within	  the	  VWF,	  particularly	  between	  the	  D3	  and	  A1	  
regions	   (1238-­‐1260).	   These	   actions	   protect	   the	   A1	   from	   the	   platelet	   GPIbα	   rather	  
than	   having	   a	   direct	   effect	   on	   the	   VWF-­‐A1	   GPIbα	   bond.	   O-­‐linked	   glycosylation	  
enhances	  and	  protects	   the	  stability	  of	   the	  1238-­‐1260	  amino	  acid	  residue	  sequence	  
by	  providing	  rigidity	  to	  the	  amino	  backbone	  and	  preventing	  unwanted	  platelet-­‐VWF	  
interactions	  under	  normal	  circulatory	  conditions	  (Nowak	  et	  al.,	  2012).	  	  
	  
The	   VWF-­‐A1	   N-­‐terminal	   flanking	   region	   (1238-­‐1260)	   regulates	   the	   VWF-­‐GPIbα	  
interaction	  by	   impeding	   the	   interaction	   at	   low	   force,	   but	   providing	   stabilisation	   as	  
force	   increases	   (Ju	  et	  al.,	   2013).	   The	   initial	   interaction	  of	  VWF-­‐GPIbα	  behaves	  as	  a	  
biphasic	  mechanism	  such	  that	  bond	  lifetimes	  are	  initially	  prolonged	  then	  shortened	  
as	   force	   increases	   (Yago	   et	   al.,	   2008).	   Increased	   bond	   lifetimes	   result	   in	   the	   force	  
deceleration	   (catch	   bonds)	   of	   the	   platelet	   and	   decreased	   bond	   lifetimes	   result	   in	  
force	  acceleration	  (slip	  bonds)	  of	  the	  platelet,	  as	  the	  GPIbα	  dissociates	  from	  VWF	  (Ju	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et	   al.,	   2013).	   Catch	   and	   slip	   bonds	   can	   be	   defined	   as	   bond	   lifetimes	   that	   initially	  
increase	  (catch	  bond)	  then	  decrease	  (slip	  bond)	  with	  applied	  force.	  These	  catch	  and	  
slip	  mechanisms	  are	  not	  just	  unique	  to	  platelets,	  and	  have	  been	  shown	  to	  play	  a	  role	  
in	  selectin-­‐ligand	  bonds	  that	  mediate	  rolling	  and	  tethering	  of	  leukocytes	  on	  vascular	  
surfaces	  (Marshall	  et	  al.,	  2003,	  Lou	  et	  al.,	  2006).	  
	  
Kim	  et	  al.,	  (2010)	  examined	  GPIbα	  dissociation	  from	  VWF	  at	  low	  forces	  (10pN)	  using	  
optical	   tweezers	   (OT).	   The	   study	   highlighted	   that	   when	   using	   A1-­‐VWF	   constructs	  	  
(1261-­‐A1)	  at	  low	  forces,	  GPIbα	  could	  flex	  between	  two	  slip	  bond	  states	  known	  as	  a	  
flex	  bond.	  One	  state	   in	   low	  force	  was	  followed	  by	  a	  second	  state	  with	  higher	  force	  
with	   a	   20-­‐fold	   greater	   lifetime.	   OT	   utilises	   infrared	   laser	   light	   to	   manipulate	  
individual	  molecules	  within	  cells	  and	  therefore,	  make	  them	  suitable	  for	  investigating	  
GPIbα-­‐VWF	   interactions	   (Block,	   1992).	   Ju	   et	   al.,	   (2013)	   examined	   how	   GPIbα	  
dissociates	  from	  VWF	  in	  a	  construct	  containing	  the	  N-­‐terminal	  flanking	  region	  (1238-­‐
A1)	   in	  order	  to	  elucidate	   its	  mechanism.	  Firstly,	  using	  a	  bio-­‐membrane	  force	  probe	  
(BFP),	  Ju	  and	  colleagues	  showed	  that	  sequence	  lengths	  of	  VWF	  could	   influence	  the	  
GPIbα	   dissociation	   behaviour	   from	   VWF.	   A	   BFP	   was	   used	   as	   it	   is	   very	   sensitive	  
technique	   for	   measuring	   single	   molecular	   bonds	   (Gourier,	   2008).	   BFPs	   are	   very	  
versatile	   and	   can	   be	   used	   with	   a	   wide	   range	   of	   forces	   (0.1	   pN	   to	   1	   nN).	   This	   is	  
because	   the	   stiffness	   of	   the	   force	   sensor	   allows	   the	   end-­‐user	   to	   set	   the	   force	  
measurements	  at	  will	   (Merkel	  et	  al.,	   1999).	   Ju	  et	  al.,	   (2013)	  used	   the	  BFP	   to	   show	  
that	  full-­‐length	  VWF	  formed	  catch-­‐slip	  bonds,	  1238-­‐A1	  constructs	  formed	  slip-­‐catch-­‐
slip	   and	   1261-­‐A1	   constructs	   formed	   slip	   bonds	   only.	   Ju	   and	   colleagues	   observed	  
when	  using	  low	  forces	  (<	  15	  pN),	  the	  same	  flex	  bond	  in	  the	  1261-­‐A1	  constructs	  which	  
were	  originally	  described	  by	  Kim	  et	  al.,	  (2010).	  Another	  study	  ustilising	  Atomic	  Force	  
Microscopy	  	  (AFM),	  Yago	  et	  al.,	  (2008)	  did	  not	  reach	  similar	  conclusions.	  	  
	  
Ju	  et	  al.,	  (2013)	  using	  flow	  chambers	  coated	  with	  VWF,	  identified	  that	  bond	  lifetimes	  
regulate	   platelet-­‐rolling	   velocities.	   Slower	   rolling	   velocities	   were	   associated	   with	  
longer	  bond	  lifetimes	  and	  vice	  versa.	  Catch	  bonds	  have	  stronger	  bond	  lifetimes	  than	  
slip	   bonds	   and	   this	   suggests	   that	   catch	   bonds	   regulate	   flow-­‐enhanced	   rolling	   on	  
VWF.	  Platelet	  rolling	  velocities	  on	  full-­‐length	  and	  VWF-­‐A1	  constructs	  were	  shown	  to	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be	   governed	   by	   their	   respective	   catch/slip	   bond	   dissociation	   behaviours	   of	   GPIbα	  
from	  VWF	   (Yago	   et	   al.,	   2008,	   Yago	   et	   al.,	   2004,	   Ju	   et	   al.,	   2013).	   Ju	   and	   colleagues	  
demonstrated	   that	   the	  N-­‐terminal	   flanking	   terminal	   region	  present	   in	   the	  1238-­‐A1	  
constructs	   formed	   slip/catch/slip	   bonds	   but	   not	   in	   the	   1261-­‐A1,	   where	   slip	   only	  
bonds	  were	  observed.	  Thus,	   the	  N-­‐terminal	   flanking	  region	  controls	  platelet	   rolling	  
and	  stability	  of	  VWF-­‐GPIbα	  dissociation	  to	   increasing	  force.	  The	  addition	  of	  soluble	  
Q1238-­‐E1260	   (contains	   N-­‐terminal	   flanking	   region)	   could	   successfully	   rescue	   the	  
catch	   bond	   in	   1261-­‐A1	   constructs	   but	   resulted	   in	   a	   reduction	   in	   GPIbα	   binding	  
lifetimes	  with	  VWF	  and	  1238-­‐A1	  constructs.	  	  
1.7 Platelet	  function	  assays	  
There	  are	  a	  number	  of	  platelet	  function	  tests	  available	  for	  clinical	  use.	  While	  these	  
tests	  are	  useful	   there	  are	  several	  major	  drawbacks	  with	  most	  of	   these	   tests,	   these	  
include	  the	  volume	  of	  blood	  used,	  technical	  difficulties,	  the	  fact	  that	  a	  single	  agonist	  
is	  used	  at	  a	  maximal	  concentration	  and	  significantly	  that	  most	  of	  these	  assays	  do	  not	  
assess	  platelet	  function	  in	  a	  manner	  that	  occurs	  in	  the	  arterial	  system.	  	  
	  
Current	   platelet	   function	   tests	   measure	   blood	   clotting	   time	   (PFA-­‐100	   analyser),	  
platelet	  aggregation	  (Light	  Transmission	  Aggregometry,	  Whole	  Blood	  Aggregometry,	  
VerifyNow®,	   Plateletworks™)	   and	   platelet	   adhesion	   (Impact	   Cone	   and	   Plate(let)	  
Analyzer).	  	  
1.7.1 Platelet	  Function	  Analyser	  (PFA-­‐100)	  
The	  Platelet	  Function	  Analyser	  measures	  time-­‐to	  clot-­‐occlusion.	  It	  is	  microprocessor-­‐
controlled	   and	   has	   disposable	   test	   cartridges	   coated	   with	   either	   collagen	   and	  
epinephrine	   (CEPI)	   or	   collagen	   and	   ADP	   (CAPD).	   The	   PFA-­‐100	   uses	   citrated	   whole	  
blood	  that	  is	  aspirated	  through	  the	  device	  under	  high	  shear	  conditions	  (5000	  to	  6000	  
s-­‐1)	   (Harrison	   and	   Lordkipanidze,	   2013).	   Platelets	   interact	   with	   the	   CEPI	   or	   CAPD-­‐
coated	  surface	  which	  results	  in	  adhesion,	  activation	  and	  aggregation	  of	  platelets.	  The	  
time	   taken	   for	   platelets	   to	   occlude	   the	   aperture	   is	  measured	   and	   reported	   as	   the	  
closure	   time	   (CT)	   (Kundu	   et	   al.,	   1995).	   This	   device	   is	   advantageous	   as	   it	   is	   simple,	  
rapid	  and	  does	  not	   require	  specialised	  training	   (Harrison	  and	  Lordkipanidze,	  2013).	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However,	   the	   diagnostic	   potential	   of	   the	   PFA-­‐100	   assay	   is	   limited	   due	   to	   its	  
insensitivity	  in	  detecting	  mild	  platelet	  bleeding	  tendencies	  (Hajdenberg,	  2004).	  
1.7.2 Light	  transmission	  aggregometry	  (LTA)	  
LTA	  measures	  platelet	  aggregation	  in	  platelet-­‐rich	  plasma	  (PRP)	  induced	  by	  agonists	  
such	  as	  ADP,	  arachidonic	  acid,	  epinephrine	  and	  collagen.	  Platelet	  poor	  plasma	  (PPP)	  
is	   used	   to	   calibrate	   the	   system.	   The	   PPP	   represents	   100	   percent	   aggregation.	   The	  
PRP	   prior	   to	   aggregation	   causes	   light	   scattering.	   Upon	   addition	   of	   agonists	   to	   the	  
stirred	  PRP,	  platelets	  become	  activated	  and	  aggregate,	  reducing	  light	  scattering	  and	  
increasing	   the	   light	   transmitted.	   The	   amount	   of	   aggregation	   is	   therefore	   directly	  
proportional	   to	   the	   amount	   of	   transmitted	   light	   (Born,	   1962).	   The	   system	   offers	  
advantages	   in	   terms	   of	   being	   able	   to	   test	   multiple	   agonists.	   However,	   LTA	   has	  
disadvantages	   including	   (i)	   it	   is	   labour	   intensive,	   (ii)	   it	   requires	   expertise,	   (iii)	   large	  
volumes	   of	   blood	   and	   (iv)	   is	   non-­‐physiological.	   The	   diagnostic	   potential	   of	   LTA	   is	  
limited	   and	   is	   relatively	   insensitive	   to	   pre-­‐existing	   aggregates	   or	   early-­‐phase	  
aggregation	  (Harrison	  and	  Lordkipanidze,	  2013,	  Thompson	  et	  al.,	  1986).	  
1.7.3 Whole	  blood	  aggregometry	  (WBA)	  
Improvements	   to	   classical	   LTA	   to	   make	   it	   more	   physiological	   include	   the	   use	   of	  
whole	   blood	   aggregometry	   (WBA),	   which	   was	   first	   described	   in	   the	   early	   1980s	  
(Cardinal	   and	   Flower,	   1980).	   WBA	   uses	   whole	   blood	   rather	   than	   PRP	   to	   assess	  
platelet	   aggregation.	   The	   assay	   measures	   the	   change	   of	   electrical	   impedance	   as	  
opposed	  to	  light	  transmission,	  as	  measured	  by	  LTA.	  Addition	  of	  the	  agonist	  to	  blood	  
causes	   platelet	   sticking	   between	   two	   platinum	   electrodes.	   Over	   time,	   impedance	  
increases	  as	  aggregation	  occurs	  between	  the	  electrodes,	  hence	  correlating	  with	  the	  
degree	  of	  platelet	  aggregation.	  Comparative	  studies	  of	  WBA	  versus	  LTA	  gave	  similar	  
results	  (Nicholson	  et	  al.,	  1998).	  WBA	  eliminates	  the	  centrifugation	  steps	  needed	  for	  
LTA,	  but	  still	  requires	  expertise	  and	  is	  insensitive	  to	  small	  platelet	  aggregates	  (<	  100	  
platelets)	   while	   being	   relatively	   expensive	   (Harrison	   and	   Lordkipanidze,	   2013).	   In	  
recent	   times,	   an	   impedance-­‐based	   multichannel	   platelet	   analyser	   has	   become	  
available	   (Roche	  Multiplate	  device).	  This	  device	  has	  been	  shown	  to	  be	  comparable	  
with	  LTA,	  have	  similar	  intra-­‐individual	  variability	  but	  can	  be	  performed	  more	  rapidly	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(Seyfert	  et	   al.,	   2007).	   The	  Multiplate	  device	   is	  useful	   in	  predicting	   the	   risk	  of	  early	  
drug-­‐eluting	  stent	   thrombosis	   in	   those	  patients	  with	  poor	   responses	   to	  clopidogrel	  
(Sibbing	  et	  al.,	  2009).	  
1.7.4	  VerifyNow®	  	  
The	  VerifyNow®	  is	  a	  point	  of	  care	  test	  that	  measures	  whole	  blood	  aggregation.	  Blood	  
drawn	   in	   sodium	   citrate	   is	   aspirated	   into	   the	   device;	   a	   steel	   ball	  mixes	   lyophilised	  
fibrinogen-­‐coated	  beads	  and	  a	  single	  agonist.	  Platelet	  aggregation	  is	  measured	  via	  a	  
detector	   that	   measures	   transmitted	   light.	   The	   device	   uses	   a	   total	   of	   3	   separate	  
cartridges	   to	   measure	   P2Y12,	   aspirin	   and	   αIIbβ3	   inhibition	   individually.	   The	   P2Y12	  
cartridge	   has	   two	   chambers	   containing	   the	   agonists	   ADP	   and	   TRAP.	   The	   aspirin	  
cartridge	   contains	   arachidonic	   acid	   and	   the	   αIIbβ3	   cartridge	   contains	   TRAP.	   The	  
major	   advantage	   of	   this	   device	   is	   that	   it	   uses	   whole	   blood	   and	   is	   user-­‐friendly.	  
However,	   it	   suffers	   from	   a	   number	   of	   drawbacks	   including	   that	   the	   cartridges	   are	  
expensive,	   can	   only	   measure	   a	   single	   anti-­‐platelet	   drug	   response	   and	   has	   limited	  
sensitivity	  (Harrison,	  2009,	  Bal	  Dit	  Sollier	  et	  al.,	  2010).	  	  	  	  	  
1.7.5	  Plateletworks™	  
Plateletworks™	  is	  another	  point	  of	  care	  test	  that	  that	  uses	  platelet	  count	  to	  measure	  
platelet	   aggregation.	   Whole	   blood	   in	   EDTA	   is	   passed	   through	   an	   aperture,	   which	  
interrupts	   a	   constant	   electrical	   response,	   providing	   an	   electrical	   impulse.	   This	  
electrical	   impulse	   is	   used	   to	   provide	   a	   baseline	   platelet	   count.	   The	   platelets	   are	  
activated	  within	   device	   via	   agonists	   such	   as	   collagen,	   arachidonic	   acid	   or	  ADP	   and	  
platelet	  count	  is	  measured.	  The	  difference	  between	  the	  baseline	  platelet	  count	  and	  
platelet	   count	   after	   addition	   of	   the	   agonist	   is	   used	   to	   determine	   the	   degree	   of	  
platelet	  aggregation	  (Hussein	  et	  al.,	  2013).	  The	  advantages	  of	  this	  device	  include	  that	  
it	  is	  user	  friendly	  and	  it	  has	  a	  low	  sample	  volume	  (2	  mL	  of	  blood	  per	  assay).	  However,	  
the	  assay	  is	  highly	  time	  dependent	  and	  fails	  to	  predict	  adverse	  cardiovascular	  events	  
(Seidel	  et	  al.,	  2011).	  	  
1.7.6	  The	  IMPACT	  [Cone	  and	  Plate(let)	  Analyzer	  (CPA)	  technology]	  
Cone	   and	   platelet	   technology	   examines	   platelet	   adhesion	   to	   extracellular	   matrix	  
(ECM)	  under	  defined	   shear	   conditions	   (venous,	   arterial	   or	   pathological	   shear).	   The	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device	   gives	   two	   result	   outputs	   including	   platelet	   surface	   coverage	   and	   mean	  
aggregate	  size	  (Varon	  et	  al.,	  1997).	  This	  technology	  is	  now	  commercially	  available	  as	  
the	  IMPACT	  platform.	  It	  is	  possible	  to	  perform	  an	  experiment	  in	  130	  μL	  of	  blood.	  The	  
blood	  is	  placed	  in	  polystyrene	  wells	  coated	  with	  ECM.	  An	  arterial	  shear	  rate	  of	  1800	  
s-­‐1	  is	  applied	  for	  2	  minutes.	  Platelet	  adhesion	  is	  assessed,	  once	  washing	  and	  staining	  
of	   the	  plate	  has	  occurred.	  The	  analysis	   is	  performed	  using	   image	  analysis	   software	  
provided	  with	  the	  system.	  The	  system	  has	  been	  shown	  to	  be	  sensitive	  to	  aggregation	  
defects	   in	   patients	   with	   storage	   pool	   disease,	   severe	   von	  Willebrand	   disease	   and	  
epinephrine	  response	  deficiency	  (Shenkman	  et	  al.,	  2008).	  However,	  experience	  with	  
the	   system	   is	   limited	   and	   the	   test	   does	   not	   reliably	   predict	   cardiovascular	   events	  
(Breet	  et	  al.,	  2010).	  
1.7.7	  Summary	  of	  platelet	  function	  testing	  
Platelet	   function	   testing	   has	   the	   potential	   to	   provide	   clinical	   benefit.	   This	   is	  
supported	   in	   the	   literature	  by	   studies	  which	  have	  demonstrated	   that	  high	  platelet	  
reactivity	  as	  measured	  by	  platelet	  function	  assays	  is	  associated	  with	  an	  increased	  risk	  
of	  thrombotic	  events	  (Brar	  et	  al.,	  2011,	  Parodi	  et	  al.,	  2011,	  Bliden	  et	  al.,	  2007).	  The	  
technical	   challenge	   here	   is	   to	   produce	   tests	   that	   can	   effectively	   replicate	   the	   flow	  
and	   shear	   environment	   that	   platelets	   experience	   in	   vivo.	   Currently,	   the	   only	  
clinically-­‐validated	  assay	  of	  platelet	  function	  under	  high	  shear	  conditions	  is	  the	  PFA-­‐
100.	   However,	   this	   assay	   has	   failed	   to	   reliably	   detect	   platelet	   hyperreactivity	   and	  
thus	  identify	  prothrombotic	  states	  (Gorog	  and	  Fuster,	  2013).	  This	  thesis	  will	  discuss	  
the	  optimisation	  and	  clinical	  validation	  of	  a	  physiological	  assay	  of	  platelet	   function	  
under	  arterial	  shear	  conditions.	  
	  
1.8 The	  Dynamic	  Platelet	  Function	  Assay	  (DPFA)	  
Parallel	  plate	  flow	  chambers	  have	  been	  used	  over	  the	  past	  three	  decades	  and	  have	  
become	  indispensible	  research	  tools	  for	  studying	  platelet	  interactions	  with	  vascular	  
matrix	  proteins	  under	  defined	  rheological	  conditions	  (Roest	  et	  al.,	  2011).	  Previously,	  
our	   research	   group	   developed	   a	   flow-­‐based	   assay	   of	   platelet	   function	   using	   novel	  
parallel	  plate	  flow	  chambers	  coated	  with	  purified	  human	  VWF	  and	  custom-­‐designed	  
platelet	   tracking	   software	   (Kent	   et	   al.,	   2010).	   This	   assay	   is	   termed	   the	   “Dynamic	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Platelet	   Function	   Assay	   (DPFA)”	   (described	   in	   detail	   in	   the	   methods	   section	   of	  
Chapter	   2).	   In	   brief,	   blood	   is	   pumped	   through	   custom-­‐made	   parallel	   plate	   flow	  
chambers	  with	  channel	  dimensions	  of	  50	  μm	  height	  2	  mm	  width,	  coated	  with	  VWF	  
under	  arterial	  shear	  (1,500	  s-­‐1).	  Platelet	  interactions	  with	  VWF	  are	  recorded	  using	  an	  
Andor	  camera	  at	  a	  frame	  rate	  of	  30	  frames/second.	  A	  platelet	  tracking	  algorithm	  is	  
then	   used	   to	   accurately	   identify	   individual	   platelets	   in	   each	   frame	   of	   an	   image	  
sequence	   of	   500	   frames	   (corresponding	   to	   the	   first	   16.7	   seconds	   of	   image	  
acquisition).	  The	  platelet	  algorithm	  accurately	   identifies	   individual	  platelets	   in	  each	  
frame	  of	  an	  image	  sequence	  of	  500	  frames	  (corresponding	  to	  the	  first	  16.7	  seconds	  
of	   image	   acquisition).	   The	   software	   using	   an	   Image	   Processing	   Toolkit	   in	   MatLab	  
(MATLAB,	  2011)	  detects	  the	  size	  and	  (x,y)	  centroid	  position	  of	  each	  of	  the	  platelets	  
in	  the	   imaged	  area	  against	  a	  continuously	  changing	  background.	  Platelet	  tracks	  are	  
constructed	  as	  each	  individual	  platelet’s	  movement	  is	  tracked	  from	  one	  frame	  to	  the	  
next.	  A	  weighted	  distance	  matrix	   is	  generated	  between	  the	  platelet	   track’s	  current	  
position	   and	   other	   platelets	   on	   the	   frame	   that	   gives	   preference	   to	   platelet	  
movement	   in	   the	   direction	   of	   flow	   over	   cross-­‐stream	   movement.	   Each	   track	   is	  
extended	  by	  assigning	  the	  original	  platelet	  to	  a	  platelet	  positioned	  in	  the	  next	  frame,	  
using	   a	   set	   of	   rules	   to	   the	   weighted	   distance	   matrix.	   Each	   platelet	   in	   the	   image	  
sequence	  is	  linked	  using	  a	  list	  of	  tracks	  with	  (x,y)	  positions	  and	  area	  (A)	  that	  relate	  to	  
each	   individual	   platelet’s	   movement.	   The	   result	   is	   a	   list	   of	   platelet	   tracks	  
corresponding	   to	   the	   associated	   positions	   over	   time	   for	   each	   platelet	   in	   an	   image	  
sequence.	   Using	   this	   information,	   we	   can	   derive	   multiple	   parameters	   of	   platelet	  
translocation	  behaviour	  (Chapter	  2,	  Table	  2.4).	  	  
	  
There	   are	   some	   advantages	   but	   some	   limitations	   to	   the	   DPFA.	   Advantages	   of	   the	  
DPFA	  include:	  	  
• Use	  of	  whole	  blood,	  thereby	  limiting	  manipulation	  of	  the	  platelets.	  
• Low	  volume	  blood	  requirement	  (<	  100	  μL)	  
• Use	   of	   a	   shear	   environment	   (1500	   s-­‐1),	  mimicking	   conditions	   that	   platelets	  
experience	  in	  vivo	  in	  the	  arterial	  system.	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• Ability	  to	  measure	  multiple	  behaviours	  of	  platelets	  translocating	  on	  VWF	  in	  
real-­‐time.	  
• Evidence	   in	  our	   laboratory	  also	  demonstrates	   that	   the	  assay	   is	   sensitive	   to	  
platelet	   inhibitors	   such	   as	   aspirin	   (manuscript	   in	   preparation),	   clopidogrel	  
(manuscript	  in	  preparation)	  and	  ReoPro	  (Lincoln	  et	  al.,	  2010).	  
	  
Limitations	  of	  the	  DPFA	  include:	  
• Requires	  expertise.	  	  
• Knowledge	  of	  platelet	  function.	  
• Labour	  intensive	  process.	  
• Surface	  only	  contains	   immobilised	  VWF,	   thereby	  neglects	  effects	  of	  platelet	  
receptors	  such	  as	  GPVI.	  	  
	  
1.9 Thesis	  aims	  
The	  aim	  of	  the	  thesis	  is	  to	  validate,	  clinically	  evaluate	  and	  enhance	  the	  DPFA	  
	  
In	  order	  to	  achieve	  this	  aim,	  this	  thesis	  sets	  out	  to:	  	  
	  
• Validate	  and	   improve	  the	  accuracy	  of	  the	  custom-­‐designed	  platelet	  tracking	  
software	  (Chapter	  3).	  
• Determine	  the	  biological	  factors	  that	  can	  influence	  dynamic	  platelet	  adhesion	  
to	  VWF	  (Chapter	  3)	  
• Establish	  a	  normal	  reference	  range	  for	  the	  healthy	  donor	  population	  (Chapter	  
3)	  	  
• Characterise	   platelet	   function	   in	   adults,	   neonates,	   healthy	   pregnancy	   and	  
pregnancy	  with	  utero-­‐placental	  disease	  (Chapter	  4,5	  &	  6).	  	  
• Finally,	   to	   explore	   a	   synthetic	   surface	   that	   has	   the	   ability	   to	   capture	   donor	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2.1	  Reagents	  and	  buffers	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Table	  2.2	  Stock	  solutions	  of	  JNL	  
	  
1.	   JNL	  A,	  JNL	  B,	  JNL	  D	  and	  JNL	  E	  were	  stored	  in	  the	  fridge	  at	  4oC.	  
2.	   Before	  use,	  aliquots	  of	  JNL	  A,	  JNL	  B,	  JNL	  D	  and	  JNL	  E	  were	  taken	  from	  the	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  fridge	  and	  allowed	  to	  come	  to	  room	  temperature	  (RT).	  
3.	   10	  mL	  of	  each	  JNL	  A/B/D	  and	  1	  mL	  of	  JNL	  E	  were	  mixed	  together.	  
4.	   40	  mL	  of	  deionized	  water	  was	  added	  to	  the	  solution	  and	  ACD	  (38mM	  citric	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  acid	  anhydrous,	  75mM	  sodium	  citrate	  tribasic	  dihydrate,	  124mM	  dextrose)	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  was	  used	  to	  pH	  the	  solution	  to	  7.4.	  
6.	   The	  JNL	  solution	  was	  made	  up	  to	  100	  mL	  with	  deionised	  water.	  
	  
	  	  	  
	   Component	   FW	   Amount	   Dilution	   FC	  
JNL	  A	   60mM	  Dextrose	   180.2	   5.4g/500ml	   10X	   6mM	  
	  
JNL	  B	   1.3M	  NaCl	   58.44	   37.99g/500ml	   10X	   130mM	  
	   90mM	  Na	  Bicarb	   84.01	   3.78g/500ml	   10X	   9mM	  
	   100mM	  Na	  Citrate	  
(Tribasic,dehydrate)	  
294.1	   14.7g/500ml	   10X	   10mM	  
	   100mM	  Tris	  base	   121.14	   6.06g/500ml	   10X	   10mM	  
	   30mM	  KCl	   74.56	   1.12g/500ml	   10X	   3mM	  
	  
JNL	  D	   8.1mM	  KH2PO4	  
(monobasic	  anhydrate)	  
136.1	   0.55g/500ml	   10X	   0.81mM	  
	  
JNL	  E	   90mM	  MgCl26H2O	   203.3	   1.83g/100mls	   100X	   0.9mM	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2.2	  Experimental	  equipment	  
Table	  2.3	  List	  of	  experimental	  equipment	  
Experimental	  equipment	  	   Source	  
NEMESYS	   precision	   microfluidic	   syringe	  
pump	  
Cetoni	  GmbH,	  Korbussen,	  Germany	  
Sysmex-­‐KX21N	  haematology	  analyser	   Sysmex	  Corp.,	  Kobe,	  Japan	  
Digital	  EM-­‐CCD	  camera	  (iXON	  EM+)	   Andor	  Technology,	  Belfast,	  Ireland	  
Zeiss	  Axiovert-­‐200	  epi-­‐fluorescence	   Carl	  Zeiss	  Microscopy,	  LLC,	  United	  States	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2.3	  Research	  ethics	  
Ethical	   approval	   for	   all	   studies	   was	   obtained	   from	   the	   Medical	   Research	   Ethics	  
Committees	  of	  the	  Royal	  College	  of	  Surgeons	  in	  Ireland,	  Beaumont	  Hospital,	  Rotunda	  
Hospital	  and	  National	  Maternity	  Hospital,	  Holles	  St.,	  Dublin,	  Ireland	  (Appendix	  A).	  All	  
blood	  samples	  were	  collected	  in	  accordance	  with	  the	  declaration	  of	  Helsinki.	  Written	  
informed	   consent	   was	   obtained	   from	   all	   donors	   prior	   to	   phlebotomy.	   For	   donors	  
under	   the	   age	   of	   18,	   written,	   informed	   consent	   was	   provided	   by	   parents	   or	  
guardians.	  	  
	  
2.4	  Blood	  collection	  
Venous	   blood	   was	   drawn	   from	   the	   antecubital	   vein	   using	   a	   19-­‐gauge	   butterfly	  
needle	   connected	   to	   a	   sterile	   polypropylene	   syringe.	   Blood	  was	   drawn	   into	   3.2	  %	  
(w/v)	   trisodium	   citrate	   anticoagulant	   (1:9	   volume	   of	   citrate	   to	   blood,	   final	   citrate	  
concentration	  of	  0.32	  %).	  Blood	  samples	  were	  kept	  at	  room	  temperature	  with	  gentle	  
rocking	   and	   used	   within	   1	   hour	   of	   phlebotomy.	   Whole	   blood	   cell	   counts	   were	  
recorded	   for	   each	   donor,	   using	   a	   Sysmex-­‐KX21N	   haematology	   analyser	   (Sysmex	  
Corp.,	  Kobe,	  Japan).	  
	  
2.5	  The	  Dynamic	  Platelet	  Function	  Assay	  (DPFA)	  
2.5.1	  Assembly	  of	  parallel	  plate	  flow	  chambers	  	  	  
The	   parallel	   plate	   flow	   chambers	  were	  made	   up	   of	   3	   parts	   and	   assembled	   (Figure	  
2.1).	  Part	  (A)	  consisted	  of	  a	  25	  x	  55	  mm	  polymethylmethacrylate	  (PMMA)	  top	  plate	  
with	   inbuilt	  1/16-­‐inch	  polypropylene	   inlet	  and	  outlet	  attached	  via	  epoxy	  glue.	  Part	  
(B)	  comprised	  of	  a	  pressure	  sensitive	  adhesive	  (PSA)	  layer	  containing	  the	  microfluidic	  
channel	   of	   interest	   that	   is	   50	   μM	   in	   depth,	   2	  mm	   in	  width	   and	   35	  mm	   in	   length.	  










Figure	   2.1	   Parallel	   plate	   flow	   chamber	   layers	   (A)	   PMMA	   top	   layer.	   (B)	   Pressure	  
sensitive	   adhesive	   containing	   the	   microfluidic	   channel.	   (C)	   The	   coverslip.	   The	  
assembled	   flow	   chamber	   has	   channel	   dimensions	   of	   large	   aspect	   ratios	   (50	   μm	   in	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2.5.2	  Preparation	  of	  parallel	  plate	  flow	  chamber	  	  	  
The	   channel	   of	   the	   assembled	   parallel	   plate	   flow	   chamber	   was	   coated	   with	   100	  
μg/mL	   of	   the	   vascular	   protein	   von	   Willebrand	   Factor	   (VWF),	   that	   is	   diluted	   in	  
phosphate	  buffered	   saline	   (PBS)	   buffer	   overnight	   at	   4	   °C	   (Figure	   2.2).	   The	   channel	  
was	  then	  washed	  3	  times	  with	  PBS,	  blocked	  with	  1	  %	  BSA	  in	  PBS	  for	  1	  hour	  at	  room	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Figure	  2.2	  Coated	  channel	  of	  parallel	  plate	  flow	  chamber	  with	  VWF.	  (A)	  Assembled	  
flow	  chamber	   (B)	  Microscope	   image	  of	   the	  channel	  coated	  with	  VWF,	  stained	  with	  
sheep-­‐anti-­‐human	  fluorescein	  isothiocyanate	  (FITC)-­‐labelled	  anti-­‐VWF	  antibody.	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2.5.3	  Labeling	  of	  platelets	  with	  fluorescent	  dye	  	  
Blood	  was	  drawn	  in	  3.2	  %	  trisodium	  citrate	  (10	  %	  v/v).	  200	  μL	  of	  blood	  was	  aliquoted	  
to	  an	  eppendorf.	   1	  µM	  3,3’-­‐dihexyloxacarbocyanine	   iodide	   (DiOC6)	   fluorescent	  dye	  
was	   added	   to	   the	   blood.	   This	   dye	   is	   not	   specific	   to	   platelets	   but	   localises	   to	   the	  
endoplasmic	   reticulum	   and	   mitochondria	   of	   platelets.	   This	   dye	   has	   been	   used	  
previously	   to	   visualise	  platelets	   translocating	  on	  VWF	   (Lincoln	  et	   al.,	   2010,	  Kent	  et	  
al.,	   2010).	   The	   dye	   allowed	   the	   platelets	   to	   be	   visualised	   in	   real-­‐time.	   Blood	   was	  
incubated	  with	  the	  dye	  for	  10	  minutes	  at	  37	  °C	  prior	  to	  perfusion.	  
	  
2.5.4	  Perfusion	  of	  blood	  and	  image	  acquisition	  in	  parallel	  plate	  flow	  chamber	  
The	   parallel	   plate	   flow	   chambers	  were	  mounted	   on	   an	   inverted	  microscope	   (Zeiss	  
Axiovert-­‐200	  epi-­‐flouresence).	  A	  NEMESYS	  syringe	  pump	  was	  used	  to	  draw	  the	  blood	  
across	  the	  surface	  of	  the	  flow	  chamber	  containing	  the	  immobilised	  VWF.	  The	  DPFA	  
requires	  <	  100	  μL	  of	  blood	  per	  flow	  run.	  	  A	  flow	  rate	  (Q)	  of	  75	  μL/min	  was	  used.	  This	  
flow	  rate	  gives	  an	  arterial	  shear	  rate	  (γ)	  of	  1,500	  s-­‐1,	  corresponding	  to	  a	  shear	  stress	  
(τ)	  of	  6	  Pa	   (6	  N/m2)	  at	   the	  wall	  of	   the	  surface	  where	  the	  platelets	   interact.	   Images	  
were	   captured	  using	   a	   vacuum-­‐cooled	   (-­‐80	   °C)	   digital	   EM-­‐CCD	   camera	   (iXON	  EM+,	  
Andor	   Technology,	   Belfast,	   Ireland)	   connected	   to	   MetaMorph	   (version	   7.7,	  
Molecular	  Devices	  Ltd.,	  UK)	   illuminated	  with	  an	  Osram	  103-­‐W	  mercury	   light	  source	  
and	  a	  fluorescein	  isothiocyanate	  (FITC)	  filter	  set	  providing	  excitation	  and	  emission	  at	  
490	  nm	  and	  528	  nm,	  respectively	  (Chroma	  Technology	  Corp,	  Vermont,	  USA).	  A	  total	  
of	  1000	  Images	  were	  acquired	  at	  30	  frames	  per	  second	  using	  a	  63x	  objective	  (512	  x	  
512	   pixel,	   128.768	   x	   128.768	   μm)	   field	   of	   view	   for	   visualisation	   of	   platelet	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Figure	   2.3	   The	   Dynamic	   Platelet	   Function	   Assay	   (DPFA).	   (A)	   Schematic	  
representation	   of	   assay	   system	   with	   mounted	   microfluidic	   parallel-­‐plate	   flow	  
chamber	   illustrating	   blood	   perfusion	   with	   a	   syringe	   pump,	   Zeiss	   Axiovert-­‐200	   epi-­‐
flouresence	   inverted	  microscope	  enclosed	   in	  a	  37	  °C	  chamber	  fitted	  with	  an	  Andor	  
camera	   connected	   to	  PC	  with	  MetaMorph	   software	   for	   image	   capture.	   (B)	  Parallel	  
plate	  flow	  chamber	  containing	  an	  inlet	  (I),	  an	  outlet	  (O)	  and	  50	  μm	  in	  height	  2	  mm	  
width	   channel	   which	   defines	   the	   flow	   path	   (C)	   Microfluidic	   parallel-­‐plate	   flow	  
chamber	   mounted	   in	   the	   stage	   area	   of	   the	   inverted	   microscope.	   (D)	   PC	   with	  








(60 dyn/cm2), corresponding to physi logically rel v nt
arterial shear rates, for 8 min. Whole blood samples were
labeled with 1 μM DiOC6 (Invitrogen, Carlsbad, CA) fluo-
rescent dye, which localizes to the endoplasm c reticulum
and mitochondria of platelets. Flow chambers were mounted
on an epifluorescence inverted microscope (Zeiss Axiovert-
200; Fig. 1a, c). I ages were captured at one frame per
second using a liquid-cooled Quantix-57 CCD camera (Pho-
tometrics, Tucson, AZ) with output processed by
MetaMorph software (version 7.5, Molecular Devices Ltd.,
UK). Illumination was from a mercury lamp and a FITC
filter set (excitation filter S490, emission filter S528; Chro-
ma Technology, Bellows Falls, VT). A ×63 objective lens
was used to record platelet interactions with the collagen
matrix protein (Fig. 1a, d).
Image analysis
Acquired images were analyzed for the surface area covered
by labeled adhered platelets using a previously described
algorithm [13] designed in LabVIEW (National Instru-
ments, Austin, TX), primarily based on the fluorescent
intensity of platelets relative to the background. The algo-
rithm assigns pixels with intensities above a predetermined
threshold a numeric value of 1 and those below it a value of 0.
A percent surface coverage value as a function of time was
calculated over 8 min for each image from the number of pixels
that are occupied normalized to the total number of available
pixels in the image. Rates of aggregate formation at various
surface coverages were calculated as follows:
Rate of aggregate formation ¼ aggregate area %ð Þ $ time sð Þ:
Mean aggregate-covered areas were also calculated for




salt, an antagonist of the P2Y12 receptor, was purchased from
Sigma-Aldrich (M1434) and dissolved in PBS. Cyclooxygen-
ase inhibitor acetylsalicylic acid (ASA) from Tocris Biosci-
ences (4092, UK) was dissolved in 10 % dimethyl sulfoxide
(DMSO) prior to use and added to 1 μMDiOC6 fluorescently
labeled whole blood for a final concentration of 0.01 %
DMSO. Inhibitor incubation times in whole blood were
15 min for 2-MeSAMP (50 μM) and 30 min for ASA
(20 μM) at 37 °C prior to perfusion through the flow chamber.
Blood sample collection and patient population
Blood was obtained from healthy individuals who had not
taken medication within the previous 10 days. Cardiovascular
Fig. 1 Device schematic. a Schematic of assay system with mounted
microfluidic parallel-plate flow chamber illustrating blood perfusion
with a syringe pump, Zeiss epifluoresc nce inverted microscope
enclosed in a 37 °C chamber fitted with a liquid-cooled Quantix-57
CCD camera connected to PC with MetaMorph software for image
capture. b Microfluidic parallel-plate flow chamber with a 6-mm-thick
poly(methyl methacrylate) top plate containing an inlet (I) and outlet
(O); a laser-patterned, double-sided pressure-sensitive adhesive
intermediate layer 50 μm thick×2 mm wide defines the flow path
(FP); and a standard glass microscope coverslip which is the bottom
plate. c Microfluidic parallel-plate flow chamber mounted in the stage
area of the inverted microscope. d Image storage by MetaMorph
s ftwar on a PC computer following c pture using the Quantix-57
CCD camera from whole blood perfused through the microfluidic
parallel-plate flow chamber using a Harvard syringe pump





(60 dyn/cm2), corresponding to physiologically relevant
arterial shear rates, for 8 min. Whole blood samples were
labeled with 1 μM DiOC6 (Invitrogen, Carlsbad, CA) fluo-
rescent dye, whi h localizes to the endoplasmic reticu um
and mitochondria of platelets. Flow chambers were mounted
on an epifluoresce ce inverted microscope (Zeiss Axiovert-
200; Fig. 1a, c). Images were captured at one frame per
second using a liquid-cooled Quantix-57 CCD camera (Pho-
tometrics, Tucson, AZ) with output processed by
MetaMorph software (version 7.5, Molecular Devices Ltd.,
UK). Illumination was from a mercury lamp and a FITC
filter set (excitation filter S490, emission filter S528; Chro-
ma Technology, Bellows Falls, VT). A ×63 objective lens
was used to record platelet interactions with the collagen
matrix protein (Fig. 1a, d).
Image analysis
Acquired images were analyzed for the surface area covered
by labeled adhered platelets using a previously described
algorithm [13] designed in LabVIEW (National Instru-
ments, Austin, TX), prim rily based on the fluorescent
intensi y of platelets relative to the background. The algo-
rithm assigns pix s with intensities ab ve a predetermined
threshold a numeric value of 1 and those below it a value of 0.
A percent surface coverage value as a function of time was
calculated over 8 min for each image from the number of pixels
that are occupied normalized to the total nu ber of available
pixels in the image. Rates of a gregate for ti t ri us
surface coverages w re calculated as fo lo s:
Rate of aggregate formation ¼ a gregate area ð sÞ:
Mean aggregate-covered areas were also calculated for




salt, an antagonist of the P2Y12 receptor, was purchased from
Sigma-Aldrich (M1434) and dissolved in PBS. Cyclooxygen-
ase inhibitor acetylsalicylic acid (ASA) from Tocris Biosci-
ences (4092, UK) was dissolved in 10 % dimethyl sulfoxide
(DMSO) prior to use and added to 1 μMDiOC6 fluorescently
labeled whole blood for a final concentration of 0.01 %
DMSO. Inhibitor incubation times in whole blood were
15 min for 2-MeSAMP (50 μM) a d 30 min f r ASA
(20 μM) at 37 °C prior to perfusion through the flow chamber.
Blood sample collection and patient population
Blood was obtained from healthy individuals who had not
taken medication within the previous 10 days. Cardiovascular
Fig. 1 Device schematic. a Schematic of assay system with mounted
microfluidic parallel-plate flow chamber illustrating blood perfusion
with a syringe pump, Zeiss epifluorescence inverted microscope
enclosed in a 37 °C chamber fitted with a liquid-cooled Quantix-57
CCD camera connected to PC with MetaMorph software for image
capture. b Microfluidic parallel-plate flow chamber with a 6-mm-thick
poly(methyl methacrylate) top plate containing an inlet (I) and outlet
(O); a laser-patterned, double-sided pressure-sensitive adhesive
intermediate layer 50 μm thick×2 mm wide defines the flow path
(FP); and a standard glass microscope coverslip which is the bottom
plate. c Microfluidic parallel-plate flow chamber mounted in the stage
area of the inverted microscope. d Image storage by MetaMorph
software on a PC computer following capture using the Quantix-57
CCD camera from whole blood perfused through the microfluidic
parallel-plate flow chamber using a Harvard syringe pump
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2.5.5	  Platelet	  tracking	  algorithm	  software	  
Platelet	   tracking	   software	   was	   used	   to	   track	   platelet	   movement	   on	   VWF.	   This	  
software	  has	  previously	  been	  described	  Lincoln	  et	  al.,	  (2010)	  and	  Kent	  et	  al.,	  (2010).	  
The	  original	  platelet	  tracking	  software	  used	  a	  probability	  function	  and	  cut-­‐off	  based	  
on	  the	  typical	  movement	  of	  a	  platelet	  on	  a	  clutter-­‐free,	  smooth	  surface.	  That	   is	   to	  
say,	  there	  was	  a	  strong	  preference	  for	  platelet	  movement	   in	  a	  narrow	  angle	   in	  the	  
direction	  of	  the	  flow.	  However,	  this	  approach	  had	  errors	  in	  its	  tracking	  process	  due	  
to	  merging	  and	  separating	  of	  platelet	  groups	  and/or	  movement	  around	  obstructions.	  
The	   main	   source	   of	   mistracking	   related	   to	   platelet	   fragmentation.	   Platelet	  
fragmentation	   occurs	  where	   a	   single	   platelet	   track	   is	   recorded	   as	   a	   set	   of	   smaller	  
tracks.	   Over	   the	   past	   four	   years,	   significant	   enhancements	   to	   this	   software	  
programme	   have	   been	   undertaken	   with	   the	   help	   of	   software	   engineers,	   Martin	  
Somers	  Dublin	  City	  University	   (DCU),	   and	   the	   Irish	  Centre	   for	  High	  End	  Computing	  
(ICHEC,	  Grand	   Canal	   Dock,	   Dublin).	   These	   enhancements	   include	   a	   less	   directional	  
distance	   weighting	   method	   of	   tracking	   that	   allows	   us	   to	   identify	   those	   platelets,	  
which	  are	  part	  of	  a	  platelet	  group	  and	  to	  track	  them	  as	  they	  merge	  and	  split	  from	  the	  
group.	   This	   allows	   for	   construction	   of	   the	   full	   platelet	   track.	   The	   process	   of	   the	  
enhanced	  method	  of	  platelet	  tracking	  is	  described	  in	  the	  sections	  below.	  
	  
2.5.5.1	  Masking	  of	  platelet	  images	  	  
Platelets	  interacting	  with	  VWF	  are	  imaged	  using	  an	  Andor	  camera	  at	  a	  frame	  rate	  of	  
30	  frames	  per	  second.	  A	  total	  of	  1000	  images	  are	  acquired.	  The	  first	  500	  images	  are	  
assessed	   using	   the	   platelet	   tracking	   software.	   The	   platelet	   software	   accurately	  
identifies	   the	  centroid	  positions	  of	   individual	  platelets	   in	  each	   frame	  for	   the	   image	  
sequence	   of	   500	   frames	   (corresponding	   to	   the	   first	   16.7	   seconds	   of	   image	  
acquisition).	  The	  software	  masks	  each	  platelet	  (Figure	  2.4)	  using	  an	  Image	  Processing	  
Toolkit	   in	  MatLab	  which	  detects	   the	   size	  and	   (x,y)	   centroid	  position	  of	  each	  of	   the	  
platelets	   in	  the	  imaged	  area	  against	  a	  continuously	  changing	  background	  (MATLAB,	  
2011,	  Lincoln	  et	  al.,	  2010).	  	  
	  
	  





Figure	  2.4	  Masking	  of	  platelet	  images.	  (A)	  Acquired	  platelet	  images	  (B)	  Masking	  of	  
platelets	  captured	  in	  (A)	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2.5.5.2	  Generation	  of	  platelet	  tracks	  	  
Once	   all	   the	   platelets	   on	   each	   of	   the	   500	   frames	   are	   masked,	   platelet	   tracks	   are	  
constructed.	   The	   platelet	   tracks	   are	   constructed	   as	   each	   individual	   platelet’s	  
movement	  is	  tracked	  from	  one	  frame	  to	  the	  next.	  A	  weighted	  distance	  matrix	  is	  then	  
applied	   between	   the	   platelet	   track’s	   current	   position	   and	   other	   platelets	   on	   the	  
frame	  which	   gives	   preference	   to	   platelet	  movement	   in	   the	   direction	   of	   flow	   over	  
cross-­‐stream	  movement.	  Each	  track	  is	  extended	  by	  assigning	  the	  original	  platelet	  to	  
a	  platelet	  positioned	  in	  the	  next	  frame,	  using	  a	  set	  of	  rules	  to	  the	  weighted	  distance	  
matrix	   (Appendix	   B).	   Each	   platelet	   in	   the	   image	   sequence	   is	   linked	   using	   a	   list	   of	  
tracks	   with	   (x,y)	   positions	   and	   area	   (A)	   that	   relate	   to	   each	   individual	   platelet’s	  
movement.	   The	   result	   is	   a	   list	   of	   platelet	   tracks	   corresponding	   to	   the	   associated	  
positions	  over	  time	  for	  each	  platelet	  in	  an	  image	  sequence	  (Figure	  2.5).	  Once	  all	  the	  
track	   sequences	  have	  been	   constructed	   some	  are	   rejected	  based	  on	   two	   rejection	  
criteria:	  tracks	  less	  than	  10	  frames	  or	  platelet	  areas	  less	  than	  3	  μm2.	  The	  first	  action	  
is	  to	  remove	  fragmented	  tracks	  and	  the	  second	  action	  is	  to	  remove	  tracked	  objects	  
that	  are	  too	  small	  to	  be	  considered	  platelets.	  	  
	  
2.5.5.3	  Measured	  platelet	  behaviors	  	  	  
The	   tracked	   platelet	   movement	   is	   then	   used	   to	   generate	   a	   total	   of	   six	   platelet	  

















Figure	   2.5	   Generation	   of	   platelet	   tracks.	   (A)	   Masked	   platelets	   (B)	   Worm	   plot	   of	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2.5.6	  Statistical	  analysis	  
In	   order	   to	   address	   the	   variability	   of	   the	   assay	   related	   to	   blood	   condition	   and	  
experimental	   error,	   each	   donor's	   blood	   was	   run	   in	   triplicate	   (unless	   otherwise	  
stated)	  through	  the	  DPFA.	  All	   runs	  from	  each	  cohort	  were	  then	  analysed,	  and	  runs	  
outside	   the	   mean	   ±	   2SD	   were	   removed	   before	   each	   donor's	   parameters	   were	  
averaged	  over	  3	  or	   less	  eligible	   runs.	   This	  process	  allows	  us	   to	  detect	   and	   remove	  
any	  extreme	  outliers	  in	  order	  to	  determine	  a	  normal	  reference	  range.	  	  A	  ±	  2SD	  cutoff	  
was	   chosen	  as	   this	   is	   a	   frequently	  used	   in	  determining	   cutoff	   values	   for	  diagnostic	  
tests	   (Singh,	  2006).	   The	  numerical	   analysis	  was	  done	  with	   the	  Prism	  5.0a	   software	  
(GraphPad	  Software,	  Inc.).	  P	  values	  <	  0.05	  were	  considered	  significant.	  All	  graphs	  in	  
this	  thesis	  are	  presented	  as	  mean	  ±	  standard	  error	  of	  the	  mean	  (mean	  ±	  SEM)	  unless	  
otherwise	  stated.	  
	  
2.6	  The	  ideal	  data	  set	  
The	   ideal	   data	   set	   was	   developed	   by	   software	   engineers	   at	   DCU	   and	   ICHEC,	   in	  
conjunction	   with	   the	   RCSI	   research	   group.	   The	   data	   resulting	   from	   this	   validation	  
study	   is	   under	   review	   in	   Transactions	   on	   Image	   Processing	   (Ralph	   et	   al.,	   2015,	  
Appendix	   B).	   The	   ideal	   data	   sets	   contained	   images	   with	   known	   values	   of	   platelet	  
translocation	   behaviour,	   in	   addition	   to	   a	   range	   of	   different	   platelet	   translocation	  
behaviours	  that	  were	  experienced	  experimentally.	  Objects	  (Figure	  2.6)	  similar	  to	  the	  
size	   of	   a	   platelet	  were	   placed	  on	   each	   image	   in	   the	   data	   set.	   Each	   object	   had	   ‘no	  
noise’	  i.e.	  an	  intensity	  of	  one	  and	  a	  background	  of	  zero.	  On	  each	  start	  frame	  (frame	  
1)	   25	   objects	   were	   placed	   randomly	   on	   the	   image	   in	   the	   absence	   of	   overlapping	  
objects.	   Each	   image	   set	   contained	   a	   known	   number	   of	   ideal	   tracks	   (objects)	   that	  
equaled	   the	   final	   number	   of	   objects	   on	   the	   last	   frame	   (frame	   500).	   Objects	   were	  
added	  at	  regular	  intervals	  on	  subsequent	  frames,	  care	  was	  taken	  to	  ensure	  by	  frame	  
500	   that	   the	   expected	  number	  of	   tracks	   had	  been	   achieved.	   For	   sets	  where	   there	  
was	   no	   overlapping	   of	   objects	   a	   perfect	   tracking	   system	  would	   identify	   all	   object	  
tracks	  and	  any	  deviations	  in	  this	  number	  would	  be	  down	  to	  mistracking.	  A	  fraction	  of	  
objects	  were	  assigned	  as	  translocating	  (movement	  greater	  than	  1.5	  times	  the	  radius	  
of	   the	  object).	  Each	  of	   the	  translocating	  objects	  had	   identical	   tracks	   that	  moved	  at	  
100	  pixels	  at	  1	  pixel/frame	  before	  stopping.	  Static	  objects	  had	  no	  movement	  hence	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had	  a	  translocating	  distance	  of	  zero.	  The	  translocating	  objects	  moved	  in	  the	  direction	  
of	  the	  flow	  and	  there	  was	  no	  restriction	  on	  merging	  and	  separating	  events	  of	  objects	  
after	  frame	  1.	  
	  
For	  each	  of	  the	  measured	  platelet	  translocation	  behaviours	  (minus	  unstable	  platelet	  
interactions	   parameter)	   (Table	   2.4),	   the	   values	   were	   fixed:	   final	   object	   count	   (50,	  
100,	  150,	  200,	  250,	  300,	  350,	  400),	  the	  fraction	  of	  static	  platelets	  (10	  %,	  20	  %,	  30	  %)	  
and	  the	  translocating	  speed	  (0.5,	  1.0,	  1.5	  pixels/frame).	  There	  were	  a	  total	  of	  3	  runs	  
per	  experiment.	  
	  
In	   summary,	   a	   novel	   platelet	   tracking	   software	   was	   designed	   and	   verified	   as	  
accurate.	   The	   design	   was	   based	   on	   a	   weighted	   distance	   matrix	   using	   custom-­‐
developed	  idealized	  data	  sets,	  which	  determined	  the	  percentage	  systematic	  error	  for	  
key	  individual	  parameters	  of	  platelet	  translocation	  of	  biological	  relevance	  (discussed	  























Figure	   2.6	   The	   ideal	   data	   set	  with	   objects	  mimicking	   platelet	   size.	  An	   image	  of	  a	  
frame	   generated	   for	   the	   ideal	   data	   set	  with	   the	   centroid	   position	   of	   each	   platelet	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2.7	  Platelet	  glycoprotein	  quantitation	  	  	  	  
The	   levels	   of	   platelet	   glycoproteins	   (GpIIIa,	   GpIb	   and	  GpIa)	  were	   assessed	   using	   a	  
Platelet	  GP	  Screen	  kit	   (BIOCYTEX,	  Marseille,	  France)	  via	   flow	  cytometry,	  using	  a	  BD	  
FACSCanto	   II	   (San	   Jose,	   CA	   95121-­‐1807,	   USA)	   with	   FACSDiva	   software.	   A	   total	  
reaction	  volume	  of	  60	  μL	  consisted	  of	  monoclonal	  antibody	  (CD61,	  CD42b	  or	  CD49b),	  
diluted	  whole	   blood	   (1:4)	   or	   calibrated	   bead	   suspension	   and	   florescent	   stain	   (anti	  
mouse	  IgG	  FITC).	  	  
	  
2.7.1	  Assay	  calibration	  	  
Firstly	  the	  assay	  was	  calibrated	  using	  a	  log	  FSC	  versus	  log	  SSC	  cytogram	  to	  minimise	  
the	   background	   noise	   by	   drawing	   a	   gate	   around	   the	  main	   single	   bead	   population	  
(Figure	   2.7A).	   A	   histogram	   (log	   FL1	   versus	   count)	   was	   generated.	   The	   fluorescent	  
peaks	   corresponded	   to	   different	   platelet	   glycoproteins	   that	   were	   gated	   and	   the	  
mean	   fluorescence	   intensity	   (MFI)	   was	   recorded	   (approximate	   MFI:	   1662	   CD61,	  
10858	   CD42b	   and	   43039	   CD49b)	   (Figure	   2.7B).	   Approximately	   10,000	   beads	   were	  





















Figure	   2.7	   Calibration	   cytogram	   and	   gated	   histogram.	   (A)	   FS	   log	   versus	   SS	   log	  
cytogram.	  P1	  represents	  the	  region	  of	  calibration	  beads	  that	  were	  used	  to	  calibrate	  
the	   assay	   prior	   to	   experimentation.	   (B)	   Gated	   fluorescent	   histogram	  of	   calibration	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2.8.2	  Glycoprotein	  quantification	  
Sample	  analysis	  was	  performed	  by	  generation	  of	  a	  log	  FSC	  versus	  log	  SSC	  cytogram	  
and	   isolating	   the	   platelets	   from	   other	   whole	   blood	   cells.	   Each	   sample	   was	   run	  
analysing	   approximately	   10,000	   events	   and	   the	   MFI	   of	   each	   peak	   were	   recorded	  
































Figure	  2.8	  Histograms	  of	  platelet	  quantitation.	  (A)	  Whole	  blood	  cytogram	  with	  the	  
platelets	   gated	   in	   red	   for	   analysis.	   (B)	   Quantification	   of	   GpIIIa	   number.	   (C)	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2.8.3	  Sample	  analysis	  
The	  number	  of	  platelet	  glycoproteins	  GpIIIa,	  GpIb	  and	  GpIa	  were	  determined	  using	  a	  
calibration	   curve	   by	   plotting	   the	   LOG10	   of	   the	   MFI	   calibration	   values	   for	   the	   3	  
calibration	   beads	   on	   the	   x-­‐axis	   against	   their	   corresponding	   LOG10	   number	   of	  
monoclonal	  antibody	  molecules	  on	   the	  y-­‐axis.	  A	   linear	   line	  was	  drawn	  through	  the	  
points	   and	   the	  MFI	   values	   calculated	   for	   each	   of	   the	   sample	   tubes	   were	   used	   to	  
interpolate	   the	  expression	  numbers	  of	  platelet	  glycoproteins	  GpIIIa,	  GpIb	  and	  GpIa	  
from	  the	  calibration	  curve.	  
	  
2.9	  Preparation	  of	  polymer	  surfaces	  
The	   University	   of	   Ulster’s	   Nanotechnology	   and	   Integrated	   Bioengineering	   Centre	  
(NIBEC)	  manufactured	   the	  polymer	   surfaces.	   The	   surfaces	  were	   developed	  using	   a	  
well-­‐known	   polymer	   de-­‐mixing	   technique	   (Dalby	   et	   al.,	   2002).	   Two	   polymers,	  
polystyrene	   (PS)	   and	   polymethylmethacrylate	   (PMMA)	   were	   mixed	   together	   in	   a	  
50:50	  ratio	  at	  concentrations	  of	  1	  %,	  3	  %	  and	  5	  %	  (w/v)	  in	  chloroform.	  The	  polymer	  
mix	  was	  then	  spin	  coated	  at	  6000	  rpm	  for	  60	  seconds	  onto	  glass	  coverslips	  forming	  
different	  sized	  nanostructures	  to	  enable	  capture	  of	  vWF.	  	  
	  
2.9.1	  Analysis	  of	  polymer	  surfaces	  
Blood	  was	  perfused	  over	  the	  polymer	  surfaces	  at	  arterial	  shear	  1500	  s-­‐1	  for	  5	  
minutes.	  An	  end	  point	  image	  was	  taken	  and	  percentage	  platelet	  surface	  coverage	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3.1	  Introduction	  
Platelets	  are	  crucial	  in	  haemostasis	  but	  also	  play	  a	  central	  role	  in	  thrombosis.	  Platelet	  
function	  testing	  offers	  a	  potential	  prognostic	  marker	  in	  predicting	  those	  who	  may	  be	  
of	   increased	  risk	  of	  cardiovascular	  events	  (Tantry	  et	  al.,	  2013).	  This	   is	  supported	  by	  
platelet	   function	   studies	   which	   highlight	   that	   high	   platelet	   reactivity	   during	  
clopidogrel	   treatment	   is	   associated	   with	   an	   increased	   risk	   of	   post-­‐percutaneous	  
coronary	  intervention	  (PCI)	  thrombotic	  events	  (Brar	  et	  al.,	  2011,	  Parodi	  et	  al.,	  2011).	  
Nevertheless	  platelet	  function	  testing	  is	  not	  routinely	  performed	  in	  clinical	  practice.	  
The	  current	  limitations	  of	  platelet	  function	  tests	  include	  insufficient	  standardisation	  
(Harrison	  et	  al.,	  2011),	  a	  lack	  of	  correlation	  between	  tests	  (Sambu	  and	  Curzen,	  2011)	  
and	  most	   importantly,	   the	  desire	   for	   tests	   that	  mimic	  physiological	   conditions	   that	  
platelets	  experience	  in	  vivo	  (Gorog	  and	  Fuster,	  2013).	  
	  
During	  vascular	  damage,	  matrix	  proteins	  such	  as	  collagen	  are	  exposed	  to	  the	  flowing	  
blood	  plasma.	   Von	  Willebrand	   Factor	   (VWF)	   binds	   to	   this	   exposed	   collagen	   and	   in	  
doing	   so,	   undergoes	   a	   conformational	   change	   in	   its	   structure	   which	   facilitates	   its	  
interaction	   with	   circulating	   platelets	   in	   flow	   (Ruggeri	   and	   Mendolicchio,	   2007,	  
Ulrichts	   et	   al.,	   2006).	   Platelets	   tether	   to	   the	   VWF	   and	   platelet	   translocation	  
(stop/start	  motion	  of	  the	  platelet)	  occurs	  as	  weak	  bonds	  between	  the	  VWF	  and	  the	  
platelet	   are	   formed	   and	   broken	   on	   the	   damaged	   endothelial	   surface,	   due	   to	   the	  
dynamic	   forces	   of	   the	   blood.	   This	   process	   results	   in	   intracellular	   signaling	   which	  
activates	  the	  platelet	  and	  results	  in	  stable	  platelet	  adhesion	  to	  the	  damaged	  surface	  
(Savage	  et	  al.,	  1996,	  Zhang	  et	  al.,	  2014).	  	  
	  
Our	   research	   group	   has	   previously	   described	   a	   physiological	   assay	   of	   platelet	  
function	  which	  measures	   the	  movement	  of	   platelets	   on	  VWF	  and	  provides	  unique	  
insights	   into	   the	   behaviour	   of	   platelets	   in	   vivo,	   known	   as	   the	   Dynamic	   Platelet	  
Function	  Assay	   (DPFA)	   (Kent	  et	  al.,	  2010).	   In	  brief,	   the	  DPFA	  uses	  custom-­‐designed	  
parallel	   plate	   flow	   chambers	   coated	   with	   purified	   human	   VWF.	   Whole	   blood	   is	  
perfused	  over	  the	  VWF	  surface	  under	  arterial	  shear	  conditions	  (1500	  s-­‐1).	  An	  Andor	  
camera	   images	   platelets	   as	   they	   interact	  with	  VWF	  while	   a	   novel	   platelet	   tracking	  
software	   is	   used	   to	   monitor	   individual	   platelet	   movement	   on	   VWF.	   Multiple	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parameters	   of	   platelet	   translocation	   behaviour	   are	   derived	   and	   are	   used	   for	   the	  
assessment	  of	  platelet	  function	  in	  our	  cohorts	  of	  interest.	  The	  measured	  parameters	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In	  this	  chapter,	  I	  will	  discuss:	  
	  
• How	  the	  platelet	  tracking	  software	  (Chapter	  2)	  was	  validated.	  	  
• How	   platelet	   count	   and	   haematocrit	   (HCT)	   influence	   platelet	   adhesion	   to	  
VWF	  in	  the	  DPFA.	  
• The	  behaviour	  of	  platelets	  from	  individual	  donors	  assayed	  repeatedly.	  	  
• A	  normal	  reference	  range	  of	  platelet	  function	  for	  the	  assay. 
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3.2	  Results	  
3.2.1	  Validation	  of	  the	  DPFA	  
3.3.1.1	  Validation	  of	  platelet	  tracking	  software	  (use	  of	  an	  ideal	  image	  set)	  
The	   platelet	   tracking	   software	   (Chapter	   2)	  was	   validated	   using	   an	   ideal	   image	   set.	  
The	   data	   resulting	   from	   this	   validation	   study	   has	   been	   submitted	   for	   publication	  
(Ralph	  et	  al.,	  2015,	  under	  review	  in	  Transactions	  on	  Image	  Processing,	  Appendix	  B).	  
The	   ideal	   data	   sets	   contained	   images	   with	   known	   values	   of	   platelet	   translocation	  
behaviour,	   in	  addition	  to	  a	  range	  of	  different	  platelet	  translocation	  behaviours	  that	  
were	  experienced	  experimentally.	  The	  tracking	  software	  processed	  these	  images	  and	  
the	  values	  generated	  were	  compared	  with	  the	  expected	  values.	  There	  were	  a	  total	  
of	   3	   runs	   per	   experiment.	   The	   ideal	   data	   set	   determined	   the	   mean	   absolute	  
percentage	  error	  for	  5	  of	  6	  platelet	  translocation	  behaviours	  explored	  in	  this	  thesis.	  
The	  parameter	  measuring	  unstable	  platelet	  interactions	  with	  VWF	  was	  not	  included,	  
as	   this	   parameter	   was	   derived	   post-­‐submission	   of	   the	   manuscript.	   The	   results	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Table	   3.2	   Mean	   absolute	   percentage	   error	   of	   measured	   platelet	   translocation	  
behaviour	  versus	  object	  count.	  Increasing	  object	  count	  results	  in	  an	  increase	  in	  the	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3.3.1.2	  Validation	  of	  platelet	  tracking	  software	  (use	  of	  a	  P2Y1	  inhibitor)	  
To	   further	   validate	   the	   accuracy	  of	   the	  platelet	   tracking	   software,	   a	   selective	  P2Y1	  
inhibitor	   (MRS2179)	   was	   used	   to	   assess	   its	   effect	   on	   platelet	   translocation	  
behaviour.	   The	   P2Y1	   receptor	   has	   a	   role	   in	   calcium	   mobilization,	   platelet	   shape	  
change	  (Baurand	  et	  al.,	  2001)	  and	  has	  previously	  been	  shown	  to	  significantly	  amplify	  
platelet	   translocation	   speeds	   compared	   with	   non-­‐MRS2179-­‐treated	   controls	  
(Mazzucato	  et	  al.,	  2004).	  Therefore,	  blood	  samples	  from	  healthy	  donors	  (n=7)	  were	  
treated	   with	   or	   without	   20	   μM	   MRS2179.	   A	   significant	   increase	   in	   platelet	  
translocation	  speed	  was	  observed	  in	  donors	  treated	  with	  20	  μM	  MRS2179	  compared	  
to	  non-­‐MRS2179-­‐treated	   controls	   (3.1	  ±	  0.4	  μm/sec	  versus	  2.4	  ±	  0.3	  μm/sec;	  *p	  <	  
0.05)	   (Figure	   3.1).	   This	   demonstrates	   that	   the	   platelet	   algorithm	   is	   sensitive	   in	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Figure	   3.1	   P2Y1	   inhibition	   significantly	   increases	   platelet	   translocation	   speeds	   on	  
VWF.	  Blood	  from	  7	  healthy	  donors	  and	  treated	  with	  20	  μM	  MRS2179	  (P2Y1	  inhibitor)	  
for	  10	  minutes	  prior	  to	  perfusion	  over	  VWF	  at	  arterial	  shear.	  Each	  donor	  had	  a	  total	  
of	  6	  runs	  (3	  MRS2179-­‐treated	  and	  3	  non-­‐treated	  controls).	  Treatment	  of	  blood	  with	  
MRS2179	   significantly	   increased	   platelet	   translocation	   speeds	   on	   VWF.	   A	   paired	  
student’s	   t	   test	   was	   used	   to	   detect	   statistically	   significant	   differences	   between	  
conditions	  (*P	  <	  0.05).	  Data	  is	  represented	  as	  mean	  ±	  SEM.	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3.2.2	  Factors	  influencing	  dynamic	  platelet	  adhesion	  
3.2.2.1	  Platelet	  count	  significantly	  impacts	  on	  platelet	  adhesion	  to	  VWF	  
Thrombocytopenia	   in	   adults	  has	  been	  defined	  as	  platelet	   counts	   <	  150	   x	  103	  μL	  of	  
blood	   (Gauer	   and	   Braun,	   2012).	   To	   assess	   the	   sensitivity	   of	   the	   DPFA	   to	   platelet	  
count,	   blood	   samples	   from	   healthy	   donors	   (n=6)	   with	   platelet	   counts	   within	   the	  
normal	   range	   (150-­‐450	   x	   103	   μL	   of	   blood)	   were	   compared	   with	   the	   same	   blood	  
samples	  diluted	  to	  platelets	  counts	  of	  <	  150	  and	  <	  100	  x	  103	  μL	  of	  blood	  (Table	  3.3).	  
The	  DPFA	  data	  demonstrated	  that	  decreasing	  platelet	  count	  resulted	  in	  a	  significant	  
reduction	   in	   platelet	   interaction	   with	   VWF	   (Figure	   3.2).	   Decreasing	   platelet	   count	  
resulted	   in	  a	  significant	  decrease	   in	  the	  number	  of	  platelet	   tracks	   (273	  ±	  28	  versus	  
171	  ±	  8	  versus	  127	  ±	  7;	  slope	  ***p	  <	  0.0001,	  R2	  =	  0.83)	  and	  translocating	  platelets	  
(208	  ±	  24	  versus	  130	  ±	  5	  versus	  79	  ±	  6;	  slope	  ***p	  <	  0.0001,	  R2	  =	  0.86).	  Notably,	  no	  
significant	   difference	   was	   observed	   in	   weighted	   median	   speed	   (3.4	   ±	   0.6	   μm/sec	  
versus	  2.9	  ±	  0.3	  μm/sec	  versus	  3.9	  ±	  0.7	  μm/sec,	  R2	  =	  0.02)	  or	  in	  the	  number	  of	  static	  
platelets	   (53	  ±	  6	   versus	  45	  ±	  6	   versus	  41	  ±	  7,	  R2	  =	  0.09).	  However,	   the	  number	  of	  
unstable	  platelet	  interactions	  (460	  ±	  18	  versus	  236	  ±	  13	  versus	  173	  ±	  10;	  slope	  ***p	  
<	   0.0001,	   R2	   =	   0.71)	   and	   the	   percentage	   of	   platelet	   surface	   coverage	   (6.7	   ±	   0.3	  %	  
versus	   5.9	   ±	   0.4	   %	   versus	   5.0	   ±	   0.4	   %;	   slope	   ***p	   <	   0.0001,	   R2	   =	   0.43)	   were	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Table	  3.3	  Significant	  reductions	  in	  platelet	  count.	  Platelet	  counts	  were	  significantly	  
reduced	  (***P	  <	  0.0001,	  one-­‐way	  ANOVA)	  per	  experiment	  by	  diluting	  platelet	  counts	  
in	   JNL	   buffer	   and	   reconstituting	   back	   into	   red	   blood	   cells	   (RBCs).	   There	   was	   no	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199 ± 38 115 ± 12 85 ± 7 <0.0001*** 
% Hematocrit 36 ± 2 36 ± 2 35 ± 2 0.5705 

















Figure	  3.2	  Decreasing	  platelet	  count	  significantly	  reduces	  platelet	  interactions	  with	  
VWF.	  Platelets	   isolated	  from	  whole	  blood	  were	  diluted	  in	  JNL	  buffer	  to	  the	  desired	  
platelet	  counts	  and	  reconstituted	  back	  into	  RBCs.	  The	  blood	  was	  then	  perfused	  over	  
VWF	   at	   arterial	   shear.	   Each	   donor	   had	   a	   duplicate	   of	   runs	   for	   each	   condition.	  
Reductions	   in	   platelet	   count	   significantly	   reduced	   platelet	   translocation	   behaviour	  
on	  VWF.	  A	  simple	  linear	  regression	  model	  was	  used	  to	  test	  the	  slopes	  between	  the	  
platelet	  count	  and	  measured	  platelet	  behaviour	   (***p	  <	  0.0001).	  The	  R2	  values	   for	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3.2.2.2	  HCT	  significantly	  impacts	  on	  platelet	  adhesion	  to	  VWF	  
3.2.2.2.1	  RBC	  collisions	  reduce	  the	  time	  taken	  for	  platelets	  to	  pass	  through	  the	  cell-­‐
free	  layer	  (numerical	  simulation)	  
In	  collaboration	  with	  Professor	  Eric	  Shaqfeh	  (Stanford	  University,	  California	  USA),	   it	  
was	  demonstrated	  using	  numerical	  simulation	  models	  of	  platelet-­‐wall	  adhesion,	  that	  
RBCs	  play	  a	  significant	  role	  in	  determining	  initial	  platelet	  adhesion	  (Fitzgibbon	  et	  al.,	  
2014).	   The	   numerical	   simulation	   models	   of	   platelet-­‐wall	   adhesion	   set	   out	   to	  
determine	  whether	  RBC	  collisions	  with	  platelets	  have	  an	  effect	  on	  the	  time	  taken	  for	  
platelets	  to	  cross	  the	  cell-­‐free	  layer	  (CFL).	  The	  CFL	  refers	  to	  the	  Fahraeus–Lindquist	  
layer	  (F-­‐L),	  a	  phenomenon	  whereby	  RBCs	  migrate	  to	  the	  centre	  of	  the	  vessel	  forcing	  
the	   platelets	   to	   the	   vascular	   wall.	   The	   model	   predicted	   that	   the	   time	   taken	   for	  
platelets	  to	  pass	  through	  the	  F-­‐L	  was	  significantly	  lower	  in	  those	  simulations	  where	  
RBCs	   collided	  with	   platelets	   versus	   those	  where	   RBC	  did	   not	   collide	  with	   platelets	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Figure	  3.3	  Platelets	  cross	   the	  CFL	  at	   faster	   rates	   in	   the	  presence	  of	  RBC	  collisions	  
then	  in	  the	  absence	  of	  RBC	  collisions.	  The	  Fahraeus–Lindquist	  layer	  (F-­‐L)	  is	  set	  to	  4.2	  
μm	  in	  width.	  The	  numerical	  simulation	  model	  predicted	  that	   in	  the	  absence	  of	  RBC	  
collisions	  (no	  blood	  fluctuations)	  with	  platelets	  it	  takes	  the	  platelet	  approximately	  37	  
seconds	  to	  cross	  through	  the	  F-­‐L.	  In	  the	  presence	  of	  RBC	  collisions	  (full	  fluctuations)	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3.2.2.2.2	   Reducing	   HCT	   concentrations	   significantly	   reduce	   platelet-­‐VWF	  
interactions	  (The	  DPFA)	  
As	  demonstrated	  in	  Figure	  3.3,	  platelets	  in	  the	  absence	  of	  RBC	  collisions	  take	  longer	  
to	  cross	  the	  CFL	  than	  in	  the	  presence	  of	  RBC	  collisions.	  Using	  the	  DPFA,	  the	  effect	  of	  
reducing	  HCT	   levels	   (which	  will	   reduce	  RBC-­‐platelet	  collisions)	  on	  platelet	  adhesion	  
to	  VWF	  was	  investigated.	  The	  normal	  haematocrit	  ranges	  for	  healthy	  adults	  can	  vary	  
from	   laboratory	   to	   laboratory	   but	   in	   general	   is	   between	   35-­‐50	   %.	   Blood	   samples	  
from	   healthy	   donors	   (n=5)	   the	   percentages	   of	   HCT	   ranging	   from	   39-­‐44	   %	   were	  
compared	  with	  the	  same	  blood	  sample	  diluted	  to	  HCT	  concentrations	  ranging	  from	  
21-­‐25	  %	  and	  12-­‐17	  %	  (Table	  3.4).	  The	  DPFA	  experiments	  showed	  that	  decreasing	  HCT	  
resulted	   in	   a	   steady	   decline	   in	   platelet	   interactions	   with	   VWF	   (Figure	   3.4).	  
Furthermore,	   reducing	   HCT	   resulted	   in	   a	   significant	   decrease	   in	   the	   number	   of	  
platelet	  tracks	  (289	  ±	  48	  versus	  202	  ±	  20	  versus	  92	  ±	  16;	  slope	  ***p	  <	  0.0001,	  R2	  =	  
0.55)	   and	   translocating	   platelets	   (220	   ±	   44	   versus	   141	   ±	   22	   versus	   59	   ±	   12;	   slope	  
***p	  <	  0.001,	  R2	   =	  0.55).	  No	   significance	  was	  observed	   in	  weighted	  median	   speed	  
(3.0	  ±	  0.3	  μm/sec	  versus	  3.0	  ±	  0.6	  μm/sec	  versus	  2.7	  ±	  0.9	  μm/sec,	  R2	  =	  0.02)	  with	  
reducing	   HCT.	   However,	   there	   was	   a	   significant	   decrease	   in	   the	   number	   of	   static	  
platelets	  (66	  ±	  7	  versus	  51	  ±	  6	  versus	  27	  ±	  5;	  slope	  ***p	  <	  0.0001,	  R2	  =	  0.49),	  unstable	  
platelet	  interactions	  (505	  ±	  93	  versus	  320	  ±	  34	  versus	  130	  ±	  22;	  slope	  **p	  <	  0.01,	  R2	  =	  
0.33)	  and	  in	  the	  percentage	  of	  platelet	  surface	  coverage	  (7.2	  ±	  0.6	  %	  versus	  5.7	  ±	  0.1	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Table	   3.4	   Significant	   reductions	   in	   HCT.	   There	   was	   no	   significant	   difference	   in	  
platelet	   count.	   Blood	   HCT	   was	   significantly	   reduced	   (***P	   <	   0.0001,	   one-­‐way	  
ANOVA)	  per	  experiment	  by	  diluting	  HCT	   in	   JNL	  buffer	  and	   reconstituting	  back	   into	  




































190 ± 12 171 ±  38 176 ± 35 0.2599 
% Hematocrit 41 ± 2 24 ± 2 15 ± 2 <0.0001*** 

















Figure	   3.4	   Decreasing	   HCT	   significantly	   reduces	   platelet	   interactions	   with	   VWF.	  
RBCs	   isolated	   from	   whole	   blood	   were	   diluted	   in	   JNL	   buffer	   to	   the	   desired	   HCT	  
concentration	  and	   reconstituted	  back	   into	  PRP.	  The	  blood	  was	   then	  perfused	  over	  
VWF	   at	   arterial	   shear.	   Each	   donor	   had	   a	   duplicate	   of	   runs	   for	   each	   condition.	  
Reductions	   in	  HCT	  significantly	  reduced	  platelet	  translocation	  behaviour	  on	  VWF.	  A	  
simple	   linear	   regression	  model	  was	   used	   to	   test	   the	   slopes	   between	   the	  HCT	   and	  
measured	  platelet	  behaviour	  (**p	  <	  0.01	  and	  ***p	  <	  0.0001).	  The	  R2	  values	  for	  the	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3.2.3	  Repeatability	  of	  the	  DPFA	  
3.2.3.1	   Platelet	   translocation	   behaviour	   on	  VWF	   does	   not	   change	   significantly	   in	  
healthy	  individuals	  over	  time	  
The	  long-­‐term	  repeatability	  of	  the	  DPFA	  was	  assessed	  using	  3	  healthy	  donors,	  testing	  
each	  in	  triplicate	  over	  5	  consecutive	  months.	  No	  significant	  change	  was	  observed	  in	  
platelet	   counts	   or	   HCT	   percentages	   over	   time	   (Table	   3.5).	   Analysis	   of	   DPFA	   data	  
showed	  there	  was	  an	   insignificant	  difference	   in	  platelet	  translocation	  behaviour	  on	  
VWF	   such	   that	   the	   number	   of	   platelet	   tracks,	   translocating	   platelets,	   weighted	  
median	   speed,	   static	   platelets,	   unstable	   platelets	   interactions	   or	   percentages	   of	  
platelet	  surface	  coverage	  were	  not	  significantly	  (p	  >	  0.05)	  altered	  over	  a	  duration	  of	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Table	  3.5	  No	  significant	  change	   in	  platelet	   count	  or	  HCT	  over	   time.	  There	  was	  no	  
significant	   change	   in	   platelet	   count	   or	   HCT	   (P	   >	   0.05,	   one-­‐way	   ANOVA)	   in	   healthy	  

























Condition Month 1 Month 2 Month 3 Month 4 Month 5 P value 
Platelet count 
(x103/µl) 
177 ± 33 201 ± 46 211 ± 38 224 ± 83 220 ± 61 0.8422 
% Hematocrit 40 ± 1 41 ± 4 39 ± 2 40 ± 3 40 ± 2 0.9777 


















Figure	  3.5	  There	  was	  no	  significant	  change	   in	  platelet	   translocation	  behaviour	  on	  
VWF	   in	   healthy	   donors	   over	   time.	  Blood	   from	  healthy	  donors	   (n=3)	  was	  perfused	  
over	  VWF	  at	  arterial	  shear	  over	  5	  consecutive	  months.	  Each	  donor	  had	  a	  triplicate	  of	  
runs.	  No	  significant	  change	  was	  observed	  in	  platelet	  translocation	  behaviour	  over	  5	  
consecutive	   months.	   A	   one-­‐way	   ANOVA	   or	   Kruskal-­‐wallis	   test	   was	   used	   where	  
appropriate	   to	   detect	   statistically	   significant	   differences	   between	   the	   varying	  






































































































































































































	   90	  
3.2.4	  Normal	  reference	  range	  for	  healthy	  donors	  on	  the	  DPFA	  
A	  normal	  reference	  range	  for	  healthy	  donors	  was	  established	  for	  the	  DPFA	  using	  109	  
healthy	  volunteers	  (53	  males	  and	  56	  females).	  The	  donors	  ranged	  in	  age	  from	  19-­‐82	  
years,	  and	  had	  platelet	  counts	  in	  the	  range	  of	  120-­‐403	  x	  103	  per	  μL	  of	  blood	  and	  HCT	  
ranging	   from	   31-­‐46	   %	   (Table	   3.6).	   In	   order	   to	   address	   the	   variability	   of	   the	   DPFA	  
related	  to	  blood	  condition	  and	  experimental	  error,	  each	  donor's	  blood	  was	  assayed	  
in	   triplicate.	   All	   runs	  were	   then	   analysed,	   and	   runs	   outside	   the	  mean	   ±	   2SD	  were	  
removed	  before	  each	  donor's	  parameters	  were	  averaged	  over	  3	  or	  less	  eligible	  runs.	  
This	  process	  allowed	  us	  to	  detect	  and	  remove	  the	  extreme	  outliers	  to	  determine	  a	  
normal	  reference	  range.	  A	  normal	  reference	  range	  was	  then	  established	  for	  each	  of	  
the	   six	   parameters	  measured	   in	   this	   thesis	   (Table	   3.7).	   The	   six	   parameters	   for	   the	  
109	  donors	  recruited	  for	  the	  normal	  reference	  are	  shown	  in	  the	  scatter	  plot	  (Figure	  
3.6).	  The	  normal	  distribution	  for	  these	  donors	  is	  illustrated	  in	  Figure	  3.7.	  The	  effects	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 Characteristics   Healthy donors 
(n=109) 
Age range (years) 19-82  
Number of male 
donors 
53 
Number of female 
donors 
56 
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Table	   3.7	   Reference	   range	   of	   platelet	   function	   for	   healthy	   donors	   on	   the	   DPFA.	  
Table	  shows	  mean	  ±	  SD	  and	  the	  cut-­‐off	  range	  (mean	  ±	  2SD)	  for	  each	  of	  the	  measured	  
platelet	   translocation	   behaviours	   on	   the	   DPFA	   for	   healthy	   donor	   populations.	  




















(mean ± 2SD) 
Platelet tracks 357 ± 114 585 - 129 
Translocating 
platelets 245 ± 85 415 - 75 
Weighted median 
speed (µm/sec) 4.4 ± 1.9 8.2 - 0.6 
Static platelets 84 ± 33 150 - 18 
Unstable platelet 
interactions 99 ± 55 209 - 0 
Percentage of platelet 
surface coverage 7.9 ± 2.4 12.7 - 3.1 
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Figure	   3.6	  Reference	   range	   of	   platelet	   function	   for	   healthy	   donors	   on	   the	  DPFA.	  
Blood	   from	  healthy	  donors	   (n=109)	  was	  perfused	  over	  VWF	  at	  arterial	   shear.	   Each	  
donor	   had	   a	   triplicate	   of	   runs	   and	   normal	   reference	   range	   was	   determined	   for	  
healthy	   donor	   populations.	   Each	   dot	   on	   the	   graph	   represents	   an	   individual	   donor	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Figure	  3.7	  Histogram	  showing	  a	  normal	  distribution	   for	  platelets	   interacting	  with	  
VWF	  in	  healthy	  donors.	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3.2.5	  Correlation	  analysis	  of	  DPFA	  outputs	  
A	  Spearman	  correlation	  analysis	  was	  performed	  to	  determine	  how	  well	  each	  of	  the	  
measured	  parameters	  from	  DPFA	  correlated	  with	  another.	  The	  DPFA	  parameter	  
outputs	  taken	  from	  healthy	  donors	  (n=5)	  were	  analysed	  using	  a	  Spearman	  
correlation.	  It	  was	  determined	  that	  there	  was	  a	  significant	  correlation	  between	  the	  
number	  of	  platelet	  tracks	  and	  the	  number	  of	  platelets	  that	  translocated	  on	  VWF	  (*p	  
<	  0.05).	  No	  significant	  correlations	  were	  found	  between	  any	  of	  the	  other	  measured	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Table	  3.8	  Spearman	  correlation	  analysis	  of	  DPFA	  outputs.	  Ptracks	  =	  Platelet	  tracks,	  
Ptrans	  =	  Platelet	  translocation,	  WMS	  =	  Weighted	  median	  speed,	  Pstatic	  =	  Static	  
platelets,	  Punstable	  =	  Unstable	  platelet	  interactions	  and	  Psurface	  =	  Percentage	  of	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3.3	  Discussion	  	  
In	   this	   chapter,	   an	   ideal	   data	   set	   (described	   in	   Chapter	   2)	   and	   P2Y1	   inhibitor	  
(MRS2179)	   were	   used	   to	   validate	   the	   accuracy	   of	   the	   platelet	   tracking	   software.	  
Firstly,	   the	   software	   was	   validated	   with	   the	   ideal	   data	   set.	   The	   ideal	   data	   set	  
contained	  images	  with	  known	  values	  of	  platelet	  translocation	  behaviour.	  These	  ideal	  
images	   were	   run	   through	   the	   tracking	   software	   and	   the	   values	   generated	   were	  
compared	   with	   the	   expected	   values.	   The	   ideal	   data	   set	   determined	   the	   mean	  
absolute	   percentage	   error	   for	   each	   of	   the	   measured	   platelet	   translocation	  
behaviours.	  The	  number	  of	  merging	  and	  separating	  events	  is	  highly	  correlated	  with	  
object	  count.	  Hence,	  higher	  object	  counts	  result	  in	  greater	  numbers	  of	  merging	  and	  
separating	   events,	   which	   increase	   the	   potential	   for	   mistracking	   of	   platelets.	   The	  
tracking	  software	  marks	  the	  centroid	  position	  of	  each	  platelet	  on	  each	  frame	  and	  it	  
uses	  this	  centroid	  position	  to	  track	  platelet	  movement.	  Hence	  as	  platelets	  merge	  and	  
separate	  from	  one	  another,	  the	  centroid	  position	  of	  the	  platelet	  moves	  too,	  resulting	  
in	   platelet	   mistracking.	   Moreover,	   movement	   of	   the	   centroid	   position	   due	   to	  
merging	  and	  separating	  is	  known	  as	  artificial	  movement	  and	  this	  will	  have	  an	  effect	  
on	   the	   accuracy	   of	   the	   platelet	   tracking	   process.	   Secondly	   to	   validate	   the	   platelet	  
tracking	  process,	  a	  selective	  P2Y1	   inhibitor	   (MRS2179)	  was	  used	  to	  assess	   its	  effect	  
on	  platelet	  translocation	  behaviour.	  Mazzucato	  et	  al.,	  (2004)	  previously	  showed	  that	  
MRS2179	  could	  significantly	  amplify	  platelet	  translocation	  speeds	  on	  VWF	  compared	  
with	  non-­‐MRS2179	   treated	   controls.	   Since	   velocity	   is	   a	  new	  measure	   in	  our	   assay,	  
the	   P2Y1	   receptor	   inhibitor	  was	   chosen	   as	   opposed	   to	   classical	   antiplatelet	   agents	  
such	  as	  aspirin	  or	  experimental	  inhibitors	  such	  as	  thromboxane	  blockers,	  where	  their	  
effects	   on	   platelet	   translocation	   on	  VWF	   is	   not	   known.	  Using	   the	   platelet	   tracking	  
software	  it	  was	  observed	  that	  platelet	  translocation	  velocities	  were	  also	  significantly	  
increased	   upon	   treatment	   with	   MRS2179	   versus	   non-­‐MRS2179	   treated	   controls	  
confirming	  that	  the	  assay	  was	  capable	  of	  detecting	  the	  predicted	  effects	  of	  this	  drug.	  	  
	  
The	   possible	   biological	   factors	   that	   can	   affect	   dynamic	   platelet	   adhesion	   to	   VWF	  
including	   varying	   platelet	   counts	   and	   varying	   HCT	   were	   investigated.	   In	   previous	  
studies,	   it	   has	   been	   shown	   that	   platelet	   function	   tests	   such	   as	   the	   PFA-­‐100	   are	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sensitive	   to	   platelet	   count	   and	   HCT.	   Platelet	   count	   and	   HCT,	   when	   lowered	   to	  
pathological	   values,	   were	   shown	   to	   significantly	   prolong	   closure	   times	   (CT)	   in	   the	  
device,	  e.g.	  the	  time	  taken	  for	  platelets	  to	  occlude	  the	  aperture	  completely	  (Kundu	  
et	  al.,	  1996).	  By	  investigating	  the	  sensitivity	  of	  the	  DPFA	  to	  reduced	  platelet	  count,	  a	  
steady	   decline	   in	   platelet	   translocation	   behaviour	   on	   VWF	   in	   those	   samples	   with	  
lower	   platelet	   counts	   was	   observed.	   Platelet	   interactions	   were	   reduced	   in	   those	  
samples	  with	  lower	  platelet	  counts,	  as	  represented	  by	  the	  significant	  decrease	  in	  the	  
numbers	   of	   platelet	   tracks.	   It	   has	   been	   reported	   that	   following	   surgery	   HCT	   was	  
strongly	   correlated	   with	   bleeding	   times	   rather	   than	   platelet	   count	   and	   that	  
reductions	   in	  RBCs	   resulted	   in	   a	   significant	   increase	   in	  bleeding	   time	   (Valeri	   et	   al.,	  
2001).	  	  
	  
Large-­‐scale	   numerical	   simulations	   of	   blood	   flow	   have	   shown	   that	   platelet	  
margination	  is	  significantly	  influenced	  by	  RBCs,	  such	  that	  the	  RBCs	  drive	  the	  platelets	  
close	  to	  the	  vessel	  wall	  (Zhao	  et	  al.,	  2012).	  In	  this	  thesis,	  using	  numerical	  simulation	  
models	   of	   platelet	   wall	   adhesion,	   it	   was	   demonstrated	   that	   the	   time	   taken	   for	  
platelets	  to	  pass	  through	  the	  CFL	  was	  significantly	  lower	  in	  those	  simulations	  where	  
RBC	   collided	   with	   platelets	   versus	   those	   where	   RBC	   did	   not	   collide	   with	   platelets	  
(Fitzgibbon	  et	  al.,	  2014).	  This	  was	  confirmed	   indirectly	   in	  the	  experiments	   in	  which	  
HCT	  was	  varied	   in	  samples	  run	  on	  the	  DPFA.	  The	  results	  of	   these	  HCT	  experiments	  
demonstrated	  that	  platelet	  translocation	  behaviour	  on	  VWF	  steadily	  declined	  with	  a	  
reduction	   in	   HCT.	   This	   is	   in	   agreement	   with	   a	   study	   by	   Chen	   and	   colleagues	   that	  
observed	   that	   increasing	   or	   decreasing	   the	   levels	   of	   HCT	   could	   positively	   or	  
negatively	   regulate	   the	   adhesion	   of	   platelets	   to	   VWF	   (Chen	   et	   al.,	   2013).	   Previous	  
work	  of	  Aarts	  et	  al.,	  (1983)	  investigating	  platelet	  adherence	  to	  umbilical	  arteries	  also	  
demonstrates	   that	   RBC	   size	   can	   be	   of	   major	   importance	   in	   regulating	   platelet	  
adherence.	  	  
	  
A	   normal	   reference	   range	   of	   platelet	   function	   for	   the	   DPFA	   was	   established.	   The	  
minimum	   number	   of	   participants	   required	   to	   establish	   a	   reference	   interval	   in	   a	  
population	  is	  39	  (Solberg,	  1987).	  A	  total	  of	  109	  healthy	  donors	  were	  assayed	  on	  the	  
DPFA.	   To	   account	   for	   the	   possible	   effect	   of	   gender,	   equal	   numbers	   of	   males	   and	  
	   99	  
females	  were	   recruited	   (M=53	  and	  F=56).	  Generating	  normal	   reference	   ranges	  are	  
important	  as	   they	  can	  be	  used	   to	  potentially	   identify	   those	  donors	  who	  may	  be	  at	  
risk	  of	  bleeding	  or	  thrombosis.	  
	  
To	  conclude,	  in	  this	  chapter	  the	  accuracy	  of	  the	  novel	  platelet	  tracking	  software	  was	  
demonstrated,	   using	   custom-­‐developed	   ideal	   data	   sets	   that	   determine	   the	   mean	  
absolute	   percentage	   error	   for	   each	  measured	   trajectory	   classifier.	   Although	   these	  
errors	   represent	   the	   lower	   limit	   of	   actual	   error	   that	   is	   associated	   with	   real	  
experiments,	  the	  assay	  is	  still	  capable	  of	  detecting	  subtle	  changes	  in	  platelet	  function	  
(explored	  in	  more	  detail	  in	  Chapters	  4,	  5	  and	  6).	  The	  capability	  of	  the	  assay	  to	  detect	  
subtle	   changes	   in	   platelet	   function	   is	   demonstrated	   via	   the	   use	   of	   the	   selective	  
purinergic	  platelet	   inhibitor	  MRS2179,	  which	  shows	  significant	   increases	   in	  platelet	  
translocation	   velocities	   upon	   administration	   (Figure	   3.1).	   The	   DPFA	   is	   sensitive	   to	  
platelet	  count	  and	  HCT	  and	  this	  should	  be	  considered	  when	  comparing	  two	  cohorts	  
to	  one	  another.	  It	  was	  found	  that	  the	  DPFA	  has	  suitable	  repeatability,	  as	  there	  was	  
no	  significant	  change	  in	  platelet	  function	  in	  3	  healthy	  donors	  over	  the	  duration	  of	  5	  
consecutive	  months.	  Thus,	  this	  assay	  has	  the	  potential	  to	  provide	  unique	  insights	  to	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4.1	  Introduction	  
Age	   affects	   most	   cellular	   processes	   but	   the	   effect	   of	   age	   on	   platelet	   function	   is	  
unclear.	  Most	  studies	  to	  date	  have	  used	  non-­‐physiological	  approaches	  such	  as	  light	  
transmission	   aggregometry	   (LTA)	   or	   flow	   cytometry	   to	   investigate	   age-­‐related	  
changes	   in	   platelet	   function	   (Emery	   et	   al.,	   1995,	   Knight	   et	   al.,	   1997,	   Gleerup	   and	  
Winther,	   1995,	   Jayachandran	  et	   al.,	   2005).	   These	   studies	  have	   reported	   that	   aging	  
results	   in	   significant	   increases	   in	   the	   release	   of	   plasma	   β-­‐thromboglobulin	   (βTG),	  
plasma	  platelet	   factor	  4	   (PF4),	  phosphoinositide	   turnover,	  platelet	  aggregation	  and	  
plasma	  fibrinogen	  (Zahavi	  et	  al.,	  1980,	  Bastyr	  et	  al.,	  1990,	  Franchini,	  2006).	  	  
	  
Ideally	  assays	  of	  platelet	   function	  should	  replicate	  the	  flow	  and	  shear	  environment	  
that	   platelets	   experience	   in	   vivo.	   The	   platelet	   function	   analyser,	   the	   PFA-­‐100	  
assesses	   platelet	   function	   under	   high-­‐shear	   conditions.	   The	   device	   measures	   the	  
time	   taken	   for	  platelets	   to	  occlude	  an	  aperture	   that	   is	   coated	  with	  either	   collagen	  
and	  epinephrine	  (CEPI)	  or	  collagen	  and	  ADP	  (CADP).	  The	  results	  of	  the	  PFA-­‐100	  are	  
reported	  as	  closure	   time	   (CT)	   (Kundu	  et	  al.,	  1995).	  A	  number	  of	   studies	  have	  used	  
the	  PFA-­‐100	  to	  assess	  age-­‐related	  changes	  in	  platelet	  function.	  However,	  the	  results	  
of	  these	  studies	  are	  inconsistent.	  For	  example	  Sestito	  and	  colleagues,	  demonstrated	  
an	  absence	  of	  correlation	  between	  age	  and	  platelet	  CT	  (n=62)	  (Sestito	  et	  al.,	  1999).	  A	  
PFA-­‐100	  study	  of	  healthy	  Koreans	  (n=120)	  identified	  that	  older	  Koreans	  (	  >	  40	  years)	  
had	   platelet	   CT’s	   that	   were	   significantly	   shorter	   than	   those	   observed	   in	   younger	  
populations	  (Cho	  et	  al.,	  2007).	  	  
	  
In	  this	  thesis,	  the	  Dynamic	  Platelet	  Function	  Assay	  (DPFA)	  was	  employed	  to	  
comprehensively	  investigate	  the	  effect	  of	  age	  on	  platelet	  function	  in	  over	  100	  
healthy	  donors.	  A	  total	  of	  four	  platelet	  translocation	  behaviours	  on	  VWF	  were	  
measured,	  relating	  to	  the	  different	  stages	  of	  platelet	  interaction	  with	  VWF.	  The	  
number	  of	  platelets	  that	  interact	  with	  VWF	  (platelet	  tracks);	  the	  number	  of	  platelets	  
that	  translocate	  on	  the	  surface	  (platelet	  translocation);	  the	  number	  of	  platelets	  that	  
interact	  but	  do	  not	  adhere	  to	  the	  surface	  (unstable	  platelet	  interactions);	  and	  the	  
	   102	  
percentage	  of	  platelets	  that	  remain	  stuck	  to	  the	  VWF	  surface	  on	  the	  final	  frame	  
(percentage	  of	  platelet	  surface	  coverage)	  were	  assessed.	  	  
	  
In	  this	  chapter,	  I	  will	  discuss	  platelet	  function	  as	  measured	  by	  the	  DPFA:	  
	  
• In	  older	  and	  younger	  healthy	  adult	  populations.	  
• In	  older	  and	  younger	  healthy	  males.	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4.2	  Results	  
4.2.1	  Evaluation	  of	  the	  effects	  of	  aging	  on	  platelet	  function	  in	  the	  DPFA	  
4.2.1.1	  Platelet	  behaviour	  on	  VWF	  differs	  between	  healthy	  older	  and	  younger	  
adults	  
Older	  adults	  were	  defined	  as	  males	  ≥	  50	  years	  and	  females	  ≥	  40	  years	  and	  younger	  
adults	  as	  males	  <	  50	  years	  and	  females	  <	  40	  years.	  These	  age	  cut-­‐offs	  were	  chosen	  
because	  males	  ≥	  50	  have	  a	  higher	  mortality	   rate	   from	  coronary	  heart	  disease	  than	  
younger	  males	  (Jousilahti	  et	  al.,	  1999)	  and	  in	  females	  early	  menopause	  can	  begin	  at	  
40	  years	  and	  is	  associated	  with	  an	  increased	  risk	  for	  cardiovascular	  disease	  (Shuster	  
et	   al.,	   2010).	  A	   total	   of	   109	   subjects	  were	   studied	   (older	   adults	  n=44	  and	  younger	  
adults	  n=65).	  The	  characteristics	  of	  the	  donors	  are	  shown	  in	  table	  4.1.	  The	  inclusion	  
criteria	  were:	  healthy	  volunteers	  with	  no	  previous	  history	  of	  disease	  and	  taking	  no	  
prescribed	  medication.	  	  
	  
Older	  adults	  had	  a	   significant	   reduction	   in	   the	  number	  of	  platelet	   tracks	   (319	  ±	  15	  
versus	  384	  ±	  15;	  **p	  <	  0.01),	  translocating	  platelets	  (222	  ±	  11	  versus	  265	  ±	  11;	  **p	  <	  
0.01)	  and	  numbers	  of	  unstable	  platelet	   interactions	   (69	  ±	  6	  versus	  118	  ±	  8;	  ***p	  <	  
0.0001)	  with	  VWF.	  In	  older	  adults	  there	  was	  a	  significant	  increase	  in	  the	  percentage	  
of	  platelet	   surface	   coverage	   (8.6	  ±	  0.3	  %	  versus	  7.5	  ±	  0.2	  %;	   *p	  <	  0.05)	   compared	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Figure	  4.1	  Platelet	  behaviour	  on	  VWF	  differs	  between	  healthy	  older	  and	  younger	  
adults.	  Blood	  taken	  from	  44	  older	  adults	  and	  65	  younger	  adults	  was	  perfused	  over	  
VWF	   at	   arterial	   shear.	   Platelet	   translocation	   behaviour	   on	   VWF	   was	   measured.	  
Platelets	  from	  older	  donors	  adhered	  more	  to	  VWF	  compared	  to	  younger	  donors	  (*p	  
<	  0.05,	  **p	  <	  0.01	  and	  ***p	  <	  0.0001).	  An	  unpaired	  and	  unpaired	  Welch's	  t-­‐test	  was	  
used	  were	  appropriate	   to	  detect	   statistical	   significance.	  Data	   is	   represented	  as	   the	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4.2.2	  Evaluation	  of	  the	  effects	  of	  gender	  and	  age	  on	  platelet	  function	  in	  the	  DPFA	  	  
Having	  demonstrated	  that	  platelet	  translocation	  behaviour	  was	  significantly	  
different	  between	  older	  and	  younger	  adults,	  the	  effect	  of	  age	  in	  males	  and	  females	  
was	  compared.	  Platelet	  behaviour	  was	  compared	  in	  males	  ≥	  50	  years	  and	  males	  <	  50	  
years	  (n=20	  and	  n=33	  respectively)	  and	  females	  ≥	  40	  years	  and	  females	  <	  40	  years	  
(n=24	  and	  n=32	  respectively).	  	  
	  
4.2.2.1	  Older	  and	  younger	  males	  	  
In	  older	  males	  (≥	  50	  years)	  compared	  with	  males	  <	  50	  years,	  there	  was	  no	  significant	  
difference	  in	  the	  number	  of	  platelet	  tracks	  (308	  ±	  22	  versus	  354	  ±	  21)	  or	  in	  platelet	  
translocation	  (211	  ±	  15	  versus	  236	  ±	  15).	  However,	  males	  ≥	  50	  years	  compared	  with	  
males	  <	  50	  years	  had	  a	  significant	  decrease	  in	  the	  number	  of	  unstable	  platelet	  
interactions	  (81	  ±	  12	  versus	  116	  ±	  11;	  *p	  <	  0.05)	  with	  VWF	  and	  a	  significant	  increase	  
in	  the	  percentage	  of	  platelet	  surface	  coverage	  (8.2	  ±	  0.4	  %	  versus	  7.0	  ±	  0.3	  %;	  *p	  <	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Figure	  4.2	  Platelet	  behaviour	  on	  VWF	  differs	  between	  healthy	  older	  and	  younger	  
males.	  Blood	   taken	   from	  20	  older	  males	  and	  33	  younger	  males	  was	  perfused	  over	  
VWF	   at	   arterial	   shear.	   Platelet	   translocation	   behaviour	   on	   VWF	   was	   measured.	  
Platelets	  from	  older	  males	  adhered	  more	  to	  VWF	  compared	  to	  younger	  males	  (*p	  <	  
0.05).	   An	   unpaired	   and	   unpaired	   Welch's	   t-­‐test	   was	   used	   where	   appropriate	   to	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4.2.2.2	  Older	  and	  younger	  females	  	  
Older	  females	  (≥	  40	  years)	  compared	  with	  younger	  females	  <	  40	  years	  had	  a	  
significant	  reduction	  in	  the	  number	  of	  platelet	  tracks	  (323	  ±	  21	  versus	  426	  ±	  20;	  
**p<0.01),	  platelet	  translocation	  (228	  ±	  16	  versus	  290	  ±	  14	  **p	  <	  0.01)	  and	  number	  
of	  unstable	  platelet	  interactions	  (65	  ±	  6	  versus	  123	  ±	  11;	  ***p	  <	  0.0001).	  There	  was	  
no	  significant	  difference	  in	  the	  percentage	  of	  platelet	  surface	  coverage	  (8.8	  ±	  0.5	  %	  


























	   109	  
	  
Figure	  4.3	  Platelet	  behaviour	  on	  VWF	  differs	  between	  healthy	  older	  and	  younger	  
females.	  Blood	  taken	  from	  24	  older	  females	  and	  32	  younger	  females	  was	  perfused	  
over	  VWF	  at	  arterial	  shear.	  Platelet	  translocation	  behaviour	  on	  VWF	  was	  measured.	  
Platelets	   from	  older	   females	   adhered	  more	   to	  VWF	   compared	   to	   younger	   females	  
(**p	  <	  0.01	  and	  ***p	  <	  0.0001).	  An	  unpaired	  and	  unpaired	  Welch's	  t-­‐test	  was	  used	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4.3	  Discussion	  
The	  results	  of	  this	  chapter	  demonstrates	  that	  age	  has	  a	  significant	  effect	  on	  platelet	  
translocation	  behaviour	  on	  VWF.	  Aging,	  results	  in	  enhanced	  platelet	  adherence	  to	  
VWF	  (increases	  in	  platelet	  surface	  coverage	  and	  decreases	  in	  unstable	  platelet	  
interactions	  with	  VWF)	  with	  this	  effect	  being	  more	  profound	  in	  females	  than	  in	  
males.	  	  
	  
Previous	  studies	  have	  reported	  that	  platelet	  activation	  increases	  with	  age.	  For	  
example,	  Bastyr	  et	  al.,	  (1990)	  demonstrated	  increased	  platelet	  phospholipid	  content,	  
suggesting	  increases	  in	  transmembrane	  signalling	  with	  age.	  It	  has	  also	  been	  shown	  
that	  age	  is	  associated	  with	  an	  increase	  in	  platelet	  aggregability	  (Gleerup	  and	  
Winther,	  1995).	  Reilly	  and	  FitzGerald,	  (1986)	  showed	  that	  bleeding	  times	  were	  
significantly	  reduced	  in	  older	  subjects.	  In	  this	  thesis,	  the	  DPFA	  was	  used	  to	  assess	  
platelet	  function	  in	  real	  time	  and	  to	  characterise	  platelet	  behavior	  in	  a	  cohort	  of	  
normal	  individuals.	  Overall	  the	  results	  were	  consistent	  with	  the	  concept	  that	  age	  was	  
associated	  with	  more	  reactive	  platelets.	  This	  was	  readily	  apparent	  in	  the	  surface	  
coverage	  of	  VWF	  where	  there	  was	  greater	  platelet	  adhesion	  in	  the	  older	  cohort.	  
These	  increases	  in	  platelet	  surface	  coverage	  in	  the	  older	  cohorts	  are	  unlikely	  to	  be	  a	  
result	  of	  increased	  plasma	  levels	  of	  VWF.	  Although,	  plasma	  levels	  of	  VWF	  in	  this	  
study	  were	  not	  measured,	  it	  was	  previously	  demonstrated	  by	  Wu	  and	  co-­‐workers	  
that	  plasma	  levels	  of	  VWF	  have	  no	  significant	  effect	  on	  platelet	  adhesion	  to	  glass	  
surfaces	  coated	  with	  immobilised	  VWF	  (Wu	  et	  al.,	  1996).	  Also,	  the	  DPFA	  measures	  
the	  initial	  interaction	  of	  platelets	  with	  VWF	  (first	  16.7	  seconds),	  therefore	  it	  is	  
unlikely	  that	  increases	  fibrinogen	  levels	  would	  increase	  platelet	  adhesion	  to	  the	  VWF	  
surface	  in	  older	  donors	  because	  the	  assay	  measures	  single	  platelets	  rather	  than	  the	  
formation	  of	  platelet	  aggregates.	  The	  older	  population	  had	  significantly	  less	  platelets	  
interacting	  with	  VWF	  that	  did	  not	  adhere	  to	  the	  surface	  as	  defined	  by	  a	  reduction	  in	  
unstable	  platelet	  interactions	  with	  VWF.	  This	  element	  of	  the	  study	  has	  identified	  that	  
there	  was	  greater	  platelet	  adherence	  in	  the	  older	  population.	  This	  also	  demonstrates	  
the	  advantage	  of	  measuring	  multiple	  parameters	  of	  platelet	  behaviour	  on	  VWF.	  A	  
reduction	  in	  platelet	  interactions	  with	  VWF	  could	  be	  interpreted	  as	  a	  reduction	  in	  
the	  activity	  of	  the	  platelets,	  but	  using	  the	  DPFA’s	  other	  measure	  outputs,	  it	  is	  evident	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that	  there	  are	  less	  platelet’s	  that	  unstably	  adhere	  to	  the	  VWF	  surface	  which	  results	  
in	  a	  significant	  increase	  in	  platelet	  surface	  coverage	  on	  VWF	  in	  older	  individuals.	  
	  
The	   results	   of	   this	   study	   suggest	   that	   the	   effect	   of	   aging	   on	   platelet	   translocation	  
behaviour	   on	   VWF	   was	   more	   pronounced	   in	   females	   than	   in	   males.	   This	   may	   be	  
related	   to	   the	   potential	   influence	   of	   sex	   hormones	   such	   as	   testosterone	   and	  
estrogen.	  Previous	  studies	  of	  platelet	  function	  have	  suggested	  that	  testosterone	  and	  
estrogen	  can	  have	  a	  regulatory	  role	  in	  platelet	  function	  (Tarantino	  et	  al.,	  1994,	  Ajayi	  
et	   al.,	   1995,	   Campelo	   et	   al.,	   2012).	   Testosterone	   has	   been	   shown	   to	   significantly	  
enhance	   platelet	   thromboxane	   A2	   receptor	   density	   and	   heighten	   platelet	  
aggregation	  responses	  to	  arachidonic	  acid	   (Ajayi	  et	  al.,	  1995).	  Platelets	  express	  the	  
estrogen	  receptor	  β	  (Khetawat	  et	  al.,	  2000,	  Nealen	  et	  al.,	  2001)	  and	  deletion	  of	  the	  
estrogen	   receptor	   β	   in	   aged	   female	   mice	   results	   in	   the	   amplification	   in	   the	  
thrombogenicity	  of	  platelets	  (Jayachandran	  et	  al.,	  2010).	  The	  results	  conveyed	  in	  this	  
thesis	  show	  more	  pronounced	  change	  in	  platelet	  translocation	  behaviour	  on	  VWF	  in	  
older	  females	  when	  compared	  to	  that	  of	  older	  males	  and	  this	  may	  be	  reflective	  of	  a	  
reduction	  in	  estrogen	  levels	  experienced	  in	  females	  rather	  than	  the	  gradual	  decline	  
of	   testosterone	   levels	   in	  males	   associated	  with	   aging.	   This	   is	   recommended	   as	   an	  
area	  for	  future	  research.	  In	  this	  thesis,	  no	  significant	  differences	  in	  platelet	  count	  or	  
HCT	   were	   observed	   between	   the	   measured	   groups.	   This	   is	   in	   contrast	   to	   a	  
Scandinavian	  study	  of	  platelet	  counts	  in	  males	  and	  females	  that	  demonstrated	  that	  
females	  have	  greater	  platelet	  counts	  than	  males	  (Bain,	  1985).	  Males	  however,	  have	  
been	   demonstrated	   to	   have	   higher	   HCT	   than	   females	   (Zeng	   et	   al.,	   2001).	   It	   is	  
unknown	   why	   there	   were	   no	   observed	   differences	   in	   platelet	   count	   and	   HCT,	  
between	  males	  and	   females	   in	   this	   thesis.	  However,	   it	  must	  be	  acknowledged	  that	  
measures	  of	   platelet	   count	   and	  HCT	   can	   vary	  widely	   between	   individuals	   and	   that	  
these	   values	   can	   differ	   from	   laboratory	   to	   laboratory.	   In	   this	   thesis,	   males	   had	  
platelet	   counts	   ranging	   from	   121-­‐258	   and	   HCT	   34-­‐45	   %	   (Table	   4.1).	   Females	   had	  
platelet	   counts	   ranging	   from	   120-­‐387	   and	   HCT	   20-­‐46	   %	   (Table	   4.1).	   Significant	  
differences	   between	   genders	   are	   seen	   in	   large	   population	   studies	   and	   while	   this	  
group	   of	   over	   a	   100	   normal	   donors	   is	   large	   it	   is	   not	   large	   enough	   to	   provide	  
differences	  in	  these	  values.	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There	  is	  a	  paucity	  of	  studies	  on	  the	  influence	  of	  age	  on	  platelet	  adhesion	  to	  vascular	  
proteins.	  Significantly	  this	  study	  demonstrates,	  for	  the	  first	  time,	  that	  aging	  has	  a	  
significant	  impact	  on	  platelet	  adhesion	  to	  VWF	  under	  arterial	  shear	  conditions;	  
resulting	  in	  enhanced	  platelet	  adherence	  to	  VWF.	  This	  novel	  DPFA	  with	  its	  multi-­‐
parameter	  analysis	  of	  platelet	  translocation	  behaviour	  on	  VWF	  is	  capable	  of	  
detecting	  subtle	  changes	  in	  platelet	  function.	  These-­‐age	  related	  alterations	  in	  
platelet	  function	  may	  contribute	  to	  the	  increased	  incidence	  of	  thrombotic	  events	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5.1	  Introduction	  
A	  fetus	  has	  platelet	  counts	  within	  the	  normal	  adult	  range	  by	  22	  weeks	  of	  gestation	  
(Sola-­‐Visner,	   2012).	   The	   incidence	   of	   haemorrhage	   in	   preterm	   neonates	   is	   higher	  
than	   that	   of	   full-­‐term	   neonates,	   in	   particular	   intraventricular	   haemorrhage	   (IVH)	  
(Ballabh,	   2010).	   IVH	   is	  multifactorial	   but	   platelet	   dysfunction	   in	   preterm	   neonates	  
may	  be	  a	   contributing	   factor	   to	   these	   increased	   incidences	  of	   bleeding.	  Michelson	  
and	  colleagues	  found	  that	  platelet	  hyporeactivity	  in	  preterms	  neonates	  was	  maximal	  
on	  days	   3	   to	   4	   of	   life,	  which	   coincides	  with	   the	  peak	   in	   IVH	   incidence	   (Michelson,	  
1998).	  This	  finding	  is	  indirectly	  related	  to	  a	  more	  recent	  study	  in	  adults	  that	  showed	  
that	  reduced	  platelet	  activity	  is	  associated	  with	  increased	  incidence	  of	  IVH	  (Naidech	  
et	  al.,	  2009).	  
	  
It	   is	   unclear	   whether	   platelet	   function	   is	   significantly	   different	   between	   very	   low	  
birth	  weight	  (VLBW)	  preterm	  and	  full-­‐term	  neonates	  as	  there	  are	  limited	  studies	  on	  
platelet	  function	  in	  neonates.	  The	  majority	  of	  studies	  have	  been	  conducted	  in	  either	  
cord	   blood	   or	   in	   full-­‐term	   neonates,	   due	   to	   the	   availability	   of	   larger	   circulating	  
volumes	   of	   blood	   (Sola-­‐Visner,	   2012,	   Ferrer-­‐Marin	   et	   al.,	   2013).	   Despite	   having	  
platelet	  counts	  similar	  to	  adults,	  the	  evidence	  suggests	  that	  platelets	  from	  neonates	  
are	   hyporesponsive.	   Platelet	   hyporesponsiveness	   in	   neonates	   has	   been	  
demonstrated	   by	   measuring	   P-­‐selectin	   expression,	   which	   reflects	   alpha	   granule	  
secretion.	   Neonates	   display	   reduced	   expression	   compared	   to	   blood	   samples	   from	  
adults	   (Israels	   et	   al.,	   2003,	   Sitaru	   et	   al.,	   2005,	   Rajasekhar	   et	   al.,	   1997).	   Platelet	  
hyporeactivity	  is	  greater	  in	  those	  VLBW	  preterm	  neonates	  at	  the	  lowest	  gestational	  
ages	   (Sola-­‐Visner,	  2012,	  Ucar	  et	  al.,	  2005,	  Sitaru	  et	  al.,	  2005).	  Notwithstanding	  this	  
observed	   neonatal	   platelet	   hyporeactivity,	   platelet	   function	   analyser,	   PFA-­‐100	  
studies	   on	   neonate	   platelets,	   show	   that	   neonates	   have	   shorter	   closure	   times	   (CT)	  
than	  adults	  (Israels	  et	  al.,	  2001,	  Boudewijns	  et	  al.,	  2003).	  Cone	  and	  plate	  studies	  also	  
demonstrate	  that	  neonates	  have	  improved	  platelet	  adhesion	  to	  extracellular	  matrix	  
(ECM)	   compared	   with	   adults.	   Nevertheless,	   preterm	   neonates	   display	   decreased	  
platelet	   adhesion	  when	   compared	   to	   full-­‐term	  neonates	   (Linder	   et	   al.,	   2002,	   Levy-­‐
Shraga	   et	   al.,	   2006).	   A	   study	   by	   Del	   Vecchio	   et	   al,	   using	   a	   device	   designed	   for	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neonates	   to	   detect	   template	   bleeding	   times	   determined	   that	   preterms	   had	  
prolonged	  bleeding	  times	  compared	  to	  full-­‐term	  neonates	  (Del	  Vecchio	  et	  al.,	  2008).	  
	  
Though	  there	  are	  relatively	   few	  platelet	  studies	   in	  preterm	  neonates,	   the	  evidence	  
suggests	   that	   platelet	   hyporeactivity	   is	   more	   pronounced	   in	   those	   VLBW	   preterm	  
neonates	  at	   the	   lowest	  gestational	  ages	   (those	  ≤	  32	  weeks	  gestation).	   	   In	  addition,	  
platelet	   translocation	  behaviour	  on	  VWF	  under	  arterial	   shear	   conditions	  has	  never	  
been	   characterised	   before	   in	   neonate	   populations.	   Hence,	   the	   DPFA’s	   low	   blood	  
volume	   requirement	   (<	  100	  μL)	  made	   it	   possible	   to	   investigate	   changes	   in	  platelet	  
translocation	  behaviour	  on	  VWF	  in	  neonates.	  Only	  1	  mL	  of	  blood	  was	  required	  from	  
each	  neonate	  per	  experiment.	  
	  
In	  this	  chapter,	  I	  will	  investigate	  platelet	  function	  in	  	  
	  
• Preterm	  and	  full-­‐term	  neonates.	  
• Preterm	  and	  preterm	  neonates	  with	  lower	  platelet	  counts.	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5.2	  Results	  	  
5.2.1	  Study	  populations	  	  	  
A	  total	  of	  26	  preterm	  neonates	  ≤	  32	  weeks	  gestation	  and	  13	  full-­‐term	  neonates	  were	  
recruited	   during	   the	   course	   of	   the	   study.	   The	  mean	   (±	   SD)	   gestational	   age	   of	   the	  
preterm	  and	  full-­‐term	  neonates	  was	  27	  ±	  2	  and	  40	  ±	  1	  weeks	  respectively.	  The	  mean	  
birth	  weight	  was	  1.0	  ±	  0.3	  kg	  and	  3.6	  ±	  0.5	  kg	   for	  preterm	  and	   full-­‐term	  neonates	  
respectively.	  The	  neonatal	  demographics	  are	  shown	  in	  table	  5.1.	  Clinical	  outcomes	  of	  
the	  neonates	  included	  level	  of	  resuscitation	  in	  the	  delivery	  room,	  culture	  proven	  or	  
clinically	   suspected	   sepsis	   treated	   with	   antibiotics	   at	   least	   for	   5	   days,	   duration	   of	  
mechanical	   ventilation,	   respiratory	   distress	   syndrome	   (RDS),	   chronic	   lung	   disease	  
(CLD)	   defined	   as	   supplementation	   of	   oxygen	   needed	   at	   36	  weeks’	   post	  menstrual	  
age	  (Shennan	  et	  al.,	  1988),	  necrotising	  enterocolitis	  (NEC)	  defined	  using	  Bell’s	  staging	  
criteria	   (Walsh	   and	   Kliegman,	   1986),	   	   patent	   ductus	   arteriosus	   (PDA),	   duration	   of	  
parenteral	  nutrition,	  retinopathy	  of	  prematurity	  (ROP),	  intraventricular	  hemorrhage	  
(IVH)	   defined	   by	   Papile’s	   classification	   (Papile	   et	   al.,	   1978),	   periventricular	  
leucomalacia	  (PVL),	  length	  of	  NICU	  stay,	  discharge	  weight	  and	  mortality.	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Table	  5.1	  Preterm	  and	   full-­‐term	  neonatal	   demographics.	  There	  was	  no	  significant	  
reduction	   in	   platelet	   count	   between	   preterm	   and	   full-­‐term	   neonates.	   However,	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5.2.2	  VLBW	  preterms	  display	  significantly	  altered	  platelet	  function	  on	  VWF	  
compared	  to	  full-­‐term	  neonates	  
Platelets	  from	  VLBW	  preterm	  neonates	  (n=15)	  with	  platelet	  counts	  >	  104	  x	  103	  per	  μl	  
of	  blood	  and	  HCT	  41	  ±	  1	  %	  exhibited	  significantly	  different	  platelet	  translocation	  
behaviour	  on	  VWF	  when	  compared	  with	  full-­‐term	  neonates	  (n=13).	  Preterm	  
neonates	  had	  a	  significant	  increase	  in	  platelet	  tracks	  (333	  ±	  29	  versus	  224	  ±	  13;	  **	  p	  
<	  0.01),	  platelet	  translocation	  (230	  ±	  21	  versus	  156	  ±	  7;	  **p	  <	  0.01)	  and	  weighted	  
median	  speed	  (4.2	  ±	  0.3	  μm/sec	  versus	  2.7	  ±	  0.2	  μm/sec;	  **p	  <	  0.01).	  No	  statistically	  
significant	  differences	  were	  seen	  in	  the	  numbers	  of	  static	  platelets	  (78	  ±	  8	  versus	  60	  
±	  7).	  Preterms	  though	  had	  significantly	  increased	  numbers	  of	  unstable	  platelet	  
interactions	  (168	  ±	  22	  versus	  58	  ±	  5;	  ***p	  <	  0.0001)	  with	  VWF	  but	  no	  significant	  
change	  in	  the	  percentage	  of	  platelet	  surface	  coverage	  (6.0	  ±	  0.4	  %	  versus	  5.4	  ±	  0.3	  %)	  
(Figure	  5.1).	  No	  correlations	  were	  found	  with	  the	  clinical	  outcomes	  and	  the	  
behaviour	  of	  platelets	  on	  VWF.	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Figure	   5.1	   Platelets	   from	   VLBW	   preterm	   neonates	   display	   significantly	   altered	  
platelet	  translocation	  behaviour	  on	  VWF.	  Blood	  from	  15	  preterms	  and	  13	  full-­‐term	  
neonates	  was	  perfused	  over	  VWF	  at	  arterial	  shear.	  Platelet	  translocation	  behaviour	  
on	  VWF	  was	  measured.	  Platelets	   from	  preterm	  neonates	  displayed	  altered	  platelet	  
translocation	   behaviour	   on	   VWF	   (*p	   <	   0.05,	   **p	   <	   0.01	   and	   ***p	   <	   0.0001).	   	   An	  
unpaired	   t-­‐test	   and	   unpaired	   t-­‐test	   with	   Welch’s	   correction	   were	   used	   where	  
appropriate	  to	  detect	  statistically	  significant	  differences	  between	  the	  groups.	  Data	  is	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5.2.3	  VLBW	  preterm	  neonates	  increased	  numbers	  of	  GPIb	  on	  the	  surface	  of	  their	  
platelets	  compared	  to	  full-­‐term	  neonates	  
Platelets	  interact	  with	  VWF	  under	  arterial	  shear	  conditions	  via	  their	  GPIbα	  receptors,	  
which	   subsequently	   result	   in	   the	   activation	  of	   the	   integrin	  αIIbβ3	   and	   adhesion	  of	  
the	  platelet	  at	  the	  site	  of	  vascular	  damage	  (Savage	  et	  al.,	  1996,	  Zhang	  et	  al.,	  2014).	  It	  
was	   observed	   using	   the	   DPFA	   that	   preterm	   neonates	   had	   greater	   numbers	   of	  
platelets	   interacting	   but	   not	   adhering	   to	   VWF	   (Figure	   5.1A	   and	   F).	   Therefore,	   in	   a	  
subset	  of	  preterm	  (n=4)	  and	  full-­‐term	  neonates	  (n=6),	  GPIb	  receptor	  count	  (CD42b)	  
and	  GPIIIa	  (CD61)	  were	  measured	  (Figure	  5.2).	  Platelets	  from	  preterm	  neonates	  had	  
a	  significant	  increase	  in	  the	  number	  of	  GPIb	  on	  the	  surface	  of	  their	  platelets	  (48,000	  
±	   3868	   versus	   38,689	   ±	   1724;	   *p	   <	   0.05).	   There	   was	   no	   significance	   difference	   in	  
GPIIIa	   expression	   between	  VLBW	  preterms	   and	   full-­‐term	  neonates	   (52,892	   ±	   3331	  
versus	  53,208	  ±	  4436).	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Figure	  5.2	  VLBW	  preterm	  neonates	  have	  increased	  levels	  of	  GPIb	  on	  their	  platelet	  
surface.	  A	  BIOCYTEX	   platelet	  GP	   screen	   kit	  was	   used	   to	   quantify	   platelet	   receptor	  
counts	   of	   GPIb	   and	   GPIIIa	   in	   blood	   samples	   from	   4	   preterms	   and	   6	   full-­‐term	  
neonates.	  The	  GPIb	  and	  GPIIIa	  were	  quantified	  using	  FITC-­‐labelled	  CD42b	  and	  CD61	  
antibodies	  respectively.	  Preterm	  neonates	  had	  increased	  levels	  of	  GPIb	  (*p	  <	  0.05).	  
An	   unpaired	   t-­‐test	   was	   used	   where	   appropriate	   to	   detect	   statistically	   significant	  
differences	  between	  the	  groups.	  Data	  is	  represented	  as	  mean	  ±	  SEM.	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5.2.4	  VLBW	  preterm	  neonates	  with	  lower	  platelet	  counts	  have	  significantly	  
reduced	  platelet	  interaction	  with	  VWF	  compared	  with	  preterms	  with	  higher	  
platelet	  counts	  
IVH	   is	   a	   multifactorial	   process	   that	   occurs	   in	   preterm	   neonates	   with	  
thrombocytopenia	  but	  repeatedly	  occurs	   in	  preterm	  neonates	  with	  normal	  platelet	  
counts	   too	   (Sola-­‐Visner,	   2012).	   Thrombocytopenia	   is	   a	   common	   manifestation	   in	  
preterm	  neonates	  (Gunnink	  et	  al.,	  2014).	  A	  six-­‐year	  study	  of	  47,291	  neonates	  found	  
that	  neonates	  in	  the	  lower	  reference	  range	  (5th	  percentile;	  ≤	  32	  weeks	  gestation)	  had	  
platelet	   counts	   at	   104	   x	   103	  	  per	   μL	   of	   blood	   (Wiedmeier	   et	   al.,	   2009).	   This	   thesis,	  
using	  the	  DPFA,	  examined	  the	  effect	  of	  platelet	  counts	  <	  104	  x	  103	  	  per	  μL	  of	  blood,	  
on	  platelet	  behaviour	  on	  VWF	  in	  preterm	  neonates.	  Preterm	  neonates	  with	  platelet	  
counts	   <	   104	   x	   103	   per	  μL	   of	   blood	   and	  HCT	  of	   44	   ±	   3	   (n=5)	  were	   compared	  with	  
preterm	  neonates	  with	  platelet	  counts	  >	  104	  x	  103	  per	  μL	  of	  blood	  and	  HCT	  of	  41	  ±	  1	  
(n=15).	  Platelet	  translocation	  behaviour	  was	  drastically	  reduced	  in	  those	  preterms	  at	  
lower	  platelets	  counts	   (<	  104	  x	  103	  per	  μL	  of	  blood).	  Preterm	  neonates	  with	   lower	  
platelet	  counts	  had	  a	  significant	  decrease	  in	  the	  numbers	  of	  platelet	  tracks	  (110	  ±	  24	  
versus	  333	  ±	  29;	  ***p	  <	  0.0001)	  and	  platelet	  translocation	  (71	  ±	  19	  versus	  230	  ±	  21;	  
***p	  <	  0.0001).	  No	  significant	  difference	  was	  found	  in	  weighted	  median	  speed	  (3.5	  ±	  
1.1	  μm/sec	  versus	  4.2	  ±	  0.3	  μm/sec)	   in	   those	  preterms	  with	   lower	  platelet	  counts.	  
However,	   preterm	   neonates	   with	   lower	   platelet	   counts	   displayed	   significantly	  
reduced	  numbers	  of	  static	  platelets	   (31	  ±	  6	  versus	  78	  ±	  8;	  **p	  <	  0.01),	  numbers	  of	  
unstable	  platelet	  interactions	  (57	  ±	  18	  versus	  168	  ±	  22;	  	  *p	  <	  0.05)	  with	  VWF	  and	  a	  
reduction	  in	  the	  percentage	  of	  platelet	  surface	  coverage	  (2.5	  ±	  0.3	  %	  versus	  6.0	  ±	  0.4	  
%;	  ***p	  <	  0.0001)	  (Figure	  5.3).	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Figure	   5.3	   VLBW	  preterm	   neonates	  with	   lower	   platelet	   counts	   have	   significantly	  
reduced	   platelet	   interactions	   with	   VWF.	   Blood	   from	   5	   preterm	   neonates	   with	  
platelet	  counts	  <	  104	  x	  103	  μL	  of	  blood	  and	  15	  preterms	  with	  platelet	  counts	  >	  104	  x	  
103	  μL	  of	  blood	  were	  perfused	  over	  VWF	  at	   arterial	   shear.	   Preterm	  neonates	  with	  
platelet	  counts	  <	  104	  x	  103	  μL	  of	  blood	  displayed	  reduced	  platelet	  interactions	  with	  
VWF	  (*p	  <	  0.05,	  **p	  <	  0.01	  and	  ***p	  <	  0.0001).	  An	  unpaired	  t-­‐test	  and	  unpaired	  t-­‐
test	   with	   Welch’s	   correction	   were	   used	   where	   appropriate	   to	   detect	   statistically	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5.2.5	  Preterm	  neonates	  with	  HCT	  have	  significantly	  reduced	  platelet	  interactions	  
with	  VWF	  compared	  with	  preterms	  with	  higher	  HCT.	  
Anaemia	  is	  common	  in	  preterm	  neonates	  in	  neonatal	  intensive	  care	  for	  a	  number	  of	  
reasons	  including:	  decreasing	  red	  blood	  cell	  production,	  blood	  loss	  and	  increased	  red	  
blood	   cell	   destruction	   (Aher	   et	   al.,	   2008).	   During	   the	   first	   week	   of	   life	   preterm	  
neonates	  with	  anaemia	  (HCT	  <	  28%)	  have	  a	  prolonged	  rate	  of	  bleeding	  (Sola	  et	  al.,	  
2001).	  Therefore	  the	  effect	  of	  HCT	  in	  preterm	  neonates	  was	  assessed	  on	  the	  DPFA.	  
Preterm	   neonates	  were	   identified	  with	   a	   platelet	   count	   of	   177	   ±	   39	   x	   103	   and	   an	  
average	   HCT	   of	   28%	   (n=6)	   and	   these	   were	   compared	   to	   preterms	   with	   a	   platelet	  
count	  of	  164	  ±	  44	  x	  103	  and	  an	  HCT	  averaging	  41%	  (n=15).	  Statistical	  analysis	  of	  the	  
data	   confirmed	   that	   platelets	   from	   preterm	   neonates	   with	   lower	   HCT	   exhibited	  
significantly	   reduced	   platelet	   translocation	   behaviour	   on	   VWF	   when	   compared	  
preterm	   neonates	   with	   higher	   HCT.	   Preterm	   neonates	   with	   lower	   HCT	   had	   a	  
significant	  decrease	  in	  the	  numbers	  of	  platelet	  tracks	  (162	  ±	  25	  versus	  333	  ±	  29;	  **p	  
<	  0.01),	  platelet	   translocation	   (99	  ±	  19	  versus	  230	  ±	  21;	  **p	  <	  0.01)	  and	  weighted	  
median	   speed	   (2.4	   ±	   0.2	   μm/sec	   versus	   4.2	   ±	   0.3	   μm/sec;	   **p	   <	   0.01).	   There	  was	  
trend	   towards	   reduced	  numbers	  of	   static	   platelets	   (52	  ±	  8	   versus	  78	  ±	  8)	   in	   those	  
preterms	  with	  lower	  HCT	  but	  this	  was	  not	  statistically	  significant.	  However,	  preterm	  
neonates	  with	  lower	  HCT	  displayed	  a	  reduction	  in	  the	  numbers	  of	  unstable	  platelet	  
interactions	  (60	  ±	  22	  versus	  168	  ±	  22;	  ***p	  <	  0.0001)	  with	  VWF	  and	  a	  decrease	  in	  the	  
percentage	  of	  platelet	  surface	  coverage	  (3.7	  ±	  0.4	  %	  versus	  6.0	  ±	  0.4	  %;	  **p	  <	  0.01)	  
(Figure	  5.4).	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Figure	   5.4	   Preterm	   neonates	   with	   lower	   HCT	   have	   significantly	   reduced	   platelet	  
interactions	   with	   VWF.	   Blood	   from	   6	   preterm	   neonates	   with	   lower	   HCT	   and	   15	  
preterms	   with	   higher	   HCT	   was	   perfused	   over	   VWF	   at	   arterial	   shear.	   Preterm	  
neonates	  with	  lower	  HCT	  had	  significantly	  reduced	  platelet	  interaction	  with	  VWF	  (*p	  
<	  0.05,	  **p	  <	  0.01	  and	  ***p	  <	  0.0001).	  An	  unpaired	  t-­‐test	  and	  unpaired	  t-­‐test	  with	  
Welch’s	   correction	   were	   used	   where	   appropriate	   to	   detect	   statistically	   significant	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5.3	  Discussion	  	  
Platelet	   function	   in	   neonates	   is	   not	   well	   understood.	   In	   this	   chapter,	   platelet	  
function	  was	   investigated	   in	  VLBW	  preterm	  and	  full-­‐term	  neonates	  using	  the	  DPFA	  
and	  in	  smaller	  subset	  of	  preterm	  and	  full-­‐term	  neonates,	  using	  flow	  cytometry.	  The	  
DPFA	   was	   used	   to	   assess	   platelet	   translocation	   behaviour	   on	   VWF.	   Platelet	  
membrane	  glycoproteins	  GPIb	  (CD42b)	  and	  GPIIIa	  (CD61)	  were	  also	  quantified	  which	  
are	   responsible	   for	   platelet	   adhesion	   to	   VWF	   (Savage	   et	   al.,	   1996).	   The	   major	  
findings	   were	   that:	   (1)	   preterm	   neonates	   have	   significantly	   different	   platelet	  
translocation	   behaviour	   on	   VWF;	   (2)	   preterm	   neonates	   have	   greater	   expression	  
numbers	  of	  GPIb	  receptor	  on	  their	  platelet	  surface;	  (3)	  preterm	  neonates	  with	  lower	  
platelet	  or	  HCT	  display	  reduced	  platelet	  interaction	  with	  VWF.	  
	  
VLBW	  preterms	  are	  at	  a	  higher	  risk	  of	  bleeding	  than	  full-­‐term	  neonates	  (Sola-­‐Visner,	  
2012).	  Platelet	  dysfunction	  may	  contribute	  to	  an	  increased	  incidence	  of	  bleeding	  in	  
this	   group	   (Michelson,	   1998).	   Platelet	   activation	   studies	   have	   confirmed	   that	  
neonates	   are	   hyporesponsive	   to	   agonists	   such	   as	   epinephrine,	   ADP	   and	   thrombin	  
compared	   with	   healthy	   adults	   (Israels	   et	   al.,	   2003).	   The	   evidence	   suggests	   that	  
preterms	   have	   more	   pronounced	   platelet	   hyporesponsiveness	   than	   full-­‐term	  
neonates.	  This	  is	  consistent	  with	  studies	  demonstrating	  that	  preterm	  neonates	  have	  
decreased	   platelet	   adhesion	   and	   prolonged	   bleeding	   times	   compared	   to	   full-­‐term	  
neonates	  (Boudewijns	  et	  al.,	  2003,	  Levy-­‐Shraga	  et	  al.,	  2006,	  Del	  Vecchio	  et	  al.,	  2008).	  
Inhibition	   of	   platelet	   function	   using	   cyclooxygenase	   inhibitors,	   indomethacin	   and	  
ibuprofen,	   has	   previously	   been	   demonstrated,	   using	   ultrasound	   examinations,	   to	  
increase	  bleeding	  incidence	  in	  preterm	  neonates	  with	  patent	  ductus	  arteriosus	  (PDA)	  
(Brunner	  et	  al.,	  2013).  
 
VWF	   plays	   a	   crucial	   role	   in	   mediating	   the	   initial	   platelet	   adhesion	   at	   the	   site	   of	  
vascular	   injury	   which	   ceases	   bleeding	   (Chen	   and	   Lopez,	   2005).	   It	   was	   therefore	  
investigated	   whether	   platelet	   interactions	   with	   VWF	   were	   significantly	   different	  
between	  VLBW	  preterms	   and	   full-­‐term	  neonates	   under	   flow	   conditions.	   There	   are	  
relatively	   few	   studies	   examining	   platelet	   adhesion	   to	   vascular	   proteins	   under	  
conditions	  of	   flow	   in	  neonates.	  Cone	  and	  plate	   studies	  demonstrate	   that	  preterms	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have	  decreased	  platelet	  adhesion	   to	  extracellular	  matrix	   (ECM)	   to	   that	  of	   full-­‐term	  
neonates	   (Linder	   et	   al.,	   2002,	   Levy-­‐Shraga	   et	   al.,	   2006).	   Although,	   these	   assays	  
provide	   useful	   information	   on	   platelet	   function,	   they	   rely	   on	   a	   single	   end	   point	  
analysis	   rather	   than	   direct	   measurement	   of	   platelet	   interaction	   in	   ‘real-­‐time’.	  
Therefore,	  through	  the	  use	  of	  the	  DPFA	  it	  was	  possible	  to	  assess	  multiple	  parameters	  
of	   platelet	   translocation	   behaviour	   and	   characterise	   platelet	   profiles	   for	   both	  
preterm	  and	  full-­‐term	  neonates.	  	  
	  
Assessment	  of	  platelet	  translocation	  behaviour	  on	  VWF	  in	  preterm	  and	  full-­‐term	  
neonates	  demonstrated	  that	  preterm	  neonates	  displayed	  altered	  platelet	  function.	  
Interestingly,	  it	  was	  identified	  that	  platelets	  from	  preterm	  neonates	  exhibited	  
increased	  numbers	  of	  platelet	  tracks,	  platelet	  translocation,	  platelet	  translocation	  
velocities	  and	  unstable	  platelet	  interactions	  with	  VWF.	  The	  increased	  numbers	  of	  
platelet	  tracks	  in	  preterm	  infants	  was	  likely	  to	  be	  a	  consequence	  of	  increased	  
numbers	  of	  GPIb	  on	  the	  platelet	  surface	  which	  would	  facilitate	  platelet	  interaction	  
with	  immobilised	  VWF.	  However,	  in	  a	  subset	  of	  preterm	  and	  full-­‐term	  neonates	  (n	  =	  
5	  and	  n	  =6	  respectively),	  no	  significant	  difference	  in	  mean	  platelet	  volume	  was	  
observed	  (9.6	  ±	  0.8	  versus	  9.0	  ±	  0.8).	  Therefore,	  it	  is	  unlikely	  that	  the	  platelet	  size	  
significantly	  influenced	  the	  receptor	  numbers	  of	  GPIb	  measured	  in	  this	  thesis.	  
Despite	  preterm	  neonates	  having	  increased	  numbers	  of	  platelets	  interacting	  with	  
VWF,	  as	  measured	  by	  the	  number	  of	  platelet	  tracks,	  neither	  the	  percentage	  of	  
platelet	  surface	  coverage	  nor	  the	  numbers	  of	  static	  platelets	  on	  VWF	  were	  
significantly	  greater	  in	  preterm	  neonate	  cohorts.	  There	  was	  a	  significant	  increase	  
observed	  in	  the	  numbers	  of	  unstable	  platelet	  interactions	  (e.g.	  those	  that	  interact	  
with	  VWF	  but	  do	  not	  adhere).	  Both	  of	  the	  above	  findings	  combined	  may	  imply	  that	  
the	  adhesiveness	  of	  platelets	  to	  VWF	  is	  decreased	  in	  preterm	  neonates.	  Platelets	  
need	  to	  activate	  integrin	  αIIbβ3	  for	  platelets	  to	  adhere	  to	  VWF	  (Savage	  et	  al.,	  1996)	  
and	  this	  reduced	  adherence	  may	  be	  related	  to	  impaired	  αIIbβ3	  function.	  This	  
hypothesis	  is	  supported	  by	  PAC-­‐1	  binding	  studies	  (PAC-­‐1	  binds	  activated	  αIIbβ3)	  in	  
platelets	  from	  VLBW	  preterm	  neonates	  stimulated	  with	  thrombin	  receptor	  agonist	  
peptide	  (TRAP),	  showed	  reduced	  binding	  efficiency	  of	  PAC-­‐1	  to	  αIIbβ3	  (Sitaru	  et	  al.,	  
2005).	  The	  reduced	  activation	  of	  αIIbβ3	  may	  explain	  why	  platelet	  translocation	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velocities	  are	  significantly	  increased	  in	  preterm	  neonates.	  In	  chapter	  3,	  it	  was	  
demonstrated	  using	  the	  DPFA	  that	  MRS2179	  (selective	  P2Y1	  inhibitor)	  leads	  to	  
significant	  increases	  in	  platelet	  translocating	  velocities.	  MRS2179	  inhibits	  platelet	  
shape	  change	  and	  calcium	  mobilisation,	  thus	  impairing	  the	  ability	  of	  platelets	  to	  
activate	  (Baurand	  et	  al.,	  2001).	  The	  increased	  platelet	  translocating	  velocities	  may	  be	  
reflective	  of	  the	  more	  pronounced	  platelet	  hyporeactivity	  observed	  in	  preterm	  
populations.	  RBC’s	  as	  measured	  by	  mean	  corpuscular	  volume	  were	  also	  found	  to	  be	  
significantly	  larger	  in	  preterm	  infants	  than	  those	  in	  full-­‐term	  neonates	  (107.3	  ±	  5.5	  
versus	  101.7	  ±	  4.7,	  **p	  <	  0.01).	  The	  size	  of	  the	  RBCs	  may	  potentially	  play	  a	  role	  in	  
alternating	  how	  platelets	  behave	  on	  VWF	  but	  this	  warrants	  further	  investigation	  in	  
the	  future.	  
	  
Preterm	  neonates	  with	  lower	  platelet	  counts	  or	  lower	  HCT	  exhibited	  significantly	  
reduced	  platelet	  translocation	  behaviour	  on	  VWF	  in	  comparison	  to	  preterm	  
neonates	  with	  higher	  platelet	  counts	  or	  HCT.	  This	  finding	  is	  consistent	  with	  the	  data	  
presented	  in	  chapter	  3	  which	  demonstrated	  that	  a	  reduction	  in	  platelet	  or	  HCT	  count	  
significantly	  impairs	  platelet	  adhesion	  to	  VWF.	  Reductions	  in	  HCT	  have	  previously	  
been	  demonstrated	  to	  inhibit	  platelet	  adhesion	  to	  VWF	  (Chen	  et	  al.,	  2013).	  In	  this	  
thesis,	  it	  was	  observed	  that	  platelet	  interactions	  with	  VWF	  were	  decreased	  in	  those	  
preterms	  with	  lower	  platelet	  or	  HCT	  count.	  Also,	  it	  was	  observed	  that	  the	  number	  of	  
unstable	  platelet	  interactions	  was	  decreased	  in	  those	  preterms	  with	  lower	  platelet	  
or	  HCT.	  This	  reduction	  is	  likely	  to	  be	  caused	  by	  the	  reductions	  in	  the	  numbers	  of	  
platelets	  interacting	  with	  the	  surface.	  This	  is	  further	  validated	  by	  the	  significant	  
decrease	  observed	  in	  platelet	  surface	  coverage	  in	  those	  preterms	  with	  lower	  platelet	  
or	  HCT	  count.	  	  
	  
As	  shown	  in	  this	  thesis,	  preterm	  neonates	  display	  increased	  numbers	  of	  platelets	  
interacting	  with	  VWF	  compared	  to	  full-­‐term	  neonates.	  This	  may	  be	  a	  compensatory	  
mechanism	  to	  counteract	  the	  pronounced	  hyporeactivity	  in	  preterm	  neonate	  
populations.	  This	  compensatory	  mechanism	  is	  not	  possible	  in	  those	  neonates	  with	  
lower	  platelet	  or	  HCT	  and	  therefore	  may	  help	  explain	  why	  bleeding	  risk	  in	  those	  
preterms	  with	  thrombocytopenia	  and	  anaemia,	  is	  significantly	  greater	  than	  in	  those	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preterms	  with	  normal	  platelet	  and	  HCT	  count	  (Sola-­‐Visner,	  2012).	  Such	  results	  
complement	  the	  findings	  by	  Sola	  et	  al.,	  (2001)	  highlighting	  that	  those	  preterm	  
neonates	  with	  the	  lower	  HCT	  (<	  28%)	  experience	  the	  longest	  bleeding	  times.	  
	  
This	   work	   presented	   in	   this	   thesis	   demonstrates,	   for	   the	   first	   time,	   that	   VLBW	  
preterm	   neonates	   have	   significantly	   different	   platelet	   translocation	   behaviour	   on	  
VWF	  compared	  with	  full-­‐term	  neonates.	  Preterm	  neonate	  platelets	  display	  reduced	  
adherence	   to	   VWF	  with	   a	   significant	   increase	   in	   platelet	   translocating	   velocity.	   To	  
counteract	  this	  more	  pronounced	  hyporeactivity	  observed	  in	  preterm	  neonates	  and	  
reduced	  platelet	  adherence	  to	  VWF,	  preterm	  neonates	  may	  increase	  the	  numbers	  of	  
platelets	   that	   interact	   with	   VWF	   (platelet	   tracks).	   These	   differences	   in	   platelet	  
function	  may	   contribute	   to	   the	  higher	   incidences	  of	   bleeding	  observed	   in	   preterm	  
neonate	  populations.	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Chapter	  6	  
Platelet	  translocation	  behaviour	  in	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6.1	  Introduction	  
The	   role	   of	   platelets	   in	   haemostasis	   and	   thrombosis	   is	   well	   established.	   More	  
recently	   it	   has	   been	   identified	   that	   platelets	   serve	   as	   potential	   mediators	   in	   the	  
formation	  of	   a	  normally	   functioning	  placenta	   (Sato	  et	   al.,	   2005,	  Bodis	   et	   al.,	   2014,	  
Sato	   et	   al.,	   2010).	   It	   has	   been	   reported	   that	   alterations	   in	   platelet-­‐mediated	  
placentation	   may	   contribute	   to	   the	   development	   of	   utero-­‐placental	   conditions	  
including	   intrauterine	  growth	  restriction	  (IUGR)	   (Norris	  et	  al.,	  1994,	  Mullers,	  2015),	  
pregnancy	   induced	   hypertension	   (PIH)	   (Morrison	   et	   al.,	   1985)	   and	   preeclampsia	  
(PET)	   (Stubbs	  et	   al.,	   1986,	   Janes	  and	  Goodall,	   1994,	  Norris	   et	   al.,	   1993).	  Moderate	  
success	   has	   been	   reported	   with	   the	   use	   of	   anti-­‐platelet	   therapy	   in	   preventing	  
recurrent	  utero-­‐placental	  disease	  (Askie	  et	  al.,	  2007).	  	  
	  
Pregnancies	   complicated	  by	  growth	   restriction	  and	  hypertension	  pose	  a	   significant	  
risk	   to	   both	   mother	   and	   fetus,	   and	   these	   conditions	   contribute	   significantly	   to	  
maternal	   morbidity,	   mortality	   and	   the	   sequelae	   of	   prematurity	   (National	   Clinical	  
Practice	   Guideline	   No.29,	   2014).	   Additionally,	   the	   link	   between	   the	   later	  
development	   of	   cardiovascular	   disease	   and	   a	   history	   of	   either	   fetal	   growth	  
restriction	  or	  hypertension	  in	  pregnancy	  is	  well	  established	  (Smith	  et	  al.,	  2014).	  
	  
PIH	  is	  defined	  by	  hypertension	  of	  ≥	  140/90	  occurring	  after	  20	  weeks	  gestational	  age,	  
and	  when	  proteinuria	  is	  present,	  PET	  ensues	  (NICE	  guideline	  No.	  62,	  2006).	  It	  is	  the	  
defective	   and	   shallow	  placentation	  occurring	   in	   early	  pregnancy	   that	   is	   thought	   to	  
result	  in	  a	  spectrum	  of	  utero-­‐placental	  conditions.	  It	  may	  either	  uniquely	  effect	  the	  
fetal-­‐placental	   interface	   resulting	   in	   IUGR;	   the	   materno-­‐placental	   interface	   with	  
resulting	   PIH	   and	   PET,	   and	   in	   some	   cases	   both	   (Mullers	   2015,	   personal	  
communication,	  Rotunda	  hospital	  Dublin).	  	  
	  
There	   is	  no	  single	  biomarker	  currently	   in	  existence	  with	  sufficient	  power	  to	  predict	  
the	  development	  of	  IUGR,	  PIH	  and	  PET	  conditions	  early	  in	  pregnancy.	  Therapy	  such	  
as	   aspirin	   could	   be	   prescribed	   to	   potentially	   encourage	   healthy	   placentation	   and	  
thus	   prevent	   short	   and	   long-­‐term	   complications	   for	   both	  mother	   and	   fetus.	   In	   an	  
effort	   to	  characterise	  platelet	  behavior	   in	  pregnancy	  and	  develop	  a	   screening	   tool,	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previous	   authors	   have	   embarked	   on	   a	   number	   of	   studies	   investigating	   platelet	  
function	  in	  pregnancy	  (Morrison	  et	  al.,	  1985,	  Horn,	  1991,	  Norris	  et	  al.,	  1993,	  Norris	  
et	  al.,	  1994,	  Nicolini	  et	  al.,	  1994,	  Nadar	  and	  Lip,	  2004,	  Gatti	  et	  al.,	  1994,	  Star	  et	  al.,	  
1997,	  Can	  et	  al.,	  2010).	  The	  results	  of	  these	  studies	  are	  inconsistent,	  not	  least	  due	  to	  
a	   lack	   of	   standardisation	   of	   the	   methodology	   of	   platelet	   function	   testing	   used	  
(Cattaneo	   et	   al.,	   2013).	   More	   recently,	   a	   modified	   version	   of	   light	   transmission	  
aggregometry	   (LTA)	  was	  used	   to	   assess	   platelet	   function	   in	   normal	   pregnancy	   and	  
the	  common	  pregnancy	  conditions	  IUGR,	  PIH	  and	  PET	  by	  our	  collaborating	  research	  
team	  at	   the	  Rotunda	  hospital	  Dublin	   (Burke	  et	  al.,	  2013).	  This	  assay	  uses	  a	  96-­‐well	  
plate	   to	   examine	   platelet	   reactivity	   in	   response	   to	   multiple	   sub-­‐maximal	  
concentrations	   of	   agonists.	   When	   compared	   with	   aged-­‐matched	   non-­‐pregnant	  
controls,	   platelet	   reactivity	  was	   found	   to	   be	   significantly	   reduced	   in	   first	   trimester	  
normal	   pregnancies,	   increasing	   as	   gestational	   age	   advanced.	   	   When	   investigating	  
platelet	  function	  in	  pregnancies	  complicated	  with	  either	  hypertensive	  conditions	  or	  
fetal	   growth	   restriction,	   platelet	   reactivity	   was	   found	   to	   be	   significantly	   reduced	  
compared	   to	   that	   of	   healthy	   third	   trimester	   pregnant	   controls	   (Mullers,	   2015).	  
However,	  LTA	  does	  not	  replicate	  the	  flow	  and	  shear	  environment	  that	  platelets	  are	  
exposed	   to	   in	   vivo.	   Therefore,	   the	   Dynamic	   Platelet	   Function	   Assay	   (DPFA)	   was	  
employed	   to	   comprehensively	   investigate	   platelet	   function	   under	   arterial	   shear	  
conditions	   in	   both	   normal	   pregnancies	   and	   pregnancies	   complicated	   by	   placental	  
disease.	  
	  
In	  this	  chapter,	  I	  will	  discuss	  platelet	  function	  in:	  
	  
• Age-­‐matched	  females	  who	  are	  not	  pregnant	  with	  those	  in	  the	  third	  trimester	  
of	  a	  healthy	  pregnancy.	  
• Healthy	  pregnancy	  and	  pregnancy	  with	  IUGR.	  
• Healthy	  pregnancy	  and	  pregnancy	  with	  PIH.	  
• Healthy	  pregnancy	  and	  pregnancy	  with	  PET.	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6.2	  Results	  
6.2.1	  Study	  populations	  	  
The	  study	  enrolled	  a	  total	  of	  32	  females	  who	  were	  not	  pregnant,	  21	  third	  trimester	  
healthy	   pregnancies,	   23	   third	   trimester	   pregnancies	   with	   IUGR,	   16	   third	   trimester	  
pregnancies	   PIH	   and	   27	   third	   trimester	   pregnancies	   with	   PET.	   Haematocrits	   (HCT)	  
were	  significantly	  reduced	   in	  the	  pregnancy	  groups	   in	  comparison	  to	  non-­‐pregnant	  
controls	   (p	   <	   0.01**).	   There	   was	   a	   trend	   towards	   a	   decreased	   platelet	   count	   in	  
pregnancy	  but	  this	  was	  found	  to	  note	  be	  statistically	  significant.	  	  The	  demographics	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Table	  6.1	  Demographics	  of	  study	  populations	  	  





























n	  =	  27	  
Age	  (years)	   21-­‐38	   19-­‐47	   19-­‐47	   17-­‐37	   20-­‐43	  

















HCT	  (%)	   38	  	  (20-­‐46)	   31	  (26-­‐45)*	   31	  (25-­‐38)*	   30	  (22-­‐37)*	   32	  (16-­‐48)*	  
Nulliparous	  (%)	   -­‐	   36%	  (8/22)	   45%	  (10/23)	   44%	  (7/16)	   70%	  (19/27)	  
BMI	   -­‐	   25.2	  (19-­‐34)	   26	  (18-­‐40)	   29	  (22-­‐36)	   29	  (20.5-­‐40)	  
Caucasian	  ethnicity	  (%)	   -­‐	   91%	  (20/22)	   96%	  (22/23)	   94%	  (15/16)	   85%	  (23/27)	  
IVF	  pregnancy	  (%)	   -­‐	   5%	  (1/22)	   9%	  (2/22)	   0%	   11%	  (3/27)	  
History	  of	  IUGR	  (%)	   -­‐	   0%	   26%	  (6/23)	   6%	  (1/16)	   7%	  (2/27)	  
History	  of	  PIH/PET	  (%)	   -­‐	   0%	   9%	  (2/23)	   44%	  (7/16)	   19%	  (5/27)	  
History	  of	  essential	  
HTN	  (%)	  
-­‐	   0%	   0%	   13	  %	  (3/13)	   26%	  (7/27)	  
Smokers	  (%)	   -­‐	   9%	  (2/22)	   22%	  (5/23)	   6%	  (1/16)	   11%	  (3/27)	  
	   	   	   	   	   	  
GA	  at	  diagnosis	  (Wks,	  
days)	  








-­‐	   0%	   4%	  (1/23)	   69%	  (11/16)	   60%	  (16/27)	  
GA	  at	  blood	  draw	  
(Wks,	  days)	  








	   	   	   	   	   	  
GA	  at	  delivery	  (Wks,	  
days)	  
















Estimated	  blood	  loss	  
(mls)	  








	   	   	   	   	   	  
Blood	  
group:	  
O-­‐	   -­‐	   9%	  (2/22)	   13%	  (3/23)	   6%	  (1/16)	   4%	  (1/27)	  
O+	   -­‐	   55%	  (12/22)	   35%	  (8/23)	   38%	  (6/16)	   33%	  (9/27)	  
B-­‐	   -­‐	   0%	   13%	  (3/23)	   6%	  (1/16)	   7%	  (2/27)	  
B+	   -­‐	   5%	  (1/22)	   4%	  (1/23)	   0%	   19%	  (5/27)	  
A-­‐	   -­‐	   5%	  (1/22)	   4%	  (1/23)	   0%	   4%	  (1/27)	  
A+	   -­‐	   27%	  (6/22)	   22%	  (5/23)	   38%	  (6/16)	   30%	  (8/27)	  
AB-­‐	   -­‐	   0%	   0%	   6%	  (1/16)	   0%	  
AB+	   -­‐	   0%	   9%	  (2/23)	   6%	  (1/16)	   4%	  (1/27)	  
	  
*	  Pregnancy	  was	  within	  the	  normal	  ranges	  for	  the	  healthy	  donors,	  however,	  on	  
average	  pregnancy	  resulted	  in	  a	  significant	  decrease	  in	  HCT	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6.2.2	  Platelet	  function	  in	  healthy	  pregnancy	  	  
Platelets	   from	   females	   who	   were	   not	   pregnant	   (n=32)	   exhibited	   significantly	  
different	   platelet	   translocation	   behaviour	   on	   VWF	   when	   compared	   with	   healthy	  
females	  in	  the	  third	  trimester	  of	  pregnancy	  (n=21).	  In	  particular,	  it	  was	  observed	  that	  
healthy	  pregnant	  females	  had	  a	  significant	  decrease	  in	  the	  number	  of	  platelet	  tracks	  
(271	  ±	  20	  versus	  426	  ±	  20;	  ***p	  <	  0.0001),	  platelet	   translocation	   (165	  ±	  10	  versus	  
290	   ±	   14;	   ***p	   <	   0.0001)	   and	   a	   reduction	   in	   weighted	  median	   speeds	   (2.4	   ±	   0.2	  
μm/sec	   versus	   4.8	   ±	   0.4	   μm/sec;	   ***p	   <	   0.0001).	   However,	   when	   comparing	   the	  
results	   of	   healthy	   pregnant	   females	   to	   non-­‐pregnant	   females,	   no	   significant	  
differences	  were	  observed	  in	  the	  number	  of	  static	  platelets	  (91	  ±	  8	  versus	  93	  ±	  6)	  or	  
in	  the	  numbers	  of	  unstable	  platelet	  interactions	  (93	  ±	  14	  versus	  123	  ±	  11)	  on	  VWF.	  
Nonetheless,	  it	  was	  identified	  that	  pregnant	  females	  had	  a	  significant	  decrease	  in	  the	  
percentage	   of	   platelet	   surface	   coverage	   (5.5	   ±	   0.3	   %	   versus	   7.9	   ±	   0.5	   %;	   ***p	   <	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Figure	  6.1	  Platelet	  function	  in	  non-­‐pregnant	  and	  pregnant	  females.	  Blood	  from	  32	  
non	  pregnant	  females	  and	  21	  pregnant	  females	  in	  the	  third	  trimester	  of	  pregnancy	  
was	  perfused	  over	  VWF	  at	  arterial	  shear.	  Pregnant	  females	  showed	  a	  significant	  
change	  in	  platelet	  translocation	  behaviour	  on	  VWF	  (*p	  <	  0.05,	  **p	  <	  0.01	  and	  ***p	  <	  
0.0001).	  An	  unpaired	  t-­‐test	  and	  unpaired	  t-­‐test	  with	  Welch’s	  correction	  was	  used	  
where	  appropriate	  to	  detect	  statistically	  significant	  differences	  between	  the	  groups.	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6.2.3	  Platelet	  function	  in	  pregnancy	  with	  IUGR	  	  
In	  pregnancy	  with	  IUGR	  (n=23)	  when	  compared	  with	  healthy	  pregnancy	  (n=21)	  there	  
were	  no	  significant	  differences	  in	  the	  number	  of	  platelet	  tracks	  (238	  ±	  21	  versus	  271	  
±	  20),	  platelet	  translocation	  (160	  ±	  15	  versus	  165	  ±	  10)	  or	  in	  weighted	  median	  speeds	  
(2.3	  ±	  0.1	  μm/sec	  versus	  2.5	  ±	  0.2	  μm/sec).	  However,	  in	  pregnancy	  with	  IUGR	  there	  
was	  a	  significant	  reduction	  in	  the	  numbers	  of	  static	  platelets	  (68	  ±	  6	  versus	  91	  ±	  8;	  *p	  
<	   0.05).	   Notably	   in	   pregnancy	   with	   IUGR	   there	   were	   no	   significant	   differences	   in	  
either	   the	   numbers	   of	   unstable	   platelet	   interactions	   (72	   ±	   8	   versus	   93	   ±	   14)	  with	  
VWF	  or	  in	  the	  percentage	  of	  platelet	  surface	  coverage	  (4.9	  ±	  0.3	  %	  versus	  5.4	  ±	  0.3	  
%)	  (Figure	  6.2).	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Figure	  6.2	  Platelet	  function	  in	  pregnant	  females	  with	  IUGR.	  Blood	  from	  21	  pregnant	  
females	  with	  no	  IUGR	  and	  23	  pregnant	  females	  with	  IUGR	  was	  perfused	  over	  VWF	  at	  
arterial	  shear.	  Pregnancy	  with	  IUGR	  resulted	  in	  a	  significant	  reduction	  in	  the	  number	  
of	  platelets	  that	  stably	  adhere	  to	  VWF	  (*p	  <	  0.05).	  An	  unpaired	  t-­‐test	  and	  unpaired	  t-­‐
test	  with	  Welch’s	  correction	  was	  used	  where	  appropriate	  to	  detect	  statistically	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6.2.4	  Platelet	  function	  in	  pregnancy	  with	  PIH	  	  
In	  pregnancy	  with	  PIH	  (n=16)	  when	  compared	  with	  healthy	  pregnancy	  (n=21)	  there	  
was	   significantly	   reduced	   platelet	   translocation	   behaviour	   on	   VWF.	   Notably	   when	  
comparing	   pregnancy	   with	   PIH	   with	   healthy	   pregnancy	   there	   were	   significant	  
reductions	  in	  the	  number	  of	  platelet	  tracks	  (208	  ±	  18	  versus	  271	  ±	  20;	  *p	  <	  0.05)	  and	  
platelet	  translocation	  (133	  ±	  12	  versus	  165	  ±	  10;	  *p	  <	  0.05)	  on	  VWF.	  No	  significant	  
difference	  was	  observed	  in	  weighted	  median	  speeds	  (2.2	  ±	  0.2	  μm/sec	  versus	  2.5	  ±	  
0.2	  μm/sec)	  on	  VWF	  between	  PIH	  and	  healthy	  pregnancy.	  However,	  pregnancy	  with	  
PIH	   compared	   to	   healthy	   pregnancy,	   demonstrated	   a	   significant	   decrease	   in	   the	  
number	  of	  static	  platelets	   (59	  ±	  5	  versus	  91	  ±	  8;	  **p	  <	  0.05)	  and	   in	  the	  number	  of	  
unstable	   platelet	   interactions	   (52	   ±	   7	   versus	   93	   ±	   14;	   *p	   <	   0.05).	   There	   was	   no	  
significant	  reduction	  in	  the	  percentage	  of	  platelet	  surface	  coverage	  (4.8	  ±	  0.3	  versus	  
5.4	  ±	  0.3	  %)	  in	  pregnancy	  with	  PIH	  (Figure	  6.3).	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Figure	  6.3	  Platelet	  function	  in	  females	  with	  PIH.	  Blood	  from	  21	  females	  with	  no	  PIH	  
and	  16	  pregnant	  females	  with	  PIH	  was	  perfused	  over	  VWF	  at	  arterial	  shear.	  
Pregnancy	  with	  PIH	  resulted	  in	  a	  significant	  reduction	  in	  platelet	  translocation	  
behaviour	  on	  VWF	  (*p	  <	  0.05	  and	  **p	  <	  0.01).	  An	  unpaired	  t-­‐test	  and	  unpaired	  t-­‐test	  
with	  Welch’s	  correction	  was	  used	  where	  appropriate	  to	  detect	  statistically	  significant	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6.2.5	  Platelet	  function	  in	  pregnancy	  with	  PET	  	  
In	  pregnancy	  with	  PET	  (n=27)	  when	  compared	  with	  healthy	  pregnancy	  (n=21)	  there	  
was	   a	   significantly	   reduced	   platelet	   translocation	   behaviour	   on	   VWF.	   Also	   in	  
pregnancy	  with	  PET	  when	  compared	  with	  healthy	  pregnancy	  there	  was	  a	  significant	  
reduction	  in	  the	  number	  of	  platelet	  tracks	  (187	  ±	  10	  versus	  271	  ±	  20;	  **p	  <	  0.01)	  and	  
platelet	   translocation	   (117	  ±	  8	  versus	  165	  ±	  10;	  **p	  <	  0.01).	  No	   significant	   change	  
was	  observed	  in	  weighted	  median	  speeds	  (μm/sec	  2.3	  ±	  0.2	  versus	  2.5	  ±	  0.2	  μm/sec)	  
in	  PET	  versus	  healthy	  pregnancy.	  However,	  in	  pregnant	  females	  with	  PET	  there	  was	  a	  
significant	   decrease	   in	   the	  number	  of	   static	   platelets	   (61	   ±	   5	   versus	   91	   ±	   8;	   **p	   <	  
0.05)	  and	  the	  number	  of	  unstable	  platelet	  interactions	  (59	  ±	  7	  versus	  93	  ±	  14;	  *p	  <	  
0.05)	   with	   VWF.	   In	   pregnancy	   with	   PET	   there	   was	   a	   trend	   towards	   a	   decreased	  
percentage	  of	  platelet	  surface	  coverage	  (4.7	  ±	  0.3	  versus	  5.4	  ±	  0.3	  %)	  in	  PET,	  but	  this	  
was	  not	  statistically	  significant	  (Figure	  6.4).	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Figure	  6.4	  Platelet	  function	  in	  females	  with	  PET.	  Blood	  from	  27	  pregnant	  females	  
with	  PET	  and	  21	  pregnant	  females	  with	  healthy	  pregnancy	  was	  perfused	  over	  VWF	  at	  
arterial	  shear.	  Pregnancy	  with	  PET	  resulted	  in	  a	  significant	  reduction	  in	  platelet	  
translocation	  behaviour	  on	  VWF	  (*p	  <	  0.05	  and	  **p	  <	  0.01).	  An	  unpaired	  t-­‐test	  and	  
unpaired	  t-­‐test	  with	  Welch’s	  correction	  were	  used	  where	  appropriate	  to	  detect	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6.3	  Discussion	  
In	  this	  chapter,	  the	  results	  demonstrate	  that	  platelet	  function	  significantly	  changes	  
during	  pregnancy.	  Pregnancy	  results	  in	  an	  increase	  in	  platelet	  reactivity	  as	  
demonstrated	  by	  a	  significant	  reduction	  in	  platelet	  translocation	  speeds	  on	  VWF	  
compared	  with	  non-­‐pregnant	  controls.	  In	  utero-­‐placental	  diseases	  such	  as	  IUGR,	  PIH	  
and	  PET,	  platelet	  translocation	  behaviour	  on	  VWF	  is	  significantly	  altered	  compared	  
to	  normal	  healthy	  pregnant	  controls.	  These	  changes	  in	  platelet	  function	  maybe	  
reflective	  of	  platelet	  impairment,	  which	  was	  found	  to	  be	  greatest	  for	  those	  
pregnancies	  complicated	  by	  PET.	  
	  
The	  literature	  reports	  on	  a	  number	  of	  platelet	  studies,	  with	  overall	  inconsistent	  
results.	  There	  are	  some	  studies	  that	  suggest	  platelet	  reactivity	  increases	  during	  
pregnancy	  (Gerbasi	  et	  al.,	  1990,	  Holmes	  et	  al.,	  2002).	  Fitzgerald	  et	  al.,	  (1987)	  
Indicated	  that	  platelet-­‐derived	  thromboxane	  is	  increased	  in	  pregnancy.	  Robb	  et	  al.,	  
(2010)	  demonstrated	  that	  pregnancy	  resulted	  in	  an	  increase	  in	  the	  platelet	  
activation	  marker	  P-­‐selectin.	  More	  recently,	  using	  the	  LTA	  96-­‐well	  plate	  assay,	  Burke	  
et	  al.,	  (2013)	  established	  that	  platelet	  reactivity	  was	  significantly	  reduced	  in	  the	  first	  
trimester	  of	  pregnancy	  compared	  with	  non-­‐pregnant	  controls	  and	  subsequently	  
increased	  during	  the	  second	  and	  third	  trimester	  of	  pregnancy	  in	  comparison	  with	  
non-­‐pregnant	  controls.	  Building	  on	  in	  this	  initial	  body	  of	  work,	  the	  purpose	  of	  this	  
element	  of	  the	  thesis	  was	  to	  apply	  the	  DPFA	  to	  pregnancy	  subjects,	  to	  describe	  
platelet	  behavior	  in-­‐vivo,	  as	  evidenced	  by	  multiple	  platelet	  parameters,	  and	  to	  assess	  
a	  more	  physiological	  aspect	  of	  platelet	  function	  in	  healthy	  third	  trimester	  pregnant	  
females	  compared	  with	  age-­‐matched	  non-­‐pregnant	  controls.	  The	  results	  
demonstrated	  that	  in	  pregnancy,	  there	  is	  a	  significant	  reduction	  in	  platelet	  
interactions	  with	  VWF	  as	  shown	  by	  significantly	  less	  platelet	  tracks.	  This	  is	  most	  
likely	  due	  to	  an	  expected	  reduction	  in	  HCT	  in	  pregnancy	  compared	  with	  non-­‐
pregnant	  controls	  (Table	  6.1).	  As	  part	  of	  the	  normal	  physiological	  changes	  in	  
pregnancy,	  haemodilution	  reduces	  the	  concentration	  of	  red	  blood	  cells	  in	  circulation	  
(Faupel-­‐Badger	  et	  al.,	  2007).	  As	  shown	  in	  chapter	  3,	  reducing	  HCT	  impairs	  platelet	  
adhesion	  to	  VWF.	  Interestingly,	  in	  this	  thesis	  it	  was	  observed	  that	  platelet	  
translocation	  speeds	  were	  significantly	  reduced	  in	  pregnancy	  which	  maybe	  reflective	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of	  enhanced	  platelet	  reactivity.	  It	  is	  reasonable	  to	  suggest	  that	  the	  enhanced	  platelet	  
reactivity	  reduces	  the	  time	  taken	  for	  platelets	  to	  adhere	  to	  VWF,	  thereby	  reducing	  
platelet	  translocation	  speeds.	  This	  is	  further	  validated	  with	  the	  observation	  that	  
despite	  having	  a	  dramatic	  reduction	  in	  the	  number	  of	  platelets	  interacting	  with	  VWF,	  
there	  were	  no	  significant	  differences	  in	  either	  the	  number	  of	  static	  or	  unstable	  
platelet	  interactions	  with	  VWF	  between	  both	  groups.	  	  
	  
As	  previously	  described,	  Burke	  et	  al.,	  (2013)	  demonstrated	  decreased	  platelet	  
reactivity	  compared	  to	  non-­‐pregnant	  controls	  in	  the	  first	  trimester	  of	  healthy	  
pregnancy.	  It	  has	  been	  speculated	  that	  such	  reduced	  platelet	  reactivity	  may	  facilitate	  
a	  fundamental	  spiral	  artery	  invasion,	  without	  the	  unwanted	  coagulation	  cascade	  
(Mullers	  2014,	  personal	  communication	  Rotunda	  Hospital	  Dublin).	  Maternal	  spiral	  
artery	  invasion	  is	  a	  vital	  step	  in	  the	  development	  of	  a	  healthy	  placenta,	  with	  
complications	  in	  this	  process	  believed	  to	  result	  in	  IUGR	  and	  PET	  (Lyall	  et	  al.,	  2013).	  
Platelet	  hyperreactivity	  has	  previously	  being	  reported	  in	  PET	  in	  early	  placentation	  
with	  utero-­‐placental	  disease	  (Janes	  and	  Goodall,	  1994).	  This	  finding	  supports	  the	  role	  
of	  low	  dose	  aspirin	  in	  preventing	  defective	  placentation	  in	  early	  pregnancy	  (Bujold	  et	  
al.,	  2010).	  Platelet	  activation	  may	  well	  be	  increased	  early	  in	  pregnancies	  destined	  to	  
develop	  with	  utero-­‐placental	  disease,	  unfortunately	  longitudinal	  studies	  from	  first	  
trimester	  through	  to	  third	  trimester	  are	  considerably	  lacking	  and	  are	  warranted.	  
	  
A	  further	  number	  of	  studies	  have	  concluded	  that	  platelet	  reactivity	  is	  reduced	  in	  
pregnancies	  with	  established	  IUGR,	  PIH	  and	  PET	  (Peracoli	  et	  al.,	  2008,	  O'Brien	  et	  al.,	  
1986,	  Norris	  et	  al.,	  1993,	  Norris	  et	  al.,	  1994,	  Mullers,	  2015).	  These	  studies	  were	  
carried	  out	  in	  the	  third	  trimester	  of	  pregnancy	  and	  assessed	  platelet	  function	  by	  
measuring	  TGF-­‐beta	  levels	  (Peracoli	  et	  al.,	  2008)	  or	  agonist-­‐induced	  platelet	  
aggregation	  (O'Brien	  et	  al.,	  1986,	  Norris	  et	  al.,	  1993,	  Norris	  et	  al.,	  1994,	  Mullers,	  
2015).	  The	  finding	  of	  platelet	  hyporeactivity	  has	  been	  suggested	  to	  reflect	  granule	  
depletion,	  and	  this	  may	  directly	  describe	  a	  platelet	  release	  reaction	  for	  these	  
conditions	  (O'Brien	  et	  al.,	  1986).	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A	  number	  of	  authors	  have	  concluded	  that	  platelet	  activation	  is	  increased	  in	  these	  
conditions	  such	  as	  IUGR,	  PIH	  and	  PET	  (Konijnenberg	  et	  al.,	  1997,	  Morrison	  et	  al.,	  
1985,	  Sheu	  et	  al.,	  2002,	  Janes	  and	  Goodall,	  1994)	  citing	  the	  clinical	  condition	  of	  
vasoactive	  substance	  release	  in	  hypertensive	  disease	  in	  pregnancy	  to	  explain	  these	  
results.	  	  Further	  to	  this,	  a	  number	  of	  authors	  correlated	  both	  measures	  of	  platelet	  
activation	  with	  platelet	  functional	  assays,	  and	  felt	  that	  while	  markers	  of	  platelet	  
activation	  may	  be	  increased,	  this	  may	  represent	  a	  platelet	  releasate	  reaction,	  
culminating	  in	  overall	  reduced	  platelet	  function	  in	  utero-­‐placental	  disease	  (Peracoli	  
et	  al.,	  2008,	  Morrison	  et	  al.,	  1985,	  Norris	  et	  al.,	  1994).	  As	  previously	  discussed,	  
studies	  of	  platelet	  function	  in	  pregnancy	  to	  date	  are	  fraught	  with	  inconsistencies	  in	  
the	  methodology	  used	  to	  assess	  platelet	  function,	  and	  are	  therefore	  difficult	  to	  
compare.	  Furthermore,	  the	  platelet	  aggregation	  studies	  cited	  here	  have	  used	  either	  
a	  limited	  number	  of	  agonists,	  or	  maximal	  concentrations	  of	  agonists,	  and	  were	  not	  
designed	  to	  assess	  platelet	  function	  under	  shear	  conditions.	  	  
	  
In	  this	  thesis,	  using	  a	  near-­‐physiological	  assay	  of	  platelet	  function	  under	  arterial	  
shear,	  it	  has	  been	  demonstrated	  that	  platelet	  behavior	  is	  significantly	  altered	  across	  
a	  range	  of	  platelet	  interactions	  on	  VWF	  in	  utero-­‐placental	  disease.	  Pregnancy	  with	  
IUGR	  was	  associated	  with	  a	  significant	  reduction	  in	  the	  number	  of	  static	  platelets	  
(i.e.	  those	  platelets	  that	  travel	  less	  than	  1.5	  times	  the	  average	  radius	  of	  the	  platelet).	  
Pregnancies	  with	  PIH	  and	  PET	  resulted	  in	  multiple	  changes	  in	  platelet	  translocation	  
behaviour	  on	  VWF,	  such	  as	  reductions	  in	  platelet	  tracks,	  translocating	  platelets,	  
static	  and	  unstable	  platelet	  interactions	  with	  VWF.	  These	  changes	  in	  platelet	  
function	  were	  more	  pronounced	  in	  the	  PET	  group,	  which	  is	  not	  surprising	  
considering	  PET	  represents	  a	  more	  severe	  clinical	  form	  of	  utero-­‐placental	  disease.	  
These	  changes	  in	  platelet	  function	  may	  be	  representative	  of	  a	  gross	  platelet	  function	  
impairment.	  	  
	  
Overall	  the	  results	  of	  this	  study	  are	  consistent	  with	  the	  concept	  that	  pregnancy	  
results	  in	  a	  significant	  increase	  in	  platelet	  reactivity	  which	  is	  compensated	  by	  a	  
significant	  reduction	  in	  HCT.	  Utero-­‐placental	  disease	  is	  associated	  with	  an	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impairment	  in	  platelet	  function.	  This	  impairment	  is	  most	  apparent	  in	  those	  pregnant	  
females	  with	  PET.	  	  
	  
In	  this	  thesis,	  third	  trimester	  pregnancies	  were	  selected	  as	  utero-­‐placental	  disease	  
was	  well	  established.	  Utero-­‐placental	  disease	  can	  often	  be	  challenging	  to	  diagnose	  
early	  in	  pregnancy.	  Therefore,	  this	  chapter	  set	  out	  to	  determine	  whether	  the	  DPFA	  
could	  pick	  up	  subtle	  changes	  in	  platelet	  function	  in	  known	  cases	  of	  placental	  disease.	  
However,	  to	  predict	  development	  of	  these	  conditions	  (IUGR,	  PIH,	  PET),	  platelet	  
function	  should	  be	  assessed	  early	  in	  pregnancy.	  As	  a	  next	  logical	  step,	  it	  is	  proposed	  
that	  applying	  this	  assay	  in	  a	  large	  cohort	  across	  the	  three	  trimesters	  of	  pregnancy,	  
with	  the	  view	  to	  refining	  a	  screening	  tool	  that	  will	  identify	  cases	  that	  will	  ultimately	  

























	  	  	  
Chapter	  7	  
	  
Development	  of	  a	  synthetic	  surface	  to	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7.1	  Introduction	  
Von	   Willebrand	   Factor	   (VWF)	   circulates	   in	   human	   plasma	   at	   concentrations	   of	  
approximately	   10	   μg/mL	   (Mannucci,	   1998)	   However,	   the	   concentration	   of	   VWF	   in	  
human	   plasma	   can	   differ	   significantly	   between	   individuals	   (Franchini	   et	   al.,	   2014),	  
with	  deficiencies	  resulting	  in	  the	  onset	  of	  von	  Willebrand	  disease	  (VWD).	  VWD	  is	  the	  
most	  common	  bleeding	  disorder	  globally,	  affecting	  1%	  of	  the	  population	  (James	  and	  
Goodeve,	  2011).	  The	  gold	  standard	  test	  for	  diagnosing	  VWD	  is	  measurement	  of	  VWF	  
activity	   via	   platelet	   agglutination	   in	   the	   presence	   of	   the	   antibiotic	   Ristocetin	  
(VWF:RCo)	   (Roberts,	  2014).	  There	  are	  4	  types	  of	  VWD	  (Type	   I,	  Type	   II,	  Type	   III	  and	  
acquired	   VWD).	   The	   conventional	   tests	   are	   regarded	   as	   being	   inaccurate	   and	   can	  
often	   lead	   to	   the	   misdiagnosis	   of	   patients;	   in	   particular	   diagnosis	   of	   Type	   I	   VWD	  
(Roberts,	  2014).	  Type	  I	  VWD	  is	  the	  most	  common	  form	  of	  VWD	  and	  accounts	  for	  75	  
%	  of	  patients	  diagnosed	  with	  the	  disease.	  Type	  I	  VWD	  results	  in	  minor	  bleeding	  due	  
to	  the	  production	  of	  insufficient	  amounts	  of	  VWF	  (Sadler,	  2003).	  Type	  I	  VWD	  can	  be	  
challenging	   to	   diagnose,	   for	   example,	   individuals	   who	   are	   blood	   group	   O	   (lowest	  
VWF	  levels)	  are	  sometimes	  diagnosed	  as	  having	  Type	  I	  VWD	  but	  have	  normal	  VWF	  
levels	   for	   their	   blood	   group	   (Branchford	   and	  Di	   Paola,	   2012,	  Gill	   et	   al.,	   1987).	   The	  
same	  is	  also	  possible	  for	  individuals	  who	  are	  blood	  group	  AB	  (highest	  levels	  of	  VWF)	  
who	   are	   classed	   as	   normal	   but	   in	   reality	   have	   Type	   I	   VWD	   (Gill	   et	   al.,	   1987,	  
Branchford	  and	  Di	  Paola,	  2012).	  
	  
There	  are	  currently	  no	  diagnostic	  tests	  available	  to	  assess	  how	  VWF	  behaves	  in	  the	  
vasculature	  under	   shear	   conditions.	  Although	   the	  Dynamic	   Platelet	   Function	  Assay	  
(DPFA)	  is	  capable	  of	  detecting	  subtle	  changes	  in	  platelet	  function,	  a	  limitation	  of	  the	  
assay	   is	   that	   it	   does	   not	   use	   autologous	   VWF	   to	   measure	   platelet	   function.	   An	  
element	  of	  this	  thesis	  was	  to	  demonstrate	  the	  proof	  of	  concept	  for	  development	  of	  a	  
novel	   synthetic	   surface	   that	   mimics	   collagen,	   and	   which	   is	   capable	   of	   capturing	  
donor-­‐specific	  VWF	   from	  blood	  plasma	  as	  a	  means	  of	   recruiting	  platelets	   from	  the	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In	  this	  chapter,	  I	  will:	  
	  
• Identify	  a	  feature	  size	  in	  a	  topographically-­‐defined	  surface	  that	  captures	  VWF	  
• Determine	   whether	   platelet	   adhesion	   on	   this	   surface	   is	   dependent	   on	   the	  
capture	  of	  VWF	  in	  the	  first	  instance	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7.2	  Results	  
7.2.1	  Optimisation	  of	  polymer	  surfaces	  for	  capture	  of	  VWF	  from	  flowing	  blood	  
Previous	  work	  by	  Minelli	  et	  al.,	  (2008)	  demonstrated	  that	  a	  surface	  coated	  with	  de-­‐
mixed	  solution	  of	  poly(methyl	  methacrylate)	  PMMA	  /	  polystyrene	  had	  the	  ability	  to	  
capture	  VWF	  in	  a	  microfluidic	  device,	  through	  an	  unknown	  mechanism	  from	  flowing	  
blood.	   The	   scope	   of	   the	   first	   part	   of	   this	   experimental	   work	   was	   to	   replicate	   a	  
topographically-­‐defined	   surface	   which	   could	   facilitate	   the	   capture	   of	   VWF	   under	  
arterial	   shear.	   Polymer	   solutions	   comprised	   of	   1%,	   3%	   and	   5%	   (w/v)	   PMMA	   and	  
polystyrene	  micro-­‐beads	  were	  resuspended	  in	  chloroform	  at	  a	  ratio	  of	  50:50	  prior	  to	  
spin-­‐coating	  onto	  glass	  coverslip	  surfaces.	  These	  were	  subsequently	  allowed	  to	  air-­‐
dry,	   which	   resulted	   in	   the	   formation	   of	   nanostructures	   of	   different	   sizes.	   Larger	  
concentrations	   of	   polymer	   solution	   were	   predicted	   to	   produce	   larger	  
nanostructures.	  Platelet	  adhesion	  to	  each	  of	  the	  1%,	  3%	  and	  5%	  polymer	  de-­‐mixing	  
solutions	   under	   arterial	   shear	   flow	   was	   assessed	   (Figure	   7.1).	   There	   was	   no	  
significant	  difference	  in	  platelet	  adhesion	  to	  either	  of	  the	  polymer	  solutions	  selected	  
for	   analysis.	   However,	   a	   3%	   polymer	   de-­‐mixing	   concentration	   had	   on	   average	   the	  















	   151	  
	  
Figure	  7.1	  The	  3	  %	  de-­‐mixing	  polymer	  solution	  has	  the	  greatest	  platelet	  adhesion.	  	  
Blood	   from	   7	   healthy	   donors	   was	   perfused	   over	   each	   of	   the	   polymer	   de-­‐mixing	  
surfaces	   1%,	   3%	  and	   5%	  under	   arterial	   shear	   conditions.	   A	   single	   end-­‐point	   image	  
was	  taken	  after	  5	  minutes	  of	  perfusion	  of	  blood.	  The	  3%	  polymer	  surface	  on	  average	  
had	   the	   greatest	   platelet	   adhesion.	   A	   Kruskal-­‐Wallis	   test	   was	   used	   to	   detect	  
statistically-­‐significant	  differences	  across	  the	  varying	  polymer	  concentrations.	  Data	  is	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7.2.2	  The	  polymer	  surface	  captures	  platelets	  from	  flowing	  blood	  via	  the	  A1-­‐VWF	  
platelet-­‐GPIbα	  interaction	  
Further	  experimentation	  was	  carried	  out	  on	  the	  3%	  (w/v)	  polymer	  surface	  based	  on	  
the	   observation	   that	   this	   surface	   on	   average	   captured	   the	   greatest	   numbers	   of	  
platelets.	   Furthermore,	   the	   scope	   of	   subsequent	   experiments	   was	   to	   determine	  
whether	   the	   interactions	   of	   platelets	  with	   the	   polymer	   surface	  were	   VWF-­‐platelet	  
specific.	   To	   determine	   this,	   blood	   from	   3	   healthy	   donors	   was	   perfused	   over	   the	  
polymer	   surface	   in	   the	   presence	   and	   absence	   of	   the	  GPIbα-­‐specific	   antibody	   AK2.	  
AK2	   binds	   to	   the	   GPIbα,	   thereby	   blocking	   the	   platelets	   interaction	   with	   the	   A1	  
domain	  of	  VWF.	  It	  was	  observed	  that	  platelet	  adhesion	  to	  the	  surface	  was	  inhibited	  
in	   those	   samples	   treated	   with	   antibody	   AK2	   (Figure	   7.2a).	   To	   further	   check	   the	  
specificity	  of	  the	  surface	  to	  capture	  VWF	  under	  arterial	  shear	  conditions,	  a	  VWF-­‐A1	  
specific	  antibody	  CR1	  was	  used.	  CR1	  has	  previously	  been	  demonstrated	  to	  block	  the	  
A1	  domain	  of	  VWF	  (Dong	  et	  al.,	  2001).	  Blocking	  this	  domain	  should	  prevent	  platelet	  
adhesion	   to	   the	  polymer	   surface.	   Blood	   from	  3	  healthy	  donors	  was	   then	  perfused	  
over	   the	   polymer	   surface,	   with	   or	   without	   the	   VWF-­‐A1	   specific	   antibody	   CR1.	  
Platelet	   adhesion	   to	   the	   surface	   was	   inhibited	   in	   those	   samples	   treated	   with	  




















Figure	   7.2	   Whole	   blood	   treated	   with	   antibodies	   that	   block	   the	   platelet	   VWF	  
receptor	   GPIbα	   or	   A1-­‐VWF	   prevents	   platelet	   adhesion	   to	   the	   polymer	   surface.	  
Blood	  from	  3	  healthy	  donors	  treated	  in	  the	  presence	  and	  absence	  of	  AK2	  or	  CR1	  was	  
perfused	   over	   the	   polymer	   surface	   under	   arterial	   shear	   conditions.	   A	   single	   end-­‐
point	   image	   was	   taken	   after	   5	   minutes	   of	   perfusion	   of	   blood.	   (a)	   Representative	  
images	   of	   treatment	   of	   blood	  with	   or	  without	   25	   μg/ml	   of	   platelet	   VWF	   receptor	  
antibody	  GPIbα	  AK2	  (n=3).	  (b)	  Representative	  images	  of	  treatment	  of	  blood	  with	  or	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7.2.3	  The	  polymer	  surface	  is	  sensitive	  to	  an	  increased	  concentration	  of	  VWF	  
The	  concentration	  of	  VWF	  can	  significantly	  differ	  between	   individuals	   (Franchini	  et	  
al.,	  2014).	  Therefore,	   the	   task	  was	   to	  determine	  whether	   the	  polymer	   surface	  was	  
sensitive	  to	  an	  increased	  concentration	  of	  VWF.	  Purified	  human	  VWF	  was	  added	  to	  
blood	   from	   10	   healthy	   donors	   prior	   to	   perfusion	   over	   the	   polymer	   surface	   and	  
compared	   with	   a	   non-­‐treated	   control	   sample	   (Figure	   7.3).	   Assessment	   of	   platelet	  
adhesion	  to	  the	  surface	  showed	  that	  those	  samples	  pre-­‐treated	  with	  purified	  human	  
VWF	  had	  significantly	  increased	  platelet	  adhesion	  to	  the	  surface	  in	  comparison	  with	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Figure	   7.3	   Increasing	   the	   concentration	   of	   VWF	   in	   blood	   increases	   platelet	  
adhesion	   to	   the	   polymer	   surface.	   Blood	   from	   10	   healthy	   volunteers	   was	  
preincubated	  with	  40	  μg/mL	  of	  purified	  human	  VWF	  and	  compared	  to	  an	  untreated	  
blood	   samples	   from	   the	   same	  donor.	   The	   percentage	   of	   platelet	   surface	   coverage	  
was	  measured	  for	  each	  end-­‐point	  image,	  after	  5	  minutes	  of	  blood	  perfusion	  over	  the	  
surface.	   Platelet	   adhesion	   to	   the	   surface	   was	   significantly	   increased	   with	   the	  
addition	  of	  purified	  VWF	  (**p	  <	  0.01).	  A	  paired	  t-­‐test	  was	  used	  to	  detect	  statistically-­‐
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7.3	  Discussion	  
During	   vascular	   damage,	   vascular	  matrix	   proteins	   such	   as	   collagen	   are	   exposed	   to	  
flowing	  blood.	  The	  first	  step	   in	  this	  process	   is	  the	  adhesion	  of	  VWF	  to	  the	  exposed	  
collagen,	  followed	  by	  adhesion	  of	  the	  platelets	  to	  the	  surface.	  Collagen	  is	  commonly	  
used	  as	  a	  substrate	  for	  platelet	  function	  studies.	  However,	  the	  use	  of	  collagen	  as	  a	  
research	   tool	   for	  assessing	  platelet	   function	   is	  problematic.	   Firstly,	   there	  are	  many	  
sources	  (e.g.	  human,	  equine	  and	  murine)	  and	  types	  (type	  I,	  II,	  III	  etc.)	  of	  collagen	  and	  
it	   is	   currently	  unclear	  which	   is	  optimal	   for	  use	   in	  an	  experimental	   setup.	  Secondly,	  
collagen	  surfaces	  lack	  uniformity,	  resulting	  in	  variable	  platelet	  adhesion.	  
	  
In	   this	   chapter,	   a	   principle	   objective	   was	   to	   demonstrate	   a	   proof	   of	   concept	   to	  
develop	  a	  novel	   synthetic	   surface	   that	  mimics	  collagen	  and	   is	   capable	  of	  capturing	  
donor-­‐specific	  VWF	  from	  blood.	  This	  approach	  was	  based	  on	  the	  published	  work	  by	  
Minelli	  et	  al.,	  (2008)	  who	  demonstrated	  that	  a	  surface	  coated	  with	  de-­‐mixed	  solution	  
of	  PMMA/polystyrene	  captured	  VWF	  from	  flowing	  blood	  in	  a	  microfluidic	  device.	  To	  
develop	  the	  nano-­‐surface,	  a	  well-­‐known	  polymer	  de-­‐mixing	  technique	  ‘spin	  coating’	  
was	  used	  (Dalby	  et	  al.,	  2002).	  Different	  concentrations	  of	  polymer	  solution	  (1%,	  3%	  
and	   5%	   w/v)	   were	   tested	   to	   determine	   the	   optimum	   feature	   sizes	   for	   platelet	  
capture.	   Larger	   concentrations	   of	   polymer	   solution	   were	   predicted	   to	   provide	  
nanostructures	  of	  greater	  height	  and	  depth.	   Interestingly,	  Minelli	  et	  al.,	   (2008)	  had	  
noted	   in	   their	   experiments,	   that	   those	   surfaces	  with	   larger	   feature	   size	   and	  depth	  
favoured	  the	  greatest	  capture	  of	  VWF.	  Although	  no	  significant	  differences	  in	  platelet	  
capture	   were	   observed,	   we	   did	   observe	   that	   the	   3%	   polymer	   mix	   captured	   on	  
average	   the	   greatest	   number	   of	   platelets.	   It	   was	   determined	   that	   this	   interaction	  
between	   platelets	   and	   the	   polymer	   surface	  was	   VWF-­‐platelet	   specific	   through	   the	  
use	   of	   two	   control	   experiments	   implementing	   blocking	   antibodies.	   Treatment	   of	  
whole	  blood	  prior	   to	  perfusion	  over	   the	  polymer	   surface	  with	  either	  AK2	  antibody	  
(which	  functions	  to	   inhibit	  GPIbα)	  or	  CR1	  antibody	  (which	  blocks	  the	  A1	  domain	  of	  
VWF)	  prevented	  platelet	  adhesion	  to	  the	  surface.	  The	  efficiency	  of	  these	  antibodies	  
in	  blocking	  platelet	  adhesion	  to	  immobilized	  VWF	  surfaces	  under	  flow	  conditions	  has	  
been	  verified	  previously.	  Wu	  et	  al.,	  (1996)	  previously	  demonstrated	  with	  the	  use	  of	  
immobilised	   VWF,	   that	   treatment	   of	   whole	   blood	   with	   AK2,	   inhibited	   platelet	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adhesion	   to	   VWF	  under	   flow	   conditions.	   Dong	   et	   al.,	   (2001)	   subsequently	   showed	  
that	  the	  CR1	  antibody	  could	  also	  inhibit	  platelet	  adhesion	  to	  VWF	  under	  flow-­‐based	  
conditions.	   The	   addition	   of	   purified	   VWF	   to	   blood	   in	   vitro	   significantly	   enhanced	  
platelet	   adhesion	   to	   the	   surface.	   This	   observation	   correlates	  well	   with	   a	   study	   on	  
fibrillar	   type	   I	   collagen	  which	   demonstrated	   that	   increased	   concentrations	   of	   VWF	  
were	  associated	  with	  enhanced	  platelet	  adhesion	  (Neeves	  et	  al.,	  2013).	  
	  
The	   preliminary	   data	   reported	   in	   this	   PhD	   study	   is	   encouraging	   and	   demonstrates	  
the	   proof	   of	   concept	   for	   development	   of	   a	   novel	   synthetic	   surface	   that	   mimics	  
collagen	   and	   is	   capable	   of	   capturing	   donor	   specific	   VWF	   from	   blood	   plasma	   for	  
investigation	  of	  platelet	   interactions	  with	  autologous	  VWF.	   Identifying	  a	   functional	  
difference	   in	   the	   VWF	   interaction	   with	   platelets	   may	   be	   of	   imperative	   clinical	  
importance	   in	   the	   helping	   to	   identify	   those	   people	   who	   are	   at	   increased	   risk	   of	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Ideally,	   platelet	   function	   should	   be	   assayed	   under	   flow	   and	   shear	   conditions	   that	  
occur	   in	  vivo.	  Currently,	  the	  only	  clinically	  validated	  assay	  of	  platelet	  function	  is	  the	  
platelet	   function	   analyser,	   the	   PFA-­‐100.	   The	   PFA-­‐100	   assesses	   platelet	   function	  
under	   high-­‐shear	   conditions.	   However,	   the	   assay	   suffers	   from	   a	   number	   of	  
limitations,	   including	   its	   insensitivity	   to	   detect	  mild	   bleeding	   disorders	   (Quiroga	   et	  
al.,	   2004)	   and	   its	   reliability	   on	   a	   single	   end	   point	   analysis	   rather	   than	   direct	  
measurement	   of	   platelet	   interaction	   in	   ‘real-­‐time’.	   Previously,	   Prof	   Kenny’s	   RCSI	  
research	   group	   had	   developed	   the	   Dynamic	   Platelet	   Function	   Assay	   (DPFA),	   that	  
used	   a	   novel	   parallel	   plate	   flow	   chambers	   coated	   with	   purified	   human	   VWF	   and	  
custom-­‐designed	  platelet	   tracking	  software	   (Kent	  et	  al.,	  2010,	  Lincoln	  et	  al.,	  2010).	  
The	   custom-­‐designed	   platelet	   tracking	   software	   was	   capable	   of	   deriving	   novel	  
parameters	  of	  platelet	   function	  that	  related	  to	  the	  biological	  activity	  of	  platelets	   in	  
vivo.	  However,	  the	  reliability	  and	  the	  clinical	  relevance	  of	  the	  measured	  parameters	  
of	   the	  DPFA	  were	  unclear	   and	   there	  were	  errors	   in	   its	  platelet	   tracking	  process.	  A	  
primary	   objective	   of	   this	   thesis	   was	   to	   investigate	   the	   above	   issues	   through	  
validation	  and	  clinical	  evaluation	  of	  the	  DPFA.	  
	  
Firstly,	   as	   outlined	   in	   chapter	   3,	   with	   the	   support	   of	   software	   engineers,	   the	  
probability	   function	   detailed	   in	   Lincoln	   et	   al.,	   (2010)	   was	   replaced	   with	   a	   less	  
directional	   distance	   weighting	   method	   (Ralph	   et	   al.,	   2015,	   under	   review	   in	  
Transactions	   on	   Image	   Processing,	   Appendix	   B).	   Implementation	   of	   a	   distance	  
weighting	  method	  allowed	  for	  the	   identification	  of	   individual	  platelets,	  which	  were	  
part	  of	  a	  platelet	  group	  and	  to	  track	  them	  as	  they	  merged	  and	  split	  from	  the	  group.	  
Merging	  and	  splitting	  of	  platelets	  increased	  the	  potential	  for	  platelet	  fragmentation.	  
Platelet	  fragmentation	  occurs	  where	  a	  single	  platelet	  track	  is	  recorded	  smaller	  set	  of	  
tracks.	  Thus,	  stitching	  together	  the	  fragmented	  tracks	  to	  form	  a	  full	  track,	  enhanced	  
the	  ability	  of	  the	  tracking	  software	  to	  accurately	  measure	  platelet	  function.	  	  
	  
The	   accuracy	   of	   the	   distance	   weighting	   method	   to	   track	   platelet	   function	   was	  
validated	   computationally	   using	   an	   ideal	   data	   set	   and	   biologically	   using	   a	   P2Y1	  
receptor	   inhibitor	   MRS2179.	   The	   ideal	   data	   set	   determined	   the	   percentage	  
systematic	   error	   for	   each	   measured	   parameter	   of	   platelet	   behaviour	   and	   also	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revealed	   that	   higher	   object	   counts	   resulted	   in	   greater	   numbers	   of	   merging	   and	  
separating	   platelet	   events.	   Merging	   and	   separating	   of	   platelets	   increased	   the	  
potential	   for	  mistracking.	  Despite	   this	   potential	   for	  mistracking,	   the	  DPFA	  was	   still	  
capable	   of	   detecting	   subtle	   changes	   in	   platelet	   function.	   This	   was	   demonstrated	  
through	  the	  use	  of	  MRS2179.	  Platelets	  treated	  in	  the	  presence	  of	  the	  P2Y1	  receptor	  
inhibitor	   had	   significantly	   amplified	   platelet	   translocation	   speeds	   on	   VWF	   and	   this	  
confirmed	   the	   results	   of	   previously	   published	   data	   (Mazzucato	   et	   al.,	   2004).	   This	  
finding	   verified	   the	   ability	   of	   the	   assay	   to	   determine	   drug	   effect.	   The	   DPFA	   was	  
sensitive	  to	  HCT	  which	  matched	  predicted	  results	  generated	  by	  computer	  simulation	  
models	   of	   dynamic	   platelet-­‐wall	   adhesion	   (Fitzgibbon	   et	   al.,	   2014).	   This	   finding	  
demonstrated	   the	   importance	   of	   RBC	   platelet	   interactions	   in	   determining	   initial	  
platelet	   adhesion	   and	   the	   capability	   of	   the	   DPFA	   to	   diagnose	   altered	   platelet	  
function.	   A	   reference	   range	   of	   platelet	   function	   was	   determined	   for	   the	   assay	  
evaluating	  a	   total	  of	  109	  healthy	  donors.	   This	   is	  well	   above	   the	  number	  of	  donors	  
required	  which	  is	  39	  (Solberg,	  1987).	  	  
	  
In	  chapter	  4,	  the	  effect	  of	  age	  and	  gender	  on	  platelet	  function	  was	  investigated.	  The	  
results	  demonstrated	  that	  both	  age	  and	  gender	  play	  a	  significant	  role	  in	  altering	  the	  
behaviour	  of	  platelets.	  The	  data	  showed	  that	  platelets	  become	  more	  active	  with	  age,	  
with	   this	   effect	   being	   more	   profound	   for	   females	   than	   in	   males.	   Despite	   having	  
reduced	  numbers	  of	  platelets	  interacting	  with	  VWF,	  platelets	  from	  older	  donors	  had	  
significant	   increases	   in	   the	   platelet	   surface	   coverage.	   This	   was	   due	   to	   increased	  
adherence	   of	   platelets	   to	   VWF	   as	   measured	   by	   a	   significant	   reduction	   in	   the	  
numbers	  of	  unstable	  platelet	  interactions	  with	  VWF.	  These	  more	  profound	  changes	  
in	   platelet	   function	   associated	   with	   aging	   in	   females	   may	   be	   related	   to	   sex	  
hormones.	   Both	   estrogen	   and	   testosterone	   have	   been	   shown	   to	   affect	   platelet	  
function	  (Jayachandran	  et	  al.,	  2010,	  Ajayi	  et	  al.,	  1995).	  Estrogen	  levels	  fall	  rapidly	  in	  
older	   females	   as	   opposed	   to	   the	   rather	   gradual	   decline	   of	   testosterone	   levels	   in	  
older	  males.	  This	  may	  explain	  why	  alterations	  in	  platelet	  function	  are	  more	  extensive	  
in	  females	  than	  in	  males.	  This	  is	  recommended	  as	  an	  area	  for	  future	  research.	  
Overall,	  the	  results	  generated	  by	  the	  DPFA	  are	  consistent	  with	  the	  concept	  that	  age	  
is	  associated	  with	  more	  reactive	  platelets	  (Bastyr	  et	  al.,	  1990,	  Gleerup	  and	  Winther,	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1995,	  Reilly	  and	  FitzGerald,	  1986).	  This	  finding	  demonstrates	  the	  power	  of	  the	  DPFA	  
to	  detect	  subtle	  alterations	  in	  platelet	  function	  related	  to	  aging.	  
	  
The	   DPFA	   can	   quantify	   platelet	   function	   in	   <	   100	   μL	   of	   blood,	   thereby	   making	   it	  
suitable	   for	   research	   in	   cohorts	   where	   blood	   availability	   is	   a	   limiting	   factor.	   In	  
chapter	  5,	  platelet	  function	  in	  very	  low	  birth	  weight	  (VLBW)	  preterms	  and	  full-­‐term	  
infants	   was	   investigated.	   Studies	   in	   the	   neonatal	   area	   are	   restricted	   due	   to	   small	  
circulating	  blood	  volumes	  (80	  mL/kg).	  Utilising	  the	  DPFA,	   it	  was	  demonstrated	  that	  
VLBW	  preterm	  infants	  had	  significantly	  different	  platelet	  translocation	  behaviour	  on	  
VWF	  compared	  with	  full-­‐term	  infants.	  In	  particular,	  it	  was	  found	  that	  VLBW	  preterm	  
infants	   displayed	   decreased	   platelet	   adhesiveness	   to	   VWF	   with	   an	   accompanying	  
increase	   in	   platelet	   translocation	   speeds	   and	   unstable	   platelet	   interactions	   with	  
VWF.	  A	  possible	  explanation	  may	   relate	   to	   reduced	  PAC-­‐1	  binding	   (binds	  activated	  
αIIbβ3)	   in	   VLBW	   preterm	   infants	   (Sitaru	   et	   al.,	   2005).	   Platelets	   need	   to	   activate	  
αIIbβ3	   in	   order	   to	   adhere	   to	   immobilised	   VWF	   (Savage	   et	   al.,	   1996).	   Therefore,	  
reduced	  activation	  of	  αIIbβ3	  would	  reduce	  adherence	  of	  platelets	  to	  VWF,	  leading	  to	  
increases	   in	   platelet	   translocation	   speeds	   and	   numbers	   of	   unstable	   platelet	  
interactions	   with	   VWF.	   Notably	   VLBW	   preterm	   infants	   identified	   with	   either	   low	  
platelet	  count	  (<104	  x	  103	  μL	  of	  blood)	  or	  HCT	  (28%)	  displayed	  significantly	  reduced	  
platelet	   translocation	   behaviour	   on	   VWF.	   This	   result	   matched	   the	   behaviour	   of	  
platelets	  presented	  in	  chapter	  3	  which	  demonstrated	  that	  reducing	  platelet	  count	  or	  
HCT	  significantly	  inhibited	  platelet	  adhesion	  to	  VWF.	  	  
	  
Overall,	   the	   results	   of	   the	   DPFA	   experiments	   with	   neonates	   were	   consistent	   with	  
previous	  studies	  of	  platelet	   function	  which	   report	   that	  VLBW	  preterm	   infants	  have	  
impaired	   platelet	   function	   (Boudewijns	   et	   al.,	   2003,	   Levy-­‐Shraga	   et	   al.,	   2006,	   Del	  
Vecchio	   et	   al.,	   2008).	   These	   differences	   in	   platelet	   function	  may	   contribute	   to	   the	  
higher	  incidences	  of	  bleeding	  observed	  in	  preterm	  infant	  populations.	  This	  evidence	  
further	  validates	  the	  use	  of	  the	  DPFA	  to	  distinguish	  changes	  in	  platelet	  function.	  
Platelets	  have	  been	  identified	  to	  serve	  as	  potential	  mediators	  in	  the	  formation	  of	  a	  
normally	  functioning	  placenta	  (Sato	  et	  al.,	  2005,	  Bodis	  et	  al.,	  2014,	  Sato	  et	  al.,	  2010).	  
Alterations	  in	  platelet-­‐mediated	  placentation	  may	  contribute	  to	  the	  development	  of	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utero-­‐placental	   diseases	   (Norris	   et	   al.,	   1994,	  Mullers,	   2015,	  Morrison	   et	   al.,	   1985,	  
Stubbs	  et	  al.,	  1986,	   Janes	  and	  Goodall,	  1994,	  Norris	  et	  al.,	  1993).	   In	  chapter	  6,	   the	  
DPFA	   was	   used	   to	   assess	   platelet	   function	   changes	   in	   healthy	   pregnancy	   and	   in	  
pregnancy	   with	   utero-­‐placental	   disease.	   The	   results	   of	   the	   DPFA	   suggested	   that	  
healthy	   pregnant	   females	   in	   the	   third	   trimester	   had	   more	   reactive	   platelets	   than	  
healthy	  females	  who	  were	  not	  pregnant.	  More	  reactive	  platelets	  are	  concurrent	  with	  
decreases	   in	   platelet	   translocation	   speeds	   on	   VWF	   in	   pregnant	   females.	   In	   this	  
thesis,	  it	  hypothesised	  that	  decreases	  in	  HCT	  may	  compensate	  for	  this	  hyperreactive	  
state.	   This	   may	   explain	   why	   pregnant	   females	   had	   significant	   reductions	   in	   the	  
numbers	  of	  platelets	   interacting	  with	  VWF.	  Pregnancy	  with	  utero-­‐placental	  disease	  
was	   associated	   with	   impairment	   in	   platelet	   function.	   This	   impairment	   was	   more	  
profound	  in	  utero-­‐placental	  disease	  with	  PET.	  This	  is	  interesting	  as	  PET	  represents	  a	  
more	  severe	  clinical	   form	  of	  utero-­‐placental	  disease	   in	  comparison	  to	   IUGR	  or	  PIH.	  
This	   finding	   demonstrates	   the	   ability	   of	   the	   DPFA	   to	   extricate	   small	   changes	   in	  
platelet	  function.	  It	  is	  proposed	  that	  future	  studies	  should	  apply	  this	  assay	  in	  a	  large	  
cohort	   across	   the	   three	   trimesters	  of	  pregnancy,	   as	   these	   studies	  are	   considerably	  
lacking	  and	  are	  warranted.	  
	  
Finally,	  in	  chapter	  7,	  the	  future	  of	  the	  DPFA	  was	  explored.	  One	  of	  the	  limitations	  of	  
the	   assay	   is	   that	   is	   does	   not	   use	   autologous	   VWF	   to	   measure	   platelet	   function.	  
Previous	  work	  by	  Minelli	  et	  al.,	  (2008)	  demonstrated	  that	  a	  surface	  coated	  with	  de-­‐
mixed	   poly(methyl	   methacrylate)	   PMMA	   /	   polystyrene	   had	   the	   ability	   to	   capture	  
VWF	  from	  flowing	  blood	  in	  a	  microfluidic	  device	  through	  an	  unknown	  mechanism.	  As	  
our	   research	   group	   did	   not	   have	   the	   expertise	   to	   design	   such	   a	   surface,	   we	  
collaborated	  with	  the	  Nanotechnology	  and	  Integrated	  BioEngineering	  Centre	  (NIBEC)	  
in	   Ulster	   University	   Jordanstown.	   The	   preliminary	   work	   presented	   in	   this	   thesis	   is	  
encouraging.	  It	  was	  demonstrated	  that	  the	  polymer	  surface	  was	  capable	  of	  capturing	  
VWF	   from	   flowing	   blood,	   followed	   by	   platelet	   adhesion	   to	   the	   polymer	   surface.	  
Platelet	  interactions	  with	  the	  polymer	  surface	  were	  shown	  to	  be	  GPIα	  /	  VWF	  specific	  
through	  the	  use	  of	  blocking	  antibodies	  AK2	  (which	  functions	  to	  block	  GPIbα)	  and	  CR1	  
(which	  blocks	   the	  A1	  domain	  of	  VWF).	   The	   surface	  was	  also	   sensitive	   to	   increased	  
concentrations	   of	   VWF,	   verified	   through	   the	   addition	   of	   purified	   VWF	   to	   blood	   in	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vitro,	  which	  significantly	  enhanced	  platelet	  adhesion	  to	  the	  surface.	  The	  DPFA	  with	  a	  
polymer	  surface	  that	  can	  capture	  VWF	  from	  blood	  plasma	  to	  assess	  platelet	  function	  
would	  be	  extremely	  powerful	  in	  future	  research	  work.	  
	  
There	   are	   many	   advantages	   to	   the	   DPFA	   that	   have	   been	   discussed	   in	   this	   thesis	  
including	   the	   use	   of	   whole	   blood,	   low	   sample	   volumes	   (<	   100	   μL),	   a	   shear	  
environment	  and	  the	  measurement	  of	  multiple	  behaviours	  of	  platelets	  translocating	  
on	   VWF	   in	   real-­‐time.	   A	  major	   limitation	   of	   the	   assay	   relates	   to	   the	   assay	   surface,	  
which	   is	  only	  coated	  with	  VWF,	  so	  therefore	  only	   focuses	  on	  two	  platelet	  receptor	  
interactions.	   Firstly,	   the	   platelet	   GPIbα	   interaction	   with	   VWF	   that	   results	   in	   the	  
characteristic	  tethering	  and	  rolling	  of	  platelets,	   followed	  by	  activation	  of	  αIIbβ3	  for	  
stable	  platelet	  adhesion.	  However,	   in	   vivo	   collagen	  plays	  a	  key	   step	   in	   the	  platelet	  
activation	   process	   through	   engagement	   with	   platelet	   receptor	   GPVI.	   The	   result	   is	  
powerful	   activation	   signals	   causing	   αIIbβ3	   activation,	   release	   of	   platelets	   agonists	  
such	  as	  ADP	  and	  subsequent	  platelet	  thrombus	  formation.	  More	  recently,	  de	  Witt	  et	  
al.,	  (2014)	  demonstrated	  the	  use	  of	  a	  multi-­‐surface	  and	  multi-­‐parameter	  flow	  assay	  
that	   could	   characterise	   platelet	   thrombus	   formation	   in	   healthy	   subjects	   and	   those	  
with	   platelet	   function	   deficiencies.	   The	  major	   advantage	   of	   de	  Witt	   et	   al.,	   (2014)	  
assay	   in	   comparison	   to	   DPFA	   presented	   in	   this	   thesis	   was	   the	   ability	   to	   pick	   up	  
multiple	   receptor	   abnormalities.	   The	   assay	   incorporates	  multiple	   surfaces	   such	   as	  
collagens,	  peptides	  and	  laminin	  to	  name	  a	  few	  as	  opposed	  to	  just	  VWF	  measured	  in	  
this	   thesis.	   However,	   the	   process	   is	   labour	   intensive,	   involves	   multiple	   staining	  
procedures,	  manual	  analysis	  and	  because	  the	  assay	   incorporates	  multiple	  proteins,	  
there	  likely	  is	  a	  considerable	  expense	  in	  running	  the	  assay.	  In	  contrast	  to	  this,	  DPFA	  
involves	   a	   single	   staining	   procedure,	   prior	   to	   a	   flow	   run	   and	   a	   custom	   designed	  
platelet-­‐tracking	  software,	  which	  provides	   rapid	  analysis	  of	  cohorts	  of	   interest	   (<	  5	  
minutes).	   Morgan	   et	   al.,	   (2013)	   developed	   3D	   enclosed	   perfusable	   microvessels	  
manufactured	  in	  bioremodelable	  hydrogel	  (collagen	  type	  I).	  The	  major	  of	  advantages	  
of	   this	   system	   in	   contrast	   to	   the	   DPFA	   include	   the	   ability	   to	   visualise	   a	   3D	  
microenvironment	  in	  vitro,	  not	  only	  the	  capability	  to	  study	  models	  of	  thrombosis	  but	  
also	   to	   study	   models	   of	   tumor	   angiogenesis,	   wound	   healing	   and	   diabetes.	   The	  
limitations	   of	   assay	   described	   by	   Morgan	   et	   al.,	   (2013)	   include	   a	   complicated	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manufacturing	   procedure,	   therefore	   limits	   its	   throughput	   and	   microvessel	  
reproducibility	  at	  lateral	  dimensions	  below	  50	  μm.	  
	  	  
In	   conclusion,	   this	   thesis,	   took	   a	   previously	   described	   DPFA	   Lincoln	   et	   al.,	   (2010),	  
addressed	  the	  issues	  in	  its	  tracking	  process	  through	  refinement	  and	  validation	  of	  the	  
accuracy	   of	   its	   parameter	   outputs.	   The	  DPFA	  was	   evaluated	   clinically,	   using	   blood	  
samples	  from	  adults,	  neonates	  and	  females	  with	  healthy	  pregnancy	  and	  pregnancies	  
complicated	   with	   utero-­‐placental	   disease.	   The	   DPFA	   was	   shown	   to	   be	   capable	   of	  
detecting	  subtle	  changes	  in	  platelet	  function	  in	  these	  clinical	  cohorts.	  These	  changes	  
in	   platelet	   function	   were	   cognizant	   to	   the	   behaviours	   of	   platelets	   in	   vivo.	   It	   is	  
recommended	  that	  future	  work	  should	  seek	  to	  enhance	  and	  further	  understand	  the	  
assays	  outputs.	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Abstract—Here, we report on the enhancements made to a
method previously developed by this group to analyze complex
dynamic platelet-protein surface behavior. Platelets are imaged
on a defined von Willebrand factor (VWF) surface using a
custom-designed microfluidic parallel plate flow chamber at
arterial shear flow rates (Lincoln et al., Analytical Biochemistry
405 (2), 174-183). Using the centroids and area of each platelet
at each time frame, a time history or track can be constructed
for each platelet. Enhancements have been made to the tracking
process through the design and verification of nine key trajectory
parameters using idealized data sets where the values are known,
specifically (1) total number of tracks, (2) the number of stably-
adhered platelets, (3) the number of translocating platelets, (4)
weighted median speed, (5) mean translocation distance, (6)
percentage surface coverage, (7) percentage motion, (8) initial
pause-time distribution and (9) adhesion rate, with absolute mean
error determined for each variable. Hence, this novel analytical
method provides rapid data pertinent to platelet translocation
properties which can readily be applied for the analysis of
different disease cohorts in the presence and absence of anti-
platelet therapies (e.g. Aspirin, Clopidogrel).
Index Terms—Platelet characterization, Image analysis,
Weighted distance matrix, Microfluidic parallel-plate flow cham-
ber, Algorithms, Computer Analysis.
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Enhancements to a platelet tracking method of
shear-mediated platelet interactions with von
Willebrand factor
Adam Ralph,Martin Somers,Jonathan Cowman,Bruno Voisin,Emma Hogan,
Hannah Dunne,Eimear Dunne,Barry Byrne,Antonio Ricco,Dermot Kenny,Simon Wong
I. INTRODUCTION
PLATELETS play key roles in maintaining normalhemostasis, and in the pathogenesis of ischemic syn-
dromes occurring in the vicinity of ruptured atherosclerotic
arteries. Thus, understanding the intrinsic relationship between
platelet activation states and their kinetic properties upon
association with matrix proteins such as von Willebrand factor
(VWF) under defined flow conditions provides physiologically
relevant information directly relating to the initial responses
to vascular injury. It is well established that cardiovascular
disease (CVD) is a major cause of mortality and morbidity,
which places considerable financial burden on healthcare sys-
tems. Platelet adhesion and aggregation, essential responses to
arterial vascular injury [1], depend on the initial capture and
translocation of platelets on adhered VWF. Such interactions
are shear stress-dependent, are influenced by blood flow con-
ditions [2]–[5], are rapidly reversible and result in start-stop
platelet movements [3]–[7]. Platelets undergo changes in their
respective physiologies during thrombosis, suggesting that
the monitoring of platelet morphologies (physical) and their
functional state (biochemical) are clinically useful indicators
of acute thrombotic events that, in turn, are useful predictors
of thrombotic events.
Using the experimental methodology described previously
[8] and the VWF-doped surfaces [9], we obtain a time-series
set of images (or frames at a rate of 30 frames/s) of an
133× 133µm2 section of the surface. Platelets are incubated
with a fluorescent dye, (3,3’-Dihexyloxacarbocyanine Iodide,
DioC6) which localizes to the endoplasmic reticulum and mi-
tochondria of platelets, so that they can be imaged. However,
only those that interact with the surface are captured by the
imaging software (Metamorph R￿Image Analysis Software).
Experiments are conducted to capture the early stages of
platelet adhesion before large-scale platelet aggregation oc-
curs, in the order of 16.7s (equivalent to 500 frames). However,
during this process platelets will translocate with the direction
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of the flow and recruit others. Thus, during this period platelets
merge and separate over time making it difficult to apply
other cell tracking algorithms [10]–[14]. The challenge then
is not to locate the platelet on each frame, but to track the
platelets, over time, from one frame to the next with the
centroid position and area for each frame where a platelet
is visible, referred to as the platelet’s track. While a limited
amount of information can be obtained from the static images,
interrogation of platelet tracks produces a range of outputs
that can be qualitatively and quantitatively measured, such as:
translocation speed, translocation distance and percentage of
time in motion.
With reference to the previously described method of track-
ing platelet behavior [8], a challenge for this system is that
of platelet track fragmentation, where a single platelet track is
recorded as a set of smaller tracks. The major source of platelet
track fragmentation is the merging and separating of platelets
over time (figure 1, platelet B). The enhancement of the
tracking method described here, compared to that we described
previously [8], is to identify individual platelets which are
part of a platelet group and to track them as they merge and
split from the group. This will allow construction of the full
platelet track. This is in contrast to another method, described
by [15], where watershed segmentation was used to separate
joined platelets on the image. We did not implement watershed
segmentation in the tracking algorithm as the average number
of platelets per frame was high (in the order of a few hundred),
some were substantially overlapped (> 20%) and in a range
of sizes, making it time consuming and difficult to implement.
II. MATERIAL AND METHODS
A. Conversion Factor
A conversion factor was calculated so that all measurements
on the aforementioned microscope system can be quantita-
tively related to the physical movements of platelets within the
parallel platelet flow chamber. This was achieved through the
use of a fluorescently-labelled (Cy3) fibrinogen microcontact-
printed array comprised of ∼ 6µm dots separated in all planes
by ∼ 15µm. Due to the microcontact-printing process these
distances can vary by 1-2% [16]. A single image was taken
under conditions that mimic the settings for the assay. A
series of eight dots (figure 2), measured 5 times, were used to
determine the conversion factor from pixels to micrometers
0000–0000/00$00.00 c￿ 2012 IEEE
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(a) Frame n (b) Frame n+1
Fig. 1. Two consecutive frames of masked images, the left being the current frame and the right the next. Most platelets can be assigned uniquely, except A
is new and B merges. The flow is up the page (+y) and the images have been inverted black to white.
(µm), with ImageJ processing [17] used to quantify pixel
dimensions.
The distance over 8 spots from center to center was calcu-
lated to be 111µm, e.g. (7 × 15µm) + 3µm + 3µm, which
correlated to an average distance of 431.91 pixels. Hence,
a conversion factor of 0.2569 (111µm/431.91 pixels) was
calculated, implying this (rounded to 0.26) could be used for
converting pixel dimension into micrometers.
B. Tracking Process
Previous platelet tracking algorithms have used a probability
function and cut-off based on the typical movement of a
platelet on a clutter-free, smooth surface. That is to say,
there is a strong preference for movement in a narrow angle
in the direction of the flow [8], [15]. This can result in
tracking errors due to merging and splitting of platelet groups
and/or movement around obstructions. Previous results [15]
demonstrate that tracking is adversely affected by probability
functions that are strongly directional, in the direction of the
flow, but not by ones that are more omnidirectional. The
distance weighting method, described herein, is much less
directional.
Initially, platelets are identified in each frame of an image
sequence of 500 frames using the auto-threshold method [8].
This method reliably detects and records the (x, y) centroid
position and approximate size of each platelet in an image
frame against a continuously changing background using the
Image Processing Toolkit of MatLab [18]. Next, a platelet
track is constructed by identifying the same platelet from one
frame to the next and recording the change in (x, y) over
time. To this end, a weighted distance matrix is generated
between a track’s current position and all other platelets on
the next frame. The weighting method gives preference to
platelet movement in the direction of flow over cross-stream
movement. Each track is extended by assigning a platelet in
the next frame, if possible, by applying a set of rules to the
weighted distance matrix. Complementary changes in platelet
area allow the detection of two or more platelets merging into
one object or conversely splitting. The result is a list of tracks
with (x, y) positions and area (A) over time, linking each
platelet in an image sequence.
The weighted distance is calculated between the ends of
the currently active tracks (Ri) with the platelets on the
subsequent frame (Nj) (eq. 1). Each object (Ri andNj) has its
centroid and area calculated with the flow in the +y direction.
Using the tracking rules outlined in table I tracks are amended
using six scenarios. The current tracks can be extended by
assigning a platelet on the next frame (Nj), new tracks started
or currently active tracks are deactivated because they cannot
be assigned a platelet on the next frame. This procedure is
then repeated on the next frame, with the updated set of active
tracks, and so on until the final frame is reached.





∆x = xi − xj ,
∆y = yi − yj ,
θ = arctan (∆x/∆y) ,−π ≤ θ ≤ π
Six possible scenarios are considered when amending the
tracks:
1) Ri is unambiguously assigned to a new platelet Nj ,
2) Ri and Rk merge to form Nj on the next frame,
3) Merged tracks Ri and Rk split on the next frame to form
Nj and Nl ,
4) Ri splits to form Nj and Nl hence forming a new track
because Ri was considered a single platelet,
5) Ri cannot be assigned to a new platelet because it has
disappeared,
6) Nj cannot be assigned to a previously recorded track
because it is new.
When two platelets merge, the two tracks have the same
(x, y,A) values but are managed as two separate tracks. In
subsequent frames they are matched as one object but both
tracks (i and k) are extended until they split, at which point
the (x, y,A) for each track is different. Mergers and splits
are not restricted to just two platelets, three or more could
be involved and the algorithm keeps a record of how many
platelets form a group, to ensure a group cannot split into
more tracks than group members. It is also possible that
initially a platelet is recorded as a singlet, only to split later
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(a) Schematic (b) Image
Fig. 2. Microcontact-printed fibrinogen array, comprised of 6µm dots labelled with Cy3, which were center to center 15µm apart. Eight individual dots
were imaged and subsequently selected for determining a conversion factor for estimating µm distances, based on pixel content. Left is a schematic and right
the imaged array, the eight dots used are between A and B.
(scenario 4). In this instance, the platelet is in fact a multiple
and it is tracked retrospectively as a multiple. Appearance
and disappearance of platelets is not restricted to the top and
bottom of the image, respectively, but can occur anywhere.
Platelets can also disappear if they move out of the imaging
area, in the direction of the flow. Furthermore, Glycoprotein
Ib alpha (GPIbα) (as this is the part of the subunit of the
platelet that interacts with A1 domain of VWF) tethering can
break, due to the pressure exerted, under arterial shear, leading
to platelets disappearing anywhere on the imaged surface.
Finally, platelets can apparently disappear if they become too
faint. Tracks are allowed to reappear in the space of 5 frames,
which can happen if the high-intensity platelets move out
of frame, lowering the masking level so that dim platelets
reappear in the masked image. This occurs very infrequently
and no special conditions are applied in this case.
The distance matrix along with the area changes are used to
distinguish between the various different tracking possibilities.
Table I matches each scenario with the necessary conditions.
No cut-offs were applied to the weighted distance function but
instead hard limits (similar to yc in [8]) were applied to stop
recorded tracks being extended over distances, which were
considered physically impossible. Specially, if the distances
observed were |∆x| > 5.2µm or ∆y > 5.2µm upstream
or ∆y > 26.0µm downstream, the assignment was rejected.
These values were set empirically from manual inspection of
the algorithm’s performance. They are larger than those you
might obtain from fluid flow dynamics, to ensure that platelets
are tracked correctly when merging and separating.
Finally after all of the tracks are constructed from the image
set, some are rejected. Rejections are based on two criteria: if
the tracks are 10 frames or less and if the platelet area is less
than ∼ 3µm2. The first criterion is to remove unavoidable
fragmented tracks. The second is to remove tracked objects
that are not platelets. The limit is smaller than the area of a
small platelet (∼ 4µm2).
TABLE I
RULES UNDER WHICH NEW PLATELETS ARE ASSIGNED TO PREVIOUSLY
RECORDED TRACKS, FOR THE SIX SCENARIOS DESCRIBED ABOVE.
Scenario Tracking Results
1 Ri and Nj are closest to each other.
2 Ri and Rk are closest to Nj , with a suitable increase in
area in Nj .
3 Nj and Nl are closest to Ri (or Rk) which are
multiples, with a suitable reduction in areas for both
Nj and Nl.
4 same as 3 but Rj is a singlet.
5 all the suitable new platelets have been assigned.
6 all the suitable recorded tracks have been assigned.
C. Validation
To validate the tracking algorithm, ideal image sets were
created. A set of tracks was created with known properties,
which were then used to generate the images. The image
set can be run through the tracking process populating the
variables. As the ideal tracks have known properties, we
can compare values obtained through the process against the
expected values. Many different ideal image sets were created,
outlined below, with different track properties to cover the
range of properties we find experimentally.
Using the centroid values for each platelet on each image
(from the ideal tracks) roughly same sized circular platelets
were placed at each point. Due to pixelation of the image,
platelets cannot be all the same size or indeed completely
circular. Each object had the maximum intensity with a back-
ground of zero, i.e. no noise. Figure 3 shows an example of an
ideal image. On each start frame (frame 1), 25 platelets were
randomly placed, with the only restriction being the absence
of overlapping platelets. Each image set had a known number
of ideal tracks (object count), which is equal to the number
of platelets on the final frame (frame 500). On subsequent
frames, platelets were added at regular intervals so that on
the final frame, the expected number of tracks was achieved.
Again, platelets were placed randomly in areas where they
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Fig. 3. Example of a single image from an image set used to validate the
tracking process.
would not overlap other platelets. As no platelets overlapped
when they first appeared, a perfect tracking system would
record all tracks. Any deviation from the expected number
would be due to mistracking. A fraction of platelets were
assigned as translocating. Each translocating platelet had the
same track, e.g. they moved for 100 pixels at 1.0 pixel/frame
and then stopped. Static platelets did not move at all, hence
having a translocating distance of zero. Care was taken so that
no platelet was removed from the image. The translocating
platelets moved only in the direction of the flow with no
restrictions on the number of mergers and separations after
its initial frame.
For each dataset, five variables were fixed: the final object
count (50, 100, 150, 200, 250, 300, 350, 400), the fraction
of static platelets (10%, 20%, 30%), the translocating speed
(0.5, 1.0, 1.5 pixels/frame), the translocating distance (50,
100, 150 pixels) and the initial pause time (10, 20 and 30
frames). Three different runs were generated with the same
values for each of the 5 variables. The accuracy of each of
the variables above was determined by comparing the expected
value, which is known a priori against that obtained from the
tracking process. Errors from runs with same expected value
are averaged together to give the results shown in Section III.
Several runs were generated with no merging or separation
events. These error-free runs gave the expected values for
each variable (results not shown), allowing for detection and
elimination of inherent errors in the algorithm.
D. Artificial Movement
When considering platelet mergers and separations, there is
a large source of systematic error in the motion of the platelet
which must be addressed. When platelets merge and separate
there is an apparent movement that is larger than their actual
movement. This is due to the centroid moving to a different
location within the platelet or less frequently outside its area.
An example of artificial movement is presented in figure 1,
where two platelets (B) merge to form a single object on the















Fig. 4. Histogram of platelet translocating speeds (calculated as described in
the section II-E4). Speeds with artificial movement removed (grey bars) and
not removed (white bars) from the same image set. The grey bars have been
displaced to enable comparison. The y-axis is square rooted.
move upstream and for the lower platelet it jumps downstream.
This artificial movement, if not accounted for, will affect the
values of platelet speed and distance traveled. Figure 4 shows
the histogram of speeds from a single run with and without
artificial movement removed. When artificial movement is not
removed there is a longer tail of high velocities, which is
exactly what we would expect.
A second case of artificial movement is platelet wobble.
From frame-to-frame, platelets may appear to change shape
because the masking threshold changes or they change shape
when moving. This causes some uncertainty in each platelet’s
actual centroid position. This sort of artificial movement is
difficult to remove and will affect the instantaneous velocity
(currently we are not using shape information as part of the
tracking process). In the next section we describe the use of
moving averages to ameliorate the effect of platelet wobble.
E. Measured Variables
Below are the definitions for each of the variables, 9 in total,
which are being assessed.
1) Total Number of Tracks: The total number of tracks is
the number of platelet tracks, which the algorithm has deemed
to be unique, after rejecting tracks where the platelets are too
small.
2) Number of Stably-Adhered:
3) and Translocating Platelets: Translocating and stably-
adhered (or static) platelets are categorized from the set of
tracks, after all rejections are removed. A platelet is considered
as translocating or static, not both. The classification of static
and translocating platelets is an important one because many
of the other variables are calculated from the translocating
platelets. For this reason the classification was based on the
movements of the singlet platelets only, ignoring all motions
when part of a platelet group. A platelet is classed as translo-
cating if it has moved more than 1.5x its average radius over
the length of the track (when a singlet).
4) Weighted Median Speed: As can be seen from figure 4
a typical speed distribution will be severely skewed, limiting
the usefulness of mean-based metrics. Additionally, erroneous
speeds exist due to platelet wobble and mistracking. As previ-
ously mentioned, platelet wobble is the artificial change in the
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platelet centroid and will typically overestimate the number
of smaller speeds. To reduce the effect of platelet wobble,
instantaneous velocities were averaged in a 5-frame window.
That is to say, both speed and direction were used. The result
is reduced to a speed, which is then used in the calculation
of the weighted median. The artificial movements introduced
by merging and separating platelets, which can be identified,
are removed. Mistracking events cannot be predetermined and
will typically lead to an overestimation of higher speeds. Using
a weighted median will reduce the effect of these erroneous
speeds and provide more meaningful speed measurements.
5) Mean Translocating Distance: The translocating dis-
tance (TD) for one track is calculated from eq. 2. The per
frame x and y displacements (dx and dy) are summed sepa-
rately (including sign) and then squared and added. Artificial
movements due to merging and separation events are removed.
Thus, the distance is not the same as that calculated from the
start and end points of the track. The mean is calculated from










6) Surface Coverage: Surface coverage is the percentage
of the sum of platelet areas on a particular frame over 512×
512 pixels2. Two variations were used: the surface coverage on
the last frame and the difference in surface coverage between
the first and last frames.
7) Percentage Motion: Percentage motion for a single
translocating platelet is the ratio of the time in motion to
the time it is attached to the surface. Thus, if the platelet
continually translocates, then the percentage motion would
be 100%. Typically a platelet may translocate, stop, and then
translocate again. In this case, the percentage motion is less
than 100%. When considering a set of tracks, it is the sum of
the frames where a platelet is in motion (over all translocating
platelets) divided by the sum of the track lifetimes (in frames
over all translocating platelets).
Motion per frame is calculated the same way as the speed,
i.e. it is the distance moved over a 5-frame window, removing
artificial movements from merging and separating. If this
value is bigger than the cutoff, then the platelet is defined as
having moved that frame. A cutoff value is essential, otherwise
percentage motion will always be near 100%. The cutoff used
is twice the mean motion per frame of the stably-adhered
platelets. The motion of the stably-adhered is assumed to be
noise only.
8) Initial Pausetime Distribution: The initial pause time is
the number of frames that a translocating platelet is stationary
before it starts to move. The pausetimes for every valid track
from the run is used in the distribution.
9) Adhesion Rate: Adhesion rate is the rate at which new
tracks appear, which we assume to be roughly linear. For ease
of calculation the rate is in fact obtained from the number of
platelets per frame, which would be exact only if no platelets
moved out of frame. If the rate is clearly non-linear then the
rate is calculated from the linear part. Calculating the rate
from the number of platelets per frame has the advantage in
that image-processing irregularities are easily detected.
III. RESULTS
A. Ideal Data Sets
The main influence on the errors for all of the variables was
the object count. This is correlated with the number of merging
and separating events and hence, the number of mistracking
events i.e. the higher object count, the more mistracking
events. For this reason we present the mean absolute error over
the 8 object count levels in table II, for 7 of the nine variables.
Figures are used to illustrate the variation in error for some of
the variables. Figures 5-7 have the variable measurements on y
and object count on x. There are 3 static fraction values which
are color coded. Runs were produced and plotted in triplicate
for a fixed value of object count, translocating distance and
speed, initial pausetime and static fraction. The statistics have
been produced by the statistical package R [19] and plots by
the R ggplot2 package [20].
1) Total Number of Tracks: The error in the total number
of tracks is correlated with the object count and tends to
be overestimated. This is evident at higher object counts
where more platelets merge and separate, which can cause
mistracking. Mistracking can lead to track fragmentation or to
joining different tracks. The former is more frequent as there
is an overestimation of the number of tracks, which agrees
with what we see when inspecting image sets manually.
2) Number of Stably-Adhered:
3) and Translocating Platelets: Figure 5 shows the error
in the number of stably-adhered. The magnitude of the error
will depend on the object count and the fraction of statics. It
is clear that the error can vary over the three runs using the
same parameters but in most cases there is an over-estimate.
The errors are caused by mistracking, which increases with
object count (which tends to increase the total number of
tracks). However, if a platelet has been a singlet for only
a few frames (< 10) then it will tend to be classed as a
stably-adhered. Given that most of the other variables are
calculated from the translocating platelets, it makes sense to
class these platelets as static; the downside being that the
number of stably-adhered could be overestimated. The error
in the number of translocating platelets is directly correlated
with that of the stably-adhered.
4) Weighted Median Speed: The observed error for the
weighted median speed was very low and uncorrelated with
the object count. This shows that the weighted median speed
is indeed not influenced by the outliers. This is a substantial
improvement over the error for the mean speed, which is in
the order of 5-10%.
5) Mean Translocating Distance: The results were com-
bined from runs where platelets translocated from 50 to
150 pixels with the translocating speed kept constant at 1
pixel/frame. As can be seen in figure 6, the mean distance
is mostly underestimated and the greater error is observed
for higher object counts and static fractions. In higher object
count runs there is an overestimation of the number of tracks,
implying track fragmentation. Fragmented tracks are shorter
than expected, thus reducing the mean. Mistracking events
that lead to a translocating platelet track being matched with a
static platelet produces shorter than expected track. Increasing
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Fig. 5. Number of stably-adhered platelets verses object count. Translocating
distance (50 pixels) and speed (1 pixel/frame) are constant. The straight lines



























Fig. 6. Mean translocating distance versus object count for a fixed translo-
cating speed (1.0 pixel/frame) and distance (50 pixels). The black line is the
expected value.
the number of statics increases the likelihood of these type of
mistracking events, again leading to a reduction in the mean.
6) Surface Coverage: Table II shows that surface coverage
has a error of ∼ 10% which is always underestimated. The
expected value is just the fraction of the sum of the platelet
areas. One source of error will be that masked platelet areas
will be smaller than the actual value. In addition, merged
platelets will have a slightly smaller area than if they were
separated. For both these reasons the surface coverage will be
underestimated.
7) Percentage Motion: The error in percentage motion
increases with object count and it is mostly under-estimated
(see figure 7). There will be several factors acting on per-
centage motion: platelets could appear to move when merged
increasing percentage motion but misclassification of stably-





















Fig. 7. Percentage of time in motion versus object count. The black line
represents the expected values. Translocating speed (1.0 pixels/frame) and
distance (50 pixels) are kept constant.
TABLE III
PERCENTAGE OF CORRECTLY MEASURED INITIAL PAUSETIMES VERSUS
DIFFERENT EXPECTED PAUSETIMES.
Expected Pausetime (frames) 10 20 30
Percentage Correct (%) 92 88 85
adhered platelets tends to be under-estimated, this is the main
source of error.
8) Initial Pausetime Distribution: Three initial pausetimes
were used: 10, 20 and 30 frames with a fixed translocating
distance of 50 pixels. Speed, static fraction and object count
were varied and all the results combined for a fixed pausetime.
The errors are due to mistracking and both shorter and longer
initial pausetimes were measured (see table III).
9) Adhesion Rate: The error increases with object count
and is always an underestimate, with the maximum absolute
error of ∼ 17%. This is because the recorded values are the
number of platelets on each frame and not the number of
tracks. The number of platelets on a frame will always be less
than or equal to the number of tracks at that point in time.
B. Anti-P2Y1 Test
To further validate the accuracy of the distance-weighted
algorithm, we investigated the effect of MRS2179, a selective
antagonist of the ADP receptor P2Y1 on platelet trajectories.
The P2Y1 receptor is involved in platelet shape change and
initiation of platelet aggregation. Furthermore, it has been
shown that compounds that inhibit the P2Y1 platelet recep-
tor effect the shape of the platelet when bound to VWF
attached to a surface and hence the translocation speed [21].
We performed a test on blood from 8 healthy volunteers
who were free from any medication known to affect platelet
function within previous 10 days, with ethical approval from
the Royal College of Surgeons in Ireland. Blood samples
were treated with/without 20µM MRS2179 (P2Y1 inhibitor),
see Section IV for the experimental details. Figure 8 shows
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TABLE II
MEAN ABSOLUTE ERROR OF A MEASURED VARIABLE VERSUS OBJECT COUNT.
Mean Absolute Error (%)
Variable (Object Count)
50 100 150 200 250 300 350 400
Number of Tracks 0.4 0.7 0.5 0.5 0.8 0.9 1.1 1.6
Number of Statics 2.1 3.8 8.1 7.6 8.1 13.4 18.3 15.5
Mean Translocating Distance 1.7 3.9 5.9 7.7 8.5 9.7 10.9 12.1
Weighted Median Speed 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Surface Coverage 5.5 12.0 12.2 12.5 12.2 13.0 13.2 14.1























Fig. 8. Boxplot of weighted median translocating speed, combining results
for all donors. The notches are the 95% confidence interval on the median and
the dots are considered outliers using the standard 1.5 times the interquartile
range.
the translocating speed, combining results from treated and
untreated samples, respectively. The notches on the boxplots
give the 95% confidence interval about the median. At this
significance level there is no difference between the speeds
for the anti-P2Y1 and the control, p-value=0.12. However it
is clear there are some outliers in the data (presented by open
circles). Figure 9 shows the difference in translocating speed
between the mean of the samples for 7 donors. One donor was
removed because two of the outliers were from this donor, also
the other outlier from the anti-P2Y1 group was removed. As
you can see from figure 9 there is a significant difference
in the differential translocating speed, p-value=0.039. Both
figures were plotted using ggplot2 [?] and the p-values were
calculated from a one-sided Wilcox test [22]. A one-sided test
was used because we were looking for an increase in speed.
C. Platelet Count and Number of Tracks
Blood was obtained from healthy donors with platelet
counts ranging from 150,000 to 350,000 per µL of blood. Five
donors with 150,000 per µL, five with 250,000 per µL and
two with 350,000 per µL. Each donor had at least two runs,
with a total of 35 assay runs. Increasing platelet count resulted
in a significant increase in the number of platelets interacting




















Fig. 9. Boxplot of the differential translocating speed between treated and
untreated blood samples from the same donor. Notches are the 95% confidence
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Fig. 10. Plot of all runs for each donor of total number of tracks verses
platelet count in the three classes. The black line is the linear regression fit.
for the slope is ∼ 0.00002 (see figure III-C). Results were
obtained using the lm function from R [19].
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IV. EXPERIMENTAL SETUP
A. Assembly and Preparation of Parallel Plate Flow Cham-
bers
To perform flow-based analysis to investigate the effect of
MRS2179 (Vide Infra), parallel plate flow chambers were
comprised of 3 layers, the top layer being a polymethyl-
methacrylate (PMMA) top plate with an inlet and outlet
attached via epoxy glue. The second layer consists of pressure-
sensitive adhesive (PSA) containing the microfluidic channel
of interest. Finally, a glass coverslip containing the immobi-
lized analyte (VWF, 100µg coated overnight at 4◦C) was used
as a base. Prior to analysis, the channel was washed 3 times
with phosphate buffered saline (PBS), blocked with 1% (w/v)
BSA for 1 hour at room temperature, followed by final rinsing
with PBS buffer prior to blood perfusion.
B. Preparation of Whole Blood Prior to Perfusion
Blood was obtained from 8 healthy volunteers who were
free from any medication known to affect platelet function
within previous 10 days (e.g. Aspirin). Prior to phlebotomy,
written informed consent was obtained from all healthy vol-
unteers. Blood was drawn through a 19-gauge butterfly needle
into polypropylene syringe (Becton Dickinson, Oxford, UK)
containing a 3.2% solution of the anti-coagulant, trisodium
citrate dihydrate. 200µl of blood was aliquoted to a 2ml
eppendorf tube. Blood samples were treated with/without
20µM MRS2179 (P2Y1 inhibitor) and labelled with 1µM
DiOC6 (Invitrogen, USA) fluorescence dye, which localizes
to the endoplasmic reticulum and mitochondria of platelets
for 10 minutes at 37◦C.
C. Perfusion of Whole Blood and Image Acquisition in a
Parallel Plate Flow Chamber using MRS2179
Parallel plate flow chambers were
mounted on an inverted microscope (Zeiss
Axiovert-200 epi-fluoresence). Blood treated with/without
P2Y1 inhibitor was drawn through a bio-compatible platinum-
cured silicone tubing (Nalgene, 1/16 in internal diameter,
Thermo Fisher Scientific, Denmark). Blood was then perfused
through the flow chamber using a nemESYS syringe pump
(Nem-8001-02-C, Cetoni, Germany), at a controlled flow
rate of 75µl/min, giving a fluid shear rate of 1500s−1
corresponding to physiologically relevant arterial shear rates.
Images were captured using a vacuum-cooled (−80◦C) digital
EM-CCD camera (iXON EM+, Andor Technology, Belfast,
Ireland) connected to MetaMorph R￿ (version 7.7, Molecular
Devices Ltd., UK) illuminated with an Osram 103-W mercury
light source and a fluorescein isothiocyanat (FITC) filter
set (ExS490/20x, EmS528/38m, Chroma Technology Corp,
Vermont, USA). Images were acquired at 30 frames per
second (fps) for 500 frames.
V. CONCLUSIONS
Given the number of image sets generated to-date and
the complexity of the images themselves, routine manual
inspection of images is not viable. An automatic image anal-
ysis process is then required, but such a system can never
be 100% accurate for non-trivial image sets; when platelets
move at random times, appear and disappear anywhere on the
imaged surface and the transitory nature of platelet-platelet
interactions. Hence there is a need to validate such a system,
even if the test image sets are, of necessity, simplified.
It is clear that the major influence on the errors for each
of the variables is the number of platelets per frame. The
more platelets per frame, the more chance of mergers and
separations between platelets occurring and hence mistracking
events. However, some variables are affected more than others.
For instance the weighted median speed is weakly influenced
but stronger for the number of statics. In deciding to track
platelet groups but maintain individual tracks, artificial move-
ments are introduced which need to be removed to reduce
the bias in the measured variables. There is a penalty, in that
any real platelet movements which come with a merging or
separation event are also discarded. It might be possible to
estimate the real movement in these cases but this has not
currently been implemented.
In image sets with real platelets, tracking will inevitably
become more difficult. The mean absolute errors presented
above therefore represent a lower limit on the actual error one
would expect from a real experiment. Although in making
all the platelets the same shape and size means that in some
cases tracking becomes harder. As can be shown from the anti-
P2Y1 results it is still possible to elucidate differential platelet
properties between different drugs, disease states and healthy
individuals given enough data.
In summary, we have designed and verified the accuracy
of a novel platelet tracking algorithm based on a weighted
distance matrix using custom-developed idealized data sets,
determining the percentage systematic error for key individual
parameters of platelet translocation of biological relevance.
The ability to interrogate and elucidate platelet translocation
dynamic characteristics and utilize them in such a combinato-
rial manner facilitates the interrogation of healthy and disease
cohorts, thus providing unique insights into platelet trajectory
profiles in the presence and absence of anti-platelet therapies.
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